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PREFACE
Over the past 4 years, I have had the privilege of working with 
Professor Abraham Goldberg in the fascinating field of the porphyrias.
His clinical and scientific advice has been invaluable and h is  
personal interest in my career most encouraging. My re se a rc h  in 
the porphyrias has taught me important principles of human disease 
p rocesses as well as giving me an insight into the effects 
of such d iseases on the personal lives and fam ilies of afflicted patients.
Some of the work has been published and reprin ts of each publication 
a re  submitted with the thesis. Collaboration with a num ber of 
colleagues has been necessary  as described in the form al acknowledgements. 
Except where indicated, the work presented has been carried  out by 
m yself.
The w riting of this thesis is entirely my own work.
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SUMMARY
The acute hepatic porphyrias are  the resu lt of hereditary  partia l
/
deficiencies of individual enzymes in the pathway of haem biosynthesis. 
Seven enzymes a re  known to be involved in the pathway, converting 
glycine and succinyl CoA firs t to porphyrin p recu rso rs  and then to 
porphyrins and finally to haem. The rate of the process is regulated 
by the initial enzyme, delta - am inola e vul in ic acid (ALA) synthase, which 
is under negative feedback control, by haem. The p a r tia l block in 
this pathway, in each of the acute porphyrias,resu lts in compensatory 
increased activity of ALA synthase and,consequently,overproduction of 
porphyrins and p recu rso rs  formed p rio r to the deficient enzyme. Patients 
with acute porphyria generally enjoy good health,but exposure to certain 
recognised factors, namely specific  drugs, alcohol, horm ones and fasting^ 
may precipitate severe clinical attacks characterized by gastro -in testinal 
symptoms, psychiatric disturbances and neuropathy. All of the system ic 
m anifestations of the attack are  thought to be explained by neurological 
dys function,but the mechanism by which the abnormal haem biosynthesis 
causes the neuropathy is not known. Following a general description of 
haem biosynthesis and the porphyrias, this thesis concentrates on the 
management of acute hepatic porphyria studyiag, in turn, the detection 
of subjects with the genetic tra it, the factors which may precipitate attacks 
in these subjects and the treatm ent of patients in established attack.
(xiii)
Much of the work presented is based upon the ability to m easu re  the 
activ ities of the individual enzymes of haem biosynthesis in human 
peripheral blood cells. The mitochondrial enzymes, ALA synthase, 
coproporphyrinogen oxidase and ferrochelatase, a re  m easured  in 
leucocytes and the cytosolic enzymes, ALA dehydratase, uroporphyrinogen- 
1 -synthase (URO synthase) and uroporphyrinogen decarboxylase, in 
erythrocytes.
The m easurem ent in peripheral blood cells of the activ ities of both the . 
rate-controlling enzyme, ALA synthase, and the appropriate genetically 
deficient interm ediate enzyme, is shown to be a sensitive and specific 
m eans of detecting latent cases of acute porphyria,the m ajo rity  of whom 
have norm al excretion of porphyrins and p recu rso rs . Enzym atic screening 
of affected fam ilies confirms that the genetic tra it is inherited in an 
autosomal dominant sex-independent manner. The family studies also 
dem onstrate that the vast m ajority of subjects with the tra it  rem ain clinically 
latent, and the reason why the m inority of patients experience clinical 
manifestations is examined. The activity of the partia lly  deficient enzyme 
is sim ilar in latent and m anifest cases, but ALA synthase activity is higher 
in patients who have experienced an attack and this may re flec t higher 
circulating levels of endogenous inducing agents.
Drugs are an important exogenous precipitating factor for acute porphyria, 
and an important aspect of the prevention of attacks is the identification of
(xiv)
potentially porphyrinogenic drugs. The testing of 26 commonly prescribed 
drugs, by assessing  their effect on hepatic ALA synthase activity in ra ts , 
is described. The mechanism by which drugs stim ulate ALA synthase 
activity is examined with particu lar reference to the ro le of induction of 
the mixed function oxidase enzyme (MFO) system , A close correlation 
is noted between induction of the MFO system, as reflected  in increased 
hepatic cytochrome P450 content, and increased activity o f ALA synthase, 
though not the converse. Sequential studies following commencement of 
phenytoin adm inistration to ra ts  show that the r ise  in ALA synthase activity 
is transito ry  and coincides with the r ise  in hepatic cytochrome P450 content 
which is maintained. These observations indicate that induction of the MFO 
system  demands increased ALA synthase activity to provide the additional 
haem for synthesis of the haemoprotein, cytochrome P450.
The ability to m easure the activities of the enzymes of haem  biosynthesis in 
peripheral blood cells is used to examine the effects of the porphyrinogenic 
factors, drugs, alcohol, hormones and fasting, on the pathway in non-porphyric 
human subjects. Each of these factors, except fasting, increases ALA synthase 
activity, confirming the mechanism by which they p recip ita te  biochemical 
re lapse in porphyric subjects. Sequential studies of leucocyte ALA synthase 
activity following commencement of the porphyrinogenic drug phenytoin, 
in non-porphyric subjects, show that the pattern of r ise  In enzyme activity 
is s im ilar to that observed in animal hepatic tissue,indicating that the drug 
is inducing a haem -requiring enzyme system in leucocytes as well as in the 
liver. The acute ingestion of a m oderate amount of alcohol (200 mis Vodka)
(xv)
in healthy subjects, resu lts  in increased activity of ALA synthase and URO 
synthase, and depression of the activities of ALA dehydratase, uroporphyrinogen 
decarboxylase, coproporphyrinogen oxidase and ferrochelatase. In chronic 
alcoholic subjects, ALA synthase activity is increased, and ALA dehydratase 
and uroporphyrinogen decarboxylase activities depressed. This stimulation 
of ALA synthase and depression of uroporphyrinogen decarboxylase, explains 
the biochemical mechanism of alcohol-related porphyria cutanea tarda.
In two subjects with alcohol-induced anaemia, marked depression of 
coproporphyrinogen oxidase and ferrochelatase activities is  observed and 
these enzymatic changes in blood cells are  relevant to the mechanism by 
which alcohol causes bone m arrow depression. With respect to hormones 
and haem biosynthesis, a marked fluctuation in leucocyte ALA synthase 
activity is Observed during the female m enstrual cycle. T his hormonal 
effect on blood ALA synthase activity may be relevant to the mechanism 
of the hormonal regulation of erythropoiesis.
The two currently available means of treating  attacks of acute porphyria 
a re  assessed . The adm inistration of intravenous laevulose reduces the 
duration and severity  of the attack but in patients suffering frequent attacks 
venous access soon becomes compromised. Intravenous haematin therapy 
resu lts  in biochemical improvement,shown by repression of leucocyte ALA 
synthase activity and reduced urinary excretion of porphyrin p recurso rs.
The clinical response to haematia is less  consistent, definite improvement
(xvi)
accompanying only half of the courses. The only adverse effect noted 
following haematin is localized thrombophlebitis. In spite of the 
adm inistration of both laevulose and haematin and full intensive care 
supportive therapy, two of our patients died in attack, illu stra ting  that 
current therapy rem ains inadequate. Advancement in the treatm ent of 
acute porphyria is hindered by lack of understanding of the relationship 
between the biochemical and clinical m anifestation of the d isease , and 
it is concluded that further studies of neurological aspects of abnorm al 
haem biosynthesis are  needed.
(xvii)
ABBREVIATIONS
Abbreviations used in certain parts  of Text
ALA Delta-aminolaevulinic acid
A. LA. A llylisopropylacetamide
A IP Acute interm ittent porphyria
Cyt. P450 Cytochrome P450
COPRO oxidase Coproporphyrinogen oxidase
DHA Dehydroepiandrosterone
G A BA Gamma aminobutyric acid
M .F .O . system Mixed function oxidase enzyme system
PBG Porphobil in ogen
URO synthase U roporphyrinogen-I-synthase
Abbreviations used in certain figures and tables
L.ALA.S 
L. COPRO.O 
L.FERR 
E.ALA.D 
E. URO.S 
E.URO.D
Leucocyte delta - am inolae vul in i c acid synthase 
Leucocyte coproporphyrinogen oxidase 
Leucocyte ferrochelatase
Erythrocyte delta-am inolaevulinic acid dehydratase 
E rythrocyte uroporphyrino gen - 1 - synthase 
Erythrocyte uroporphyrinogen decarboxylase
C H A P T E R  1
H A E M  M E T A B O L I S M
I. HARM METABOLISM 
1, 1. INTRODUCTION
Haem (iron - protoporphyrin - IX) is the most ubiquitous metalloporphyrin 
chelate of the animal kingdom and catalyses the basic energy reactions 
upon which life depends (Figure 1). It is synthesized in all metabolically 
active cells in the human body, a normal adult producing about 0.45 mmol 
haem every 24 hours (Elder, 1976). Haem forms the basic structure of 
oxygen-binding haemoproteins such as haemoglobin and myoglobin, cellular 
enzymes such as catalases and peroxidases which decompose hydrogen 
peroxide,’ cellular resp irato ry  pigments such as mitochondrial cytochrome 
b's, monoxygenases such as mitochondrial cytochrome P45G, dioxygenases 
such as tryptophan pyrrolase, and microsomal cytochrome b5 which is 
important in fatty acid de saturation reactions (Maines, 1979). Eighty 
percent of the body’s daily haem production occurs in the bone marrow 
where it is required for haemoglobin formation,and most extra-m edullary 
production occurs in the liver where it is required for the many haemoprotein 
enzyme system s.
I. 2. HAEM BIOSYNTHESIS
Eight enzymes are known to be involved in the biosynthesis of haem, four 
being present within the mitochondrion and four in the cytoplasm (Figure 2). 
The process s ta rts  within the mitochondrion with the condensation of 
succinyl CoA and glycine to form delta-aminolaevulinic acid (ALA). This
III
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Figure 1
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reaction is catalysed by the initial and rate-controlling enzyme of the 
pathway, ALA synthase. Pyridoxal phosphate is required as a cofactor 
for ALA synthase. The synthesized ALA passes out of the mitochondrion 
and in the cytoplasm two molecules condense under the catalytic control 
of ALA dehydratase to form the monopyrrole porphobilinogen (PBG). The 
next step requires the concerted action of two enzymes, uroporphyr inogen -1 - 
synthase and uroporphyrinogen-III-synthase, which control the condensation 
of four molecules of PBG to form the tetrapyrrole uroporphyrinogen III.
The combined action of these two enzymes is necessary to form the 
uroporphyrinogen III isom er. Uroporphyrinogen-I-synthase acting alone, 
only produces the symm etrical uroporphyrinogen-I-isomer which cannot be 
formed into haem and is excreted as coproporphyrin I. The next step of 
the reaction is controlled by the enzyme uroporphyrinogen decarboxylase 
which catalyses the sequential decarboxylation of the octacarboxylic 
uroporphyrinogen to form the tetracarboxylic coproporphyrinogen. 
Uroporphyrinogen decarboxylase acts on both uroporphyrm I and III 
forming both isom ers of coproporphyrinogen. Coproporphyrinogen III 
then enters the mitochondrion where coproporphyrinogen oxidase catalyses 
the combined oxidation and decarboxylation of two propionyl residues on 
rings A and B of the porphyrin nucleus to form protoporphyrinogen. 
Coproporphyrinogen oxidase will not act on the coproporphyrinogen I isomer 
which, unable to proceed any further in the pathway, is excreted. Within 
the mitochondrion the protoporphyrinogen is oxidized to protoporphyrin by 
the oxygen-dependent enzyme,protoporphyrinogen oxidase. The final enzyme
of the pathway is ferrochelatase which catalyses the insertion of ferrous 
Iron into protoporphyrin to form haem.
1. 3. RFGULATION OF.THE RATE OF HAEM SYNTHESIS 
The rate of haem biosynthesis is regulated by the initial enzyme of the 
pathway^ ALA synthase^which is under negative feedback control by haem 
(Marver & Schmid, 1972). ALA synthase is particularly suited to this 
role being present in the lowest concentration and having the shortest 
half-life of any of the enzymes of the pathway and being readily inducible 
(Moore, 1980). It is postulated that within the mitochondrion tiiere exists 
a pool of "free" or "regulatory" haem which controls the activity of ALA 
synthase (Bonkowsky et al, 1979). Any depletion of this free haem pool, 
by increased destruction, reduced synthesis or increased utilization,results 
in increased activity of ALA synthase. Likewise, supplementation of the free 
haem pool depresses ALA synthase activity (Whiting & Granick, 1976).
Haem probably reduces ALA synthase activity by repression and inhibition 
at both transcriptional and translational cellular levels (Granick & Sassa, 1971).
The only other enzyme, apart from ALA synthase, with a markedly lower 
activity than the other enzymes of the pathway is uroporphyrinogen-l-synthase. 
It has been suggested that this enzyme may play a secondary rate-controlling 
role in the pathway becoming important when ALA synthase is derepressed 
(Brodie et al, 1977).
1.4. EXCRETION OF HAEM PRECURSORS
Porphyrins and porphyrin p recu rso rs  which leave the cell are very 
rapidly excreted and therefore plasm a concentrations are  normally 
very low. The quantities of haem precursors which leave the cell and 
a re  excreted are triv ial compared with the amounts used for haem synthesis 
(Elder, 1976). The hydrophilic porphyrin p recurso rs ALA and PEG are 
excreted exclusively in the urine whereas the lipophilic formed porphyrins 
are excreted mainly in the bile. In normal subjects considerable renal 
tubular reabsorption of the porphyrin p recu rso rs  occurs; when glom erular 
filtration rate is estim ated from endogenous creatinine clearance,90-95 
per cent of the filtered load of ALA and PEG is reabsorbed (Druyan et al, 
1965). In the disease situation when the plasma concentrations of ALA 
and PEG rise  their renal tubular reabsorption decreases and may fall to 
zero. The urinary ALA excretion is slightly increased by water-loading 
and reduced by w ater-deprivation (Araki, 1978). Both coproporphyrin and 
protoporphyrin^which are predominantly excreted in the bile^ undergo 
enterohepatic circulation (Struthers, 1966).
1. 5. HAEM CATABOLISM
A small proportion of the haem synthesized by the liver undergoes rapid 
catabolism, contributing to the "early labelled" bilirubin, but most is 
iucorporated into hepatic haemoproteins, of which m icrosom al cytochrome 
P450 quantitatively is the most important (Bonkowsky et al, 1979). The
m ajor route of hepatic haem catabolism involves the m icrosom al enzyme 
haem oxygenase which requires molecular oxygen and NAD PH-cytochrome C 
reductase for activity (Teiihunen et al, 1968) (Figure 3). The final products 
of the reaction are  iron, carbon monoxide and biliverdin. Haem oxygenase 
can be induced by haem (Tenhunen et al, 1970) and certain other substances 
(Maines & Kappas, 1976). The location and source of the haem which serves 
as substrate for haem oxygenase is uncertain. Biliverdin is then further 
reduced to bilirubin by the cytoplasmic enzyme biliverdin reductase. Most 
of the bilirubin formed is then conjugated by the enzyme bilirubin 
glucuronidase before being excreted in the bile (Tait, 1978).
HAEM
NADH ------------------
Cyt. C. Reductase
NADPH
Haem Oxygenase
 ^ Fe + CO 
BILIVERDIN - DC
Bilirubin Reductase
Glucuronic acid
BILIRUBIN
Glucuronyl Transferase
BILIRUBIN GLUCURONIDE
Excreted in bile  
into intestine
Hydrolysis and reduction 
by intestinal bacteria
STERCOBILINOGEN AND UROBILINOGEN
/ \
Auto-oxidation in faeces
/ \
STERCOBILIN UROBILIN
Figure 3 Hepatic Haem Catabolism
C H A P T E R  2
T H E  P O R P H Y R I A S
2. THE PORPHYRIAS
2.1 . INTRODUCTION
The porphyrias a re  a group of d iseases resulting from  h ered ita ry  
abnorm alities in the pathway of haem biosynthesis, each being 
characterized by a genetic partia l deficiency of a d ifferent interm ediate 
enzyme of the pathway. The name porphyria is derived from  the Greek 
word "porphoros" which means purple and was probably adopted on 
account of the dark-coloured porphyrin-laden urine which patients pass 
during an acute attack of the condition. The association  with the colour 
purple may have a further connotation as there  is some evidence that 
several m em bers of royal lineage suffered from the d isea se  (McAlpine, 1968). 
It is thought to have explained the attacks of m adness which plagued 
George III and some also suggest that the disease was handed down through 
Mary Queen of Scots and James VI (Figure 4). The evidence, for porphyria 
being a "Royal Malady" is not, however, totally convincing.
2. 2, CLASSIFICATION OF THE PORPHYRIAS
2 .2 .1 . Clinical Classification
The classification of the porphyrias has always been problem atic and 
depends whether one is regarding them from a clinical o r  biochemical 
point of view. From  the clinician 's viewpoint, there a r e  the acute hepatic 
porphyrias - acute interm ittent porphyria, hereditary  coproporphyria and 
variegate porphyria and the non-acute porphyrias - cutaneous hepatic
Figure 4
James VI of Scotland.
porphyria, erythropoietic protoporphyria and congenital porphyria 
(Figure 5). The acute hepatic porphyrias present with in term itten t 
attacks of system ic illness characterized by abdominal pain and often 
with accompanying neuropathy and a neuropsychiatrie syndrom e. Patients 
with variegate porphyria or hereditary  coproporphyria m ay, in addition, 
develop so lar photo-sensitivity skin lesions. The non-acute porphyrias
present solely with cutaneous m anifestations. In the acute porphyrias 
there is increased excretion of the porphyrin p recu rso rs , A LA and PBG, 
and porphyrins,w hereas,in the non-acute porphyrias,there is only 
increased excretion of porphyrins. The photosensitive skin lesions 
a re  seen where there is accumulation of formed porphyrins,w hile acute 
attacks a re  seen in association with accumulation of porphyrin p recu rso rs .
2 .2 .2 . Biochemical Classification
From  the biochem ist's viewpoint, the different form s of porphyria are 
characterized by partia l deficiencies of different enzym es in the pathway 
of haem biosynthesis (Brodie et al, 1977). As a resu lt of the enzyme 
deficiency there is reduction in haem synthesis and th erefo re  by negative 
feedback control increased activity of the ra te-contro lling  enzyme of the 
pathway, ALA synthase. The combination of increased activity of the 
initial enzyme, A LA synthase,and partia l enzymatic block la te r  in the 
pathway, resu lts  in an accumulation of porphyrins and porphyrin p recu rso rs  
formed proximal to the block and these may appear in blood, urine and 
faeces. Each of the different types of porphyria, therefo re , has a 
characteris tic  pattern of overproduction of porphyrins and p recu rso rs
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determ ined by the site of the enzymatic block. The enzyme deficiency in 
acute interm ittent porphyria is uroporphyrinogen-l-synthase, in hereditary 
coproporphyria, coproporphyrinogen oxidase, in porphyria variegata, 
protoporphyrinogen oxidase, in cutaneous hepatic porphyria, 
uroporphyrinogen decarboxylase, in erythropoietic protoporphyria, 
ferrochelatase and in congenital porphyria, uroporphyrinogen cosynthetase.
It has been reported that a further form of acute porphyria may exist 
which, in common with lead poisoning, p resen ts  with depressed  activity 
of ALA dehydratase (Doss et al, 1980). The activity of the enzyme 
uroporphyrinogen- 1 - synthase is particu larly  important in determ ining 
the biochemical and clinical presentation of the porphyrias. In acute 
interm ittent porphyria the activity of this enzyme is reduced, but in the 
other two acute porphyrias, it is norm al. In each of the non-acute porphyrias 
it is increased. This enzyme is at the point in the pathway where porphyrin 
p recu rso rs  a re  converted into porphyrins. It is probably the increased 
activity of uroporphyrinogen- 1 - synthase which prevents the accumulation of 
porphyrin p recu rso rs  in the non-acute porphyrias (Brodie e t al, 1977).
F urther details of the biochemical d isorder will be given under the 
discussion of the individual types of porphyria.
2. 3. ACUTE INTERMITTENT PORPHYRIA
2 .3 .1 . Introduction
This is the commonest and m ost severe form of acute porphyria. It 
is inherited in an autosomal dominant fashion. Estim ates of the prevalence 
of symptomatic acute interm ittent porphyria vary considerably from 
country to country. The highest rate is probably in Lapland, estim ated 
as 1/1000. In W estern A ustralia, on the other hand, the prevalence 
(including latent cases) is only 3/100, 000 (Tschudy, 1974), Though the 
genetic tra it is equally distributed between sexes the clinical disease 
is m ore commonly seen in fem ales. This is probably due to the hormonal 
fluctuations in fem ales increasing the incidence of clinical attacks.
Acute interm ittent porphyria presents with attacks of neurological 
dysfunction, the patient usually enjoying good health between attacks. It 
is the one form of porphyria not associated with photosensitive skin lesions. 
The frequency and severity  of attacks varies considerably from  patient to 
patient. In a proportion the disease rem ains latent throughout life, even in 
the presence of precipitating factors. Other patients experience frequent 
and som etim es life-endangering attacks even in the absence of ex trm sic 
precipitating factors. In spite of recent therapeutic advances,an acute attack 
of porphyria with severe neurological involvement may have a fatal outcome.
10.
2 .3 .2 . Underlying Biochemical D isorder
The basic defect in acute interm ittent porphyria appears to  be partia l 
deficiency of the enzyme uroporphyrinogen-1-synthase. T h is  has been 
dem onstrated in erythrocytes (Meyer et al, 1972), skin fib ro b las t cultures 
(Bonkowsky et al, 1975) and amniotic cells (Sassa e t al, 1975). A s a  
result, there is excess formation and urinary  excretion of the porphyrin 
p recu rso rs  ALA and PBG (Tschudy, 1965). There is a lso  increased 
urinary  and to a le sse r  extent faecal^excretion of uroporphyrin . The 
excess uroporphyrin is probably not due to hepatic overproduction but 
m erely the resu lt of spontaneous polymerization of the e x c e ss  PBG. An 
attack is always associated with increased urinary excre tion  of ALA and 
PBG though there is no close correlation between the m agnitude of this and 
the severity  of the attack. Most patients excrete ex cess  porphyrin p recu rso rs  
during asym ptom atic periods between attacks,but some have completely 
norm al excretion profiles between attacks. .
Patients with acute interm ittent porphyria a re  also  known to produce excess 
steroids of the 5 Beta-H configuration (Goldberg e t al, 1969). This is due 
to deficiency of hepatic 5 alpha reductase (Kappas e t al, 1971). Some of the 
5 Beta-H steroids which a re  found in excess can induce ALA synthase in ra t 
hepatic tissue and they may play a role in the precipita tion or exacerbation 
of the acute attacks (Moore et al, 1973).
11.
2 .3 .3 . F eatu res of the Acute Attack
The acute attacks of neurological dysfunction seen in acute in term ittent 
porphyria are s im ila r to those seen in hereditary coproporphyria and 
porphyria variegata. Attacks a re  ra re ly  seen before puberty. The highest 
incidence of onset of symptoms is between puberty and 30 y ea rs  of age and 
attacks are  m ost common in the decade from 20-30 years (Waldenstrom et al, 
1963). It should be emphasized, however, that serious attacks may occur 
for the f irs t time a t any age. In one third of reported cases th ere  is no 
family history either prospectively or retrospectively, the condition 
presum ably having remained latent for several generations (Beattie &
Goldberg, 1973).
Abdominal pain is the m ost frequent complaint, occurring In 95% of cases.
The pain is often very severe and patients frequently requ ire  paren tera l 
narcotic analgesics. It may be either colicky or constant in nature. The 
pain may be localized to one region of the abdomen but is m ore usually 
felt m ore diffusely over the abdomen. Patients a re  alm ost always constipated 
during an acute attack. About 10%, however, experience diarrhoea.
Anorexia usually occurs and there is often associated nausea and vomiting.
On abdominal examination there is usually mild generalised tenderness which 
often appears inappropriately mild for the degree of pain experienced by the 
patient. Muscle guarding is ra re ly  seen and bowel sounds a re  norm al. 
Patients presenting with their f irs t attack may be m isdiagnosed as having 
appendicitis, biliary or renal colic or small intestinal obstruction, and if 
they are  subjected to an unnecessary laparotomy their condition may be
i Z .
considerably aggravated.
Peripheral Neuropathy may be the presenting feature of an acute attack 
and it complicates m ore than 50% of porphyric attacks. In m ost cases 
the neuropathy begins with m otor symptoms consisting of m uscle 
weakness often proceeded by cram p-like pain and stiffness. The peripheral 
flexor m uscles a re  often the firs t to be affected resulting in foot-drop and 
w rist-d rop . The m otor neuropathy may extend, som etim es rapidly, to 
involve other m uscles. The tendon je rk s  become diminished or absent 
and,later, m uscle wasting becomes evident. Patients may also  complain 
of parasthaesia,and sensory diminution may be found on testing . Varying 
combinations and degrees of m otor and sensory involvement may be seen. 
Difficulty controlling m icturition may be experienced. In severe cases 
with extensive neuropathy the m uscles of ventilation become involved 
necessitating assisted  ventilation (Figure 6). It is often heralded by 
weakening of the voice. C ran ia l nerve palsies are occasionally seen.
Grand mal convulsions may also occur and are  commonest at the height of 
an attack.
Psychiatric m anifestations are  common. Waldenstrom (1957) found 
pronounced mental symptoms in 55% of 233 patients with acute interm ittent 
porphyria. Patients may be misdiagnosed as suffering from  a purely 
psychiatric condition and admitted to psychiatric w ards. In one study by 
Kaebling et al (1961), 2, 500 consecutive patients admitted to a m ental hospital
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were screened for acute porphyria. Of the 35 positive te s ts  obtained, 
the adm itting diagnoses included schizophrenia, psychiatric  depression, 
neuroses, personality d isorders, alcoholism and acute and chronic 
brain syndromes. The psychiatric symptoms occasionally p e rs is t 
between attacks.
Tachycardia and Hypertension a re  features of the vast m ajority of attacks. 
Sinus tachycardia of up to 160/m in may be seen. The hypertension may be 
severe and result in encephalopathy and cardiac failure. The hypertension 
tends to be labile. A substantial proportion of patients will be found to 
have postural hypotension, if the blood p ressu re  is checked with the patient 
e rec t as well as supine. A percentage of patients rem ain hypertensive 
between attacks (Beattie & Goldberg, 1976).
In some patients a low grade pyrexia is noted during an attack. The urinary 
output is nearly  always low during an attack. The urine itse lf is  dark 
reddish-brow n in colour and th is becomes m ore pronounced if left standing.
2 .3 .4 . Diagnosis of Acute Attack of Porphyria
Any patient presenting with unexplained abdominal pain, neuropathy or 
psychiatric m anifestations should be tested for acute porphyria. All 
patients in acute attack excrete excess ALA and PBG in the urine. The 
modified Watson Schwartz test provides a simple and rapid method of 
dem onstrating excess urinary PBG (Watson et al, I 96I). 2 ml of fresh
14.
urine is added to a test tube. The addition of a further 2ml of fresh 
Ehrlich 's Aldehyde reagent will result in a red-pink discolouration in 
the presence of excess PBG or urobilinogen. These can be differentiated 
by the further addition of 4ml chloroform. If the discolouration is due 
to excess PBG it will rem ain only in the upper aqueos layer. In order 
to confirm the diagnosis and define the type of porphyria, quantitative 
estimation of porphyrins and precurso rs should be performed on faeces 
and 24 hour urine collection.
2 .3 .5 . Other Laboratory Findings hi Acute Attack 
Haematology - The haemoglobin concentration usually rem ains normal 
during the acute attack. This is in some ways surprising in a disease 
due to a partia l block in the pathway of haem biosynthesis. The white 
cell count and erythrocyte sedimentation rate are also normal or 
occasionally slightly elevated.
Biochemistry - Electrolyte abnorm alities are common in the acute attack 
(Eales & Dowdle, 1969). Vomiting and inadequate fluid intake may result 
in hypokalaemia and varying degrees of uraemia. The creatinine clearance 
is reduced in a proportion of patients in attack (Eales et al, 1971). Severe 
dilut ional hyponatraemia may .occur as a result of inappropriate secretion 
of anti-diuretic hormone possibly due to hypothalamic dysfunction.
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The plasm a albumin concentration is frequently low in severe o r prolonged 
attacks, but there is little information available on the m echanism s responsible.
A proportion of patients in acute attacks have increased serum  concentrations 
of total thyroxine and tri-iodothyronine (Ludwig & Goldberg, 1963). This 
may be at least partly explained by increased thyroid binding globulin 
(Hollander et al, 1967). An elevation of serum  asparate  and alanine 
transam inases and creatinine kinase may occur during the acute attack 
and is probably the resu lt of muscle n ecrosis . Glucose m etabolism  is 
deranged during the acute attack, the glucose tolerance frequently being 
diabetic in type (Waxman et al, 1967). There is delayed but excessive 
insulin secretion after a glucose load and this may resu lt in hypoglycaemia 
several hours afte r glucose ingestion, H ypercholesterolaem ia occurs in 
about 50% of patients during the acute attack (Taddeini e t al, 1964).
Examination of C, S. F. is usually norm al but slight elevation of the protein 
is som etim es seen (Stein & Tschudy, 1970).
Electrophysiology - The electroencephalogram  is abnorm al in the m ajority 
of patients experiencing an acute attack and in a proportion this p e rs is ts  
during rem ission (Albers et al, 1978). This usually takes the form of a 
generalised slowing of the record  and in addition focal abnorm alities may 
be evident. Peripheral nerve conduction studies in the presence of clinically 
established neuropathy show changes consistent with axonal injury predominantly 
of m otor nerves (Cavanagh & Mellick, 1965). Wochnik-Dyjas e t al (1978) 
found nerve conduction abnorm alities which were initially reversib le  and only
16.
som etim es proceeded to axonal degeneration (Wochnik-Dyjas e t al, 1978).
2. 3. 6. Factors which may Precipitate Acute Attack 
Precipitating factors can be identified in the m ajority of patients 
presenting in acute attack (Figure 7). Drugs a re  the m ost common 
culprits, barb itu rates and the oral contraceptive pill heading the league.
Alcohol is another common precipitating agent. Hormonal fac to rs are  
im portant. Acute attacks rare ly  occur before puberty and a re  particu larly  
common during pregnancy and the puerperium . Many women with acute 
porphyria a re  troubled with recu rren t attacks in the week p r io r  to the onset 
of m enstruation. The hormonal factors undoubtedly explain why attacks 
a re  seen m ore commonly in fem ales, particu larly  between the ages of 20 
and 30 years. Attacks may also be precipitated by dieting o r fasting and 
acute infections. All of these precipitating factors are  capable of inducing 
hepatic ALA synthase and the m echanisms involved will be d iscussed in 
detail in Chapters 5-8,
2 .3 .7 . Management of Acute Attack of Porphyria
In patients presenting in an acute attack of porphyria it is im portant to 
identify and where possible remove any precipitating fac to rs . Fluid and 
electrolyte balance should be monitored and corrected appropriately . The 
maintenance of adequate carbohydrate intake is essen tia l. It is known that 
calorie restric tion  can precipitate attacks and also that the maintenance of 
a good carbohydrate intake reduces the incidence of attacks (Welland e t al, 1964; 
Felscher & Redeker, 1967). Carbohydrates have been shown to block the
Precipitating Factors 
for Acute Hepatic Porphyria
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induction of hepatic ALA synthase and many other enzymes and this 
has come to be known as the "glucose effect" (Tschudy et al, 1964;
Goldberg, 1974). Acute attacks a re  generally associated with nausea 
and vomiting and thus reduced caloric intake, which alm ost certainly 
aggravates the attack. This cycle must be broken. Adequate caloric 
intake may be maintained orally using high calorie drinks. Chlorpromazine 
or promazine may be helpful in alleviating the nausea and vom iting.
Improved o ra l calorie intake may be achieved by slow continuous infusion 
via a soft thin nasogastric  tube. The infusion of 20% laevulose (2 litre s  per 
24 hours) via a central venous line resu lts  in biochemical and clinical 
improvement in m ost patients (Brodie et al, 1977).
Great care must be taken in o rder to ensure that the patient is not prescribed 
any of the contra-indicated drugs. Analgesics a re  usually required to 
relieve the abdominal pain. Aspirin, paracetam ol, dihydro codeine, 
pethidine, morphine o r diamorphine may be used according to the severity 
of the symptoms. The abdominal pain of acute porphyria is sometim es 
very refrac to ry  and some patients require large frequent doses of 
in tram uscular narcotic  analgesics. Severe postural hypotension may 
resu lt from the use of powerful narcotics, especially if combined with any 
of the phenothiazmes. This can be treated  by keeping the patient horizontal 
and if necessary  elevating the foot of the bed. A fu ller understanding of 
the mechanism of the abdominal pain might promote m ore effective treatm ent.
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It has been suggested that it is due to autonomic neuropathy leading to 
imbalance of the innervation of the gut, with resultant a re a s  of spasm 
and dilatation (Gibson & Goldberg, 1956). Bowel spasm s have been 
observed in patients with acute porphyria subjected to laparatom y (Mason 
et al, 1933). The use of ganglion blocking drugs and splanchnicectomy 
have been tried  but with limited success (Wehrmacher, 1952). The 
hypertension and tachycardia which frequently occur in an acute attack 
can be controlled by adequate doses of propranolol (Douer e t al, 1978).
T here is also  some evidence that propranolol may have a beneficial effect 
on the abnorm al porphyrin metabolism (Blum & Atsmon, 1976). Severe 
agitation and other form s of psychiatric disturbance which may occur can 
be controlled with promazine or chlorprom azine. Diazepam may also be 
used. If long term  a n ti-convulsant therapy is required, sodium valproate 
may be safely used. Constipation is usually a problem and neostigm ine may 
be required to alleviate this.
The main innovation in the treatm ent of acute porphyria over the past decade 
has been the adm inistration of haem in the form of intravenous haematin.
The place of intravenous haematin and intravenous laevulose in the treatm ent 
of the acute attack of porphyria is examined in detail in Chapter 9.
Preventive medicine has an im portant role to play in the management of
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the acute porphyrias. Patients with the genetic tra it  m ust be identified 
and advised regarding the avoidance of precipitating fac to rs . The 
screening of patients for latent acute porphyria Is exam ined in detail in 
Chapter 4.
2 .4 . PORPHYRIA VARIEGATA
2 .4 .1 . Introduction
Porphyria variegata is so called because it p resen ts with both acute attacks 
of neurological dysfunction, as seen in acute interm ittent porphyria, and 
with photosensitive skin eruptions. It is inherited as  a Mendelian 
autosomal dominant tra it. The d isorder was described and named in 
South Africa by Dean & Barnes (1955) who traced over a thousand patients 
with porphyria variegata to a Dutch Cape se ttle r  who m a rrie d  an orphan 
g irl in 1688. The prevalence of the d isorder varies from  country to 
country and appears to be highest in the white population o f South Africa 
where it is estim ated to be 3 per 1, 000 (Dean, 1971). Porphyria V ariegata 
may presen t in an identical fashion to acute interm ittent porphyria with acute 
attacks of neurological dysfunction and no cutaneous m anifestations (Kram er, 
1980). More usually patients in acute attack will show evidence of photo­
sensitive skin eruptions. Patients may also p resen t so lely  with the cutaneous 
m anifestations. The prominence of the skin lesions is la rg e ly  determ ined by 
the extent of exposure to sunlight.
2 .4 .2 . Underlying Biochemical D isorder
The disease is m ost probably the re su lt of deficiency of the enzyme
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protoporphyrinogen oxidase. In 1979, Brenner and Bloomer dem onstrated 
a 50 per cent reduction of activity of the enzyme in fibroblasts of patients 
with variegate porphyria. Patients have m arkedly increased faecal 
excretion of protoporphyrin and to a le s s e r  extent coproporphyrin (Barnes, 
1958). T here is also a considerable increase of the porphyrin peptide 
complex known as porphyrin X in the faeces (Rimington et al, 1968;
Eales et al, 1975). There may be increased urinary  excretion of 
coproporphyrin and to a le s se r  extent uroporphyrin. During an acute 
attack there  is markedly increased urinary  excretion of ALA and PBG 
and also of uroporphyrin; the la tte r  probably being due to non-specific 
conversion from  PBG. In porphyria variegata there  is a close correlation 
between the urinary excretion of ALA and PBG and the m anifestations of 
acute neurological attacks (K ram er et al, 1973).
2 ,4 .3 . Cutaneous Manifestations
The skin lesions of porphyria variegata occur on the sun-exposed a reas  
(back of the hands, lower arm s, face and neck) as illustrated  in Figure 8,
The most im portant feature is increased skin fragility; m inim al traum a
being sufficient to cause lesions even to unblemished a re a s  of skin. Lesions
usually s ta rt as erythem a progressing to vesicles that become confluent to
form bullae. Haemorrhage may occur into the bullae which heal leaving
scars . There may be local pitting oedema at the site of lesions. Hyperpigmentation
Figure 8
This 48 year old woman developed a bullous eruption 
following sunbathing and was found to have porphyria variegata.
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may occur and h irsutism  may be troublesom e in women. Light microscopy 
examination of the skin shows the presence of an amorphous m aterial 
around the sm aller blood vessels and capillaries which stains strongly 
with PAS (Findlay et al, 1966; Van der Sar & Den Ouden, 1976). The 
bullae a re  commonly subderm al ra th e r than intraderm al in type (Magnus, 
1968).
The skin lesions In the porphyrias appear to be the re su lt of interaction 
between porphyrin deposited in the skin and visible light (Magnus, 1980). 
Monochromator studies dem onstrate that light of the same wavelength as 
that absorbed by the porphyrin molecule (4Q0nm) will cause skin lesions 
in the porphyric patient. Absorption of a suitable quantum of light is 
thought to convert the porphyrins into the so-called "trip le t state". The 
porphyrins, in this excited and reactive state, then tra n sfe r their energy to 
oxygen form ing a molecule of excited oxygen. The cellu lar damage is 
probably the re su lt of the excited oxygen forming oxidized products of 
biological substrates.
2 ,4 .4 . Management
The treatm ent and prevention of acute neurological attacks of porphyria 
variegata is the same as for acute interm ittent porphyria. There is no 
s p e c ific  tre a tm e n t fo r  the d e rm a to lo g ic a l m a n ife s ta tio n s . P atien ts should 
avoid exposure of skin to sunlight or strong daylight. The wavelength of 
light which is m ost damaging to the skin Is within the visible spectrum  and 
therefore the ultraviolet b a rrie r  cream s used to protect against sunburn are
of little use. Cream s filtering visible light would of necessity  be opaque 
and therefore unacceptable for cosmetic reasons. There is evidence that 
Beta-carotene may block the interaction of the light and porphyrin molecule 
and in this way offer a degree of protection (Magnus, 1980).
2 .5 . HEREDITARY COPROPORPHYRIA
2 .5 .1 . Introduction
H ereditary coproporphyria is the leas t common of the acute porphyrias.
The disease was named in 1955 by Berger and Goldberg when they 
reported  four cases in a Swiss family. It is inherited a s  an autosomal 
dominant and often rem ains clinically latent (Brodie & Goldberg, 1980).
It p resents with attacks of neurological dysfunction. T hese a re  sim ilar 
to the attacks seen in acute interm ittent porphyria though generally less  
severe. During an attack patients may develop photosensitive skin eruptions 
s im ilar to that seen in porphyria variegata. The skin lesions in 
hereditary  coproporphyria are  ra re ly  seen outwith an attack  (Goldberg 
e t al, 1978).
2 .5 .2 . Underlying Biochemical D isorder
H ereditary coproporphyria is thought to be due to a p a rtia l deficiency of 
the enzyme coproporphyrin on gen oxidase. This was dem onstrated in 
circulating leucocytes by Brodie et al in 1977 and la te r  in cultured skin 
fibroblasts (Elder et al, 1976) and lymphocytes (Grandchamp et al, 1978). 
Patients with hereditary  coproporphyria excrete large am ounts of
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coproporphyrin of the isom er III type in faeces and^to a le s se r  extent^ in 
urine (M arver & Schmid, 1972; Goldberg e t al, 1967). As in the other 
form s of acute porphyria^neurological attacks are associated with 
increased urinary excretion of ALA, PBG and uroporphyrin. As in 
acute interm ittent porphyria, 17 oxosteroids are  excreted in excess in 
this disease (Paxton et al, 1975).
2 .5 ,3 . Management
Prevention and treatm ent of acute neurological attacks is as for acute 
interm ittent porphyria. In addition,patients should be advised to avoid 
over-exposure to sunlight.
2 ,6 . RELATIONSHIP BETWEEN THE UNDERLYING BIOCHEMICAL 
DISORDER AND NEUROLOGICAL MANIFESTATIONS IN THE 
ACUTE HEPATIC PORPHYRIAS
2 .6 .1 . Introduction
The underlying biochemical d isorder in the acute hepatic porphyrias is 
now clearly  defined as  a partia l deficiency of one of the interm ediate 
enzymes of haem biosynthesis. This resu lts  in partia l haem deficiency 
and, therefore, de rep ress  ion of the initial and rate-controlling enzyme,
ALA synthase. The main biochemical consequences are  a) haem deficiency 
and b) excess of the haem p recu rso rs  formed p rio r to the block. The 
abnorm ality of haem biosynthesis in the acute porphyrias is p resen t in 
m ost and probably all body tissues (Brodie et al, 1977).
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The other generally accepted fact about the acute porphyrias is that all 
the clinical m anifestations of the disease can be explained by neurodysfunction 
involving the peripheral, central and autonomic nervous system s (Figure 
9 ). There a re  only a few studies of the morphological changes in 
nervous tissue in patients with acute porphyria. It is unethical to obtain 
adequate biopsies of nervous tissue during life and published studies are  
virtually  all from post-m ortem s of patients dying in acute attack. Studies 
in such patients have not always shown significant morphological changes 
and the changes which have been reported do not constitute any pathognomonic 
lesion. Gibson and Goldberg (1956) noted demyelinization and axonal 
degeneration in peripheral and autonomic nerves and also  chrom atolysis 
and vacuolization in the brain and spinal cord. Ten Eyck e t al (1961) 
noted patchy demyelination and axonal degeneration scatte red  at all levels 
of the neuraxis. Sim ilar changes w ere reported by Tschudy e t al (1975).
All of these neurohistological changes a re  non-specific and may be seen in 
a variety of toxic conditions.
The main unanswered question in the acute porphyrias is the relationship 
between the underlying abnormality in haem biosynthesis and the functional 
and s tructu ral d iso rder of the nervous system . A num ber of possibilities 
have been postulated and are  discussed below.
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2. 6 . 2. Porphyrin P recursor Neurotoxicity Theory
The sim plest explanation is that the excess circulating ALA or PBG or
m etabolites, which are  mainly hepatic in origin, are  neurotoxic. This
initially appears plausible as excess ALA and PBG are  a constant feature
of attacks of acute porphyria. Neurodysfunction does not occur in the
non-acute porphyrias (cutaneous hepatic porphyria, erythropoietic
protoporphyria and congenital porphyria) which a re  also due to hereditary
enzyme deficiencies in the pathway of haem biosynthesis and resu lt in
overproduction of porphyrins but not of porphyrin p recu rso rs . F or the
"porphyrin p recu rso r neurotoxicity" hypothesis to be tenable these substances
m ust firstly  be able to gain access to the nervous system . The few studies
of CSF concentrations in patients in acute attacks of porphyria (Percy &
Shanley, 1977; Bonkowsky et al, 1971) have shown that both a re  p resen t but
a t concentrations of less  than 20 p er cent of serum  levels. Moore and
14M eredith (1976) studied, in ra ts , the tissue concentrations of C labelled 
ALA injected intraperitoneally in a dosage of 330 ug/kg. They found brain 
concentrations of 5-10 p e r cent of blood levels. Tenability of the neurotoxicity 
theory also depends on the ability of these substances to cause neurodysfunction. 
Goldberg e t al (1954) w ere unable to dem onstrate any pharm acological effects 
of PBG. M arcus et al (1970) adm inistered high doses of ALA (3. 3 m m ol/kg) 
to ra ts  and noted no FFG or behavioural changes. Watson et al (1978) 
reported that the adm inistration of ALA and PBG to nephrectom ized ra ts
26.
resulted In no alteration of blood p ressu re  or nervous behaviour. In 
allylisopropylacetam ide-induced chemical porphyria, in which high 
blood levels of porphyrin p recu rso rs  occur, no neurological effects 
have been observed (Marcus e t al, 1970). More recently, however.
Cutler et al (1979) reported behavioural changes following the injection 
of ALA (1. 6 m m ol/kg) in ra ts . Several w orkers have repo rted  a variety 
of effects of ALA on neuro-m uscular function in a variety  of in-vitro  
preparations (McGillion, et al, 1975; Loots e t al, 1975; Becker et al, 1975;
C utler et al, 1978, Becker e t al, 1971; Becker & K ram er, 1977). No
studies in acute porphyria to date, however, have shown CSF levels
comparable with those required to produce neurological changes in these
in-vitro  models (Percy & Shanley, 1977). ALA is stru c tu ra lly  sim ilar to
the n eu ro -tran sm itte r gamma aminobutyric acid (GABA) and has been shown
to have GABA agonist effects in anim als at concentrations s im ila r  to those
occurring in acute porphyria (Muller & Snyder, 1977), The relevance,
however, of these conflicting reports  of minor behavioural and neuropharmacological
effects of ALA to the severe and widespread functional and s tructu ra l neuronal
changes seen in human acute porphyria m ust rem ain in doubt. Another obstacle
for acceptance of the neurotoxicity theory is the poor corre la tion  in clinical
practice between the urinary excretion of ALA and PBG and the presence and
severity of neurodysfunction (Miyagi et al, 1971; Watson e t al, 1978). Some
patients have very high levels of porphyrin p recu rso rs  in blood and urine
without any clinical disease w hereas in others widespread neuropathy may
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be seen with only m inimally elevated levels. Even within individual 
patients there is poor correlation of urinary porphyrin p recu rso r 
excretion and clinical disease activity. Variations in blood brain 
b a rr ie r  perm eability may be important.
2. 6. 3. D isordered Haem Synthesis within nervous tissue
The other main theory explaining the neurodysfunction of acute porphyria 
is that it is the resu lt of disordered haem biosynthesis within nerve cells.
This could resu lt in deficiency of essential haemoproteins such as
m itochondrial cytochromes required for oxidative phosphorylation or
m icrosom al cytochromes that catalyse mixed function oxidation (Meyer
& Schmid, 1974; Maxwell & Meyer, 1974). If the neuropathy of acute
porphyria is due to im paired intra-neuronal haem biosynthesis then the
precipitating factors of acute attacks must be capable of modifying neuronal
haem biosynthesis. L ittle is known of the regulation of neuronal haem
biosynthesis, Paterniti et al, (1978) w ere unable to induce ra t brain ALA
synthase with fasting o r intraperitoneal injections of a lc o h o l ,  allylisopropylacetam ide or
3, 5 dicarbethoxy-1. 4 dihydro collidine, Percy & Shanley (1979) w ere unable 
to detect any alteration in ra t brain ALA synthase activity, total haem or 
cytochrome P450 levels following intraperitoneal injections of allylisopropylacetam ide 
and /o r phenobarbitone. The rate of haem degradation in ra t brain is also
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unaffected by phenobarbitone, lead and allylisopropylacetam ide (Percy & 
Shanley, 1980). The inability to dem onstrate alterations in haem 
m etabolism in nervous tissue by porphyrinogenic agents ca s ts  doubt 
on the above theory.
2 .6 .4 . Other Postulated Mechanisms for Porphryic Neuropathy 
The abnorm ality of haem biosynthesis in the liver could affect the nervous 
system  by m echanisms other than the overproduction of haem  p recu rso rs . 
Pepplinkhuizen et al (1980) propose that the abnormal hepatic haem 
biosynthesis resu lts  in abnormal méthylation o r cyclisation of monoamines 
which could have a psychotogenic effect. The mechanism postulated is 
that the increased demand for glycine will be m et by dém éthylation of 
serine and that the released  methy^^^^ group will resu lt in méthylation of 
monoamines. Another possibility is that abnorm al hepatic haem biosynthesis 
may resu lt in deficiency of important haemoproteins requ ired  for norm al 
hepatic m etabolism . Anderson et al (1976) showed that patients with 
acute porphyria have Impaired hepatic metabolism of adm inistered  antipyrine 
and that this was m ost marked in those with the m ost sev e re  clinical history. 
Deficiency of certain hepatic haemoproteins could re su lt in im paired clearance 
of endogenously produced neurotoxins or im paired synthesis of factors 
essen tia l for the integrity of the nervous system .
The biochemical explanation for the neurological dysfunction in acute porphyria 
rem ains to be discovered. Its pursuit is im portant as  it  is likely to be of
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relevance to a wide range of neurological d isorders in addition to the 
porphyrias. Clinical studies of intravenous haematin therapy may be 
helpful in th is respect and this is discussed in detail in C hapter 9.
2. 7. THE NON-ACUTE PORPHYRIAS
2 ,7 .1 , Introduction
The non-a cute porphyrias a re  so named because they do not cause the 
attacks of neurological dysfunction characterizing the acute porphyrias.
Instead, they present with photosensitive skin eruptions, s im ila r  to 
that described for porphyria variegata and due to increased circulating 
levels of formed porphyrins. The levels of porphyrin p recu rso rs  a re  
norm al in the non-acute porphyrias, the ir accumulation being prevented 
by Increased activity of uroporphyrinogen-1 -synthase (Brodie et al, 1977).
2 .7 .2 . Cutaneous Hepatic Porphyria (Porphyria Cutanea T arda)
Cutaneous Hepatic Porphyria is the commonest form of porphyria seen in 
Europe and North Am erica. It is characterized by accumulation and 
increased urinary  excretion  of uroporphyrin which is due to deficiency of 
hepatic uroporphyrinogen decarboxylase activity (Kushner et al, 1976;
E lder at al, 1978). Both hereditary  and acquired factors a re  important 
in the aetiology of this enzymatic deficiency. A proportion of patients 
have affected relatives and family studies have shown a reduced activity 
of uroporphyrinogen decarboxylase in erythrocytes which is  inherited in 
an autosomal dominant fashion (Tiepermann et al, 1978; VerneuU et al, 1978).
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In most cases, however, there is no family history and the erythrocyte 
uroporphyrinogen decarboxylase activity is norm al. A cquired factors 
a re  important in all cases of cutaneous hepatic porphyria including the 
fam ilial ones described above. Chronic alcohol abuse resu ltin g  in 
varying degrees of hepatic dysfunction seem s to be the commonest 
precipitating agent (Brunsting, 1954) (Figure 10a and b). The relative 
contributions of the alcohol, liver damage and the alm ost constantly 
associated hepatic siderosis to the biochemical d iso rder i s  not known. 
Oestrogen adm inistration may also precipita te cutaneous hepatic  porphyria 
and there have been repo rts  of cases developing in men receiv ing  
oestrogen therapy for pro static cancer (Roenigk & Gottlab, 1970) and 
in young women on the contraceptive pill. A num ber of chem ical agents 
can resu lt in cutaneous hepatic porphyria. There was a fam ous outbreak 
in Turkey between 1956 and 1960 when several thousand new  cases appeared 
and this was found to be the resu lt of the bread being contaminated with 
hexachlorobenzene which had been sprayed onto the wheat a s  a fungicide 
(Dean, 1971). Cutaneous hepatic porphyria was also  found in a survey 
of chemical w orkers in a 2, 4-dichlorophenoxy-acetic acid and 2, 4, 5- 
trichlorophenoxy acetic  acid plant (Poland et al, 1971), S im ila r effects 
a re  likely to be associated with many halogenated hydrocarbons (Elder, 
1976).
The management of cutaneous hepatic porphyria involves the indent if icat ion 
and withdrawal of precipitating factors and this will resu lt in biochemical
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and clinical improvement. Most cases a re  associated with hepatic 
siderosis and rem oval of iron by venesection accelera tes the improvement 
(Lundvall & We infield, 1968). There a re  some reports  of the use of 
chloroquine (125mg twice weekly) in the treatm ent of cutaneous hepatic 
porphyria (Swanbeck & W ennersten, 1977). This initially re su lts  in 
m arked increase of urinary porphyrin excretion followed by biochemical 
and clinical rem ission, though the exact mechanism of the chloroquine 
effect is poorly understood.
2. 7. 3. Erythropoietic Protoporphyria
Erythropoietic Protoporphyria is inherited in a Mendelian autosomal 
dominant fashion and may present at any age including infancy and 
childhood (Lynch & Miedler, 1965), It is characterized by overproduction 
and accumulation of protoporphyrin which is m ost m arked in erythropoietic 
tissue . This is due to deficiency of the enzyme fer roche lata se which inserts  
iron into protoporphyrin to form haem. The excess protoporphyrin is 
excreted solely and in high concentrations in the bile. T here  may be 
deposition of protoporphyrin crystals  in the biliary system  and liver cells 
and this can resu lt in cholestasis, hepatitis, c irrhosis  and liver failure 
(Bloomer, 1979), Once liver damage is initiated and cholestasis develops 
the protoporphyrin cannot be excreted and there is consequently a rapid 
accumulation in the liver. The common history of patients with protoporphyria 
who have died in liver failure is that death occurred within a few months of 
the onset of jaundice. There is also an increased incidence of gall stones
àl.
in erythropoietic protoporphyria (Deleo et al, 1976). The oral
adm inistration of the chelating agent cholestyramine interrupt § the
enterohepatic circulation of protoporphyrin and may prevent hepatobiliary
complications (Strathers, 1966; Kniffen, 19 7P). B-carotene may be useful in 
controlling the cutaneous manifestations (Magnus 1980).
2 .7 .4 . Congenital (Erythropoietic) Porphyria
This is the ra re s t form of porphyria and is inherited in a Mendelian 
autosomal recessive  fashion (Dean, 1971). It presents usually in early 
childhood and the photosensitive skin lesions are  m ore severe than in any 
of the other porphyrias. There is increased urinary and to a le sse r extent 
faecal excretion of uroporphyrin. Erythrocyte and plasm a levels of 
uroporphyrin, coproporphyrin and protoporphyrin are  also mcreased. 
D ecreased activity of the enzyme uroporphyrinogen-III-cosynthase has 
been dem onstrated in erythrocytes (Romeo et al, 1970).
Haematological abnorm alities a re  also a feature of congenital porphyria. 
Splenomegaly is a consistent finding and there is usually a normochromic, 
normycytic anaemia with a m oderate reticulocytosis. Leucopenia and 
thrombocytopenia may also occur as part of the picture of hypersplenism. 
Erythrokinetic studies by Kram er e t  al (1965) suggested that the anaemia 
of congenital p o rp h y ria  is due to ineffective erythropoiesis and shortened 
red cell survival. Splenectomy improves both the anaemia and the skin 
m anifestations though the long term  prognosis rem ains poor.
C H A P T E R  3
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3. MATERIALS AND METHODS
3. 1. PORPHYRINS AND THEIR PRECURSORS 
U rinary ALA and PBG were m easured by the method of M auzerall and 
Granick (1956). Urinary uroporphyrin and coproporphyrinland erythrocyte 
and faecal coproporphyrin and protoporphyrin,were m easured as described 
by Rimington (1971). The norm al ranges for the aboveiare shown in 
Table 1.
3 .2 . ENZYMES OF HAEM BIOSYNTHESIS IN PERIPHERAL BLOOD CELLS
3 .2 .1 . Preparation of Blood
30 ml of venous blood was withdrawn from the subject and placed in 3 x 10 ml 
lithium heparin containers standing in melting ice. This was delivered to 
the laboratory within 15 min. 25 ml of the sample was centrifuged at 
2, 500 g for 30 min at 4°C. During centrifugation the rem aining 5 ml of 
whole blood was used for estim ating the packed cell volume and activity of 
ALA dehydratase. The plasma was removed from the centrifuged blood 
and the leucocyte layer separated from the erythrocytes using a glass rod.
The activ ities of the mitchondrial enzymes, ALA synthase, coproporphyrinogen 
oxidase (COPRO oxidase) and ferrochelatase, were m easured in leucocytes 
and the activities of the cytosolic enzymes ALA dehydratase, uroporphyrinogen- 
1 -synthase (URO synthase) and uroporphyrinogen decarboxylase in erythrocytes.
ERYTHROCYTE
Protoporphyr in
C opr opor phy r  in
0 - 657 nmol/1
0 - 6 4  nmol/1
FAECES
Protoporphyrin
Coproporphyrin
0 - 200 nmol/g  dry wt.
0 - 7 6  nm ol/g dry wt.
URINE
Delta-aminolaevulinic
acid
Porphobil inogen
Uroporphyrin
Coproporphyrin
0 - 4 3  umol/1 
( 0 - 4 0  umol/24h)
0 - 2 5  umol/1 
(0 - 16 umol/24h)
0 - 2 2  nmol/1 
( 0 - 4 9  nmol/24h)
0 - 227 nmol/1 
(0 - 432 nmol/24h)
Table 1
Normal ranges for porphyrins and p recu rso rs  in erythrocytes, 
urine and faeces of man.
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3 ,2 .2 . Leucocyte Enzyme Assays
The leucocytes were washed four tim es in ice-cold isotonic saline 
solution. The washed cells were lysed by freeze-thaw ing in liquid 
nitrogen and sonication^and then split into aliquots for assay  of ALA 
synthase, COPRO oxidase, ferrochelatase and protein. Protein was 
m easured by the method of Lowry et al (1951).
Leucocyte ALA synthase (EC 2. 3. 1. 37)
This was m easured by a modification of the method of F reshney & Paul 
(1970). In this 200 ul of the white cell homogenate w ere incubated with 
200 ul of reaction m ixture containing 2 (^^C) glycine as substrate (250 uCi), 
and a total glycine concentration of 375 m m ol/I. This was incubated for 
1 h at 37°C in a shaking w ater bath. The reaction was stopped by addition 
of 100 ul of a solution of 51 uM delta-am inolaevulinic acid in 1.5 M 
trich lo ro -acetic  acid. The precipitate was removed by centrifugation and 
20 ul of the clear supernatant solution spotted on to s tr ip s  of Whatman 3 MM 
paper for e lectrophoresis. Delta-aminolaevulinic acid and glycine w ere 
separated by running the electrophoretogram s for 4 h at 2000V at 4^C in 
potassium  phthalate buffer (0.05 M at pH 4). A fter electrophoresis,the spots 
w ere identified with a ninhydrin solution, cut out,and oxidized in a sample 
oxidizer (Intertechnique) p rio r to beta counting in a scintillation counter 
(Packard trica rb ). The resu lts  were expressed as nmol ALA produced per 
g protein/h.
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Leucocyte COPRO oxidase (EC 1. 3. 3. 3)
This was assayed according to a modification of the method of Battle et 
al (1965), Coproporphyrinogen was prepared from coproporphyrin by 
reduction with 3 per cent (w/w) sodium amalgam under nitrogen in the 
dark. The coproporphyrinogen was then separated by filtra tion  through 
a sintered tube into a Buchner flask containing 0.13 ml sodium thloglycollate 
(2 M) and subsequently brought to pH 7.4 with 40 per cent (w/v) phosphoric 
acid. 200ul of th is solution of coproporphyrinogen w ere taken with 2.5 ml 
of t r is  buffer (0. 01 M) pH 7.4 and 400 ul of the leucocyte preparation into a 
25 ml E rlenm eyer flask which was closed with a cotton wool stopper. This 
was incubated with shaking at 37°C in the dark for one hour. The reaction 
was stopped with 10 ml 4 : 1 ethyl acetate : acetic acid solution mixed and 
left in full daylight for 30 min to convert the residue of coproporphyrinogen 
to coproporphyrin. Protoporphyrin produced by this reaction was extracted 
and quantitated by the method of Rimington (1971). R esults w ere expressed 
as nmol protoporphyrin produced p er g protein/h.
Leucocyte Ferrochelatase (EC 4. 99. 1. 1)
This was assayed by a modification of the method of Forra  (1975). In this 
400 ul of the leucocyte preparation was added to 1.5 ml t r i s  buffer (pH 8. 2,
0.45 M) containing 1.5 mg reduced glutathione. This w as incubated with 0. 5 ml
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free mesoporphyrin (in 0.13 M sodium bicarbonate) for 10 min at 37°C.
1 ml of iron solution (16 uM Fe Clg in t r is  buffer pH 8 .2 ) was then added 
and the incubation continued for 1 h at 37*^ C in the dark. The reaction 
was stopped using alkalinized iodoacetamide and pyridine. The solution 
was then divided into two cells and a sm all amount of sodium diothionate 
added to the test cell. The te st cell was scanned against the control cell 
spectrophotom etrically from 600-500 nm. The resu lts  w ere expressed 
as pmol haem per g protein/h.
3. 2. 3. Erythrocyte Enzyme Assays 
Erythrocyte ALA dehydratase (EC 4. 2. 1. 24)
This was assayed using 0. 2 ml whole blood by the EEC standard method 
(Berlin & Schaller, 1974). The resu lts  were expressed as umol ALA 
formed per litre  RBC/min.
Erythrocyte URO synthase (EC 4. 3. 1. 8)
T his was assayed by the method of Frydman & Feinstein (1974). In this 
assay  washed red cells were sonicated in an equal volume of phosphate buffer 
(83 mmol/1) pH 7. 65. P rior to sonic at ion an aliquot was taken for packed 
cell volume determ ination. 0. 2 ml of this sonicated m ateria l was taken and 
incubated with 0. 1 ml of porphobilinogen solution (0. 82 mmol/1) and 1 ml of 
a solution of reduced glutathione (3.25 mmol/1) in phosphate buffer (S3 mmol/1) 
pH 7. 65. This was incubated in stoppered tubes in the dark for one hour at
37.
37*^ C and the reaction stopped by the addition of 9 ml of a 2:1 solution of 
ethyl acetateracetic acid. This was centrifuged to rem ove the precipitate 
and the precipitate re-ex tracted  with 5 ml aliquots of 2:1 ethyl acetate: 
acetic acid until no m ore porphyrin fluorescence was observed. The total 
volume of extract was noted and 0.4 ml mixed with 5 ml 0,5 M HCl. The 
fluorescence in th is sample was m easured on a spectrofluorim eter to 
m easure the formation of uroporphyrin. Results w ere expressed as 
nmol uroporphyrin form ed/I it re  RBC/h.
Erythrocyte uroporphyrinogen decarboxylase (EC 4. 1. 1, 37)
This method,based on that of Frydman & Feinstein (1974),utilizes two 
stages. The firs t, to produce uroporphyrinogen the substra te  for the 
reaction, is based on the previous assay of URO synthase.
For the firs t stage 0.2 ml of washed RBC haemolysate in phosphate buffer 
pH 7.65 was incubated as described for URO synthase for one hour at 37°C.
At the end of this hour 0.19 ml of a solution of potassium  dihydrogen 
orthophosphate (0.4 M) was added to the reaction m ixture and the 
incubation continued for another hour at 37°C, The reaction was stopped 
with 9 ml 2:1 ethyl aceta te :acetic  acid, and extractions continued with this 
until no further porphyrin fluorescence could be extracted from the precipitate. 
The combined extract was then back-extracted with a saturated solution of 
sodium acetate until all uroporphyrin had been extracted into the acqueous 
phase. The ethyl ace ta te /acetic  acid phase, containing the synthesized
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coproporphyrin was then treated  as for blood-porphyrin estim ations 
(Rimington, 1971) and the resu lts  of the assay expressed as nmol 
coproporphyrin produced/litre  RBC/h.
3 .2 .4 . Normal Range for enzymes and effect of age, sex and tim e of day 
The activ ities of the enzymes of haem biosynthesis in peripheral blood 
cells w ere studied in 62 healthy volunteers. Twenty eight w ere female 
and 34 m ale and the mean age was 34 years (range 9-82 years). All had 
norm al haemoglobin, erythrocyte protoporphyrin and blood lead 
concentrations. None was taking any form of m edication and all refrained 
from alcohol for 48 h p rio r to testing. None of the fem ales studied were 
pregnant or taking the contraceptive pill. The activ ities of each of the 
6 enzymes studied in these healthy subjects showed a norm al distribution 
and the mean values, standard deviations and ranges a re  shown in Table 2.
N either age or sex had any significant effect on the activ ities of the enzymes 
as  shown in Tables 3 and 4 . In 8 subjects the enzymes w ere studied at 9a.m . 
and at 10p.m. on the same day. Erythrocyte ALA dehydratase was 
si^yiificantly increased in the evening (Figure 11) but the other enzymes 
showed no evidence of diurnal rhythm (Table 5 ).
3. 3. HEPATIC ALA SYNTHASE AND CYT F450 
IN EXPERIMENTAL ANIMALS
The anim als (ra ts  and rabbits) w ere killed by cervical dislocation. The 
abdominal cavity was opened and the liver perfused with 10 ml isotonic 
saline (0. 15 M) at 30°C. The liver was then excised, chilled on ice and
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Erythrocyte ALA dehydratase activity was higher in the evening than 
m the morning in each of the 10 norm al subjects studied.
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blotted dry. Aliquots were taken and weighed for ALA synthase and 
Cyt P450 determ ination. For ALA synthase, 2 g hepatic tissue was 
homogenized in 6 ml Homogenisation Mixture. 200 ul of the homogenate 
was then used for the enzyme determ ination as already described for leucocyte 
ALA synthase. Hepatic Cyt P450 content was determined on m icrosom al 
pellets using spectrophotom etry,as described by Omura & Sato (1964).
3 .4 . PREPARATION OF HAEMATIN SOLUTION 
The haematin was prepared as personally communicated by Professor 
C .J. Watson (Minneapolis). Hemin was firs t prepared by slowly adding 
250 ml of centrifuged and washed human red blood cells (Hbs Ag negative) 
to one litre  of glacial acetic acid containing 1 ml of saturated Na Cl at 
105°C. The tem perature was maintained and the solution s tirred  for 
15 min. It was then allowed to cool slowly at room tem perature. When 
the tem perature reached 40^C the solution was filtered (using a 12 cm 
Buchner funnel and 2 black ribbon filte r papers) and the hemin crystals 
washed successively with approximately 100 ml portions of 50% acetic 
acid, absolute alcohol and diethyl ether. The hemin was re  crystallized 
by dissolving every 1 g in 5 ml pyridine, adding 8 ml of chloroform and 
shaking vigorously. This solution was then filtered through a medium 
sintered g lass funnel and the undissolved m aterial washed with a few ml 
of CHC13. What remained on the filte r was discarded. The filtra te  was
40.
added slowly to 70 ml of glacial acetic acid containing 1 ml of saturated 
NaCl and 0,8 ml of concentrated HCl at 100-105^C. The tem perature 
was maintained for 10 min and then allowed to cool to 40°C,as before^ 
and filtered on a Buchner funnel (6-8 cm) using two red ribbon filter 
papers. The crystals  were washed as described above and allowed to 
pull dry.
The haematin solution for intravenous adm inistration was prepared 
from the re  crystallized hemin with the assistance of the pharmacy 
departm ents of StobhUl Hospital and the W estern Infirm ary. This was 
done under lam iner flow sterile  cabinets. 300 mg of hemin was dissolved 
in 5 ml of 1% Na Carbonate. This solution was then filtered through a 
60 ml fine sintered glass filte r assisted  by washing with sm all amounts of 
slightly warmed 0,25% Na Carbonate solution. The pH of the filtrate was 
adjusted to 8 with HCl (1. 5N - 0. 3N) using a pH m eter. It was then filtered 
through a 0 .2  um Nalgene filter (catalog 120-0020) with gentle suction. The 
concentration of this final solution was 6-8 m g/m l and was stored in sterile  
ampoules at 4^C. Samples of the final solution w ere confirmed to be free 
of bacterial contamination by culturing for 2 and 7 days and to be pyrogen 
free by testing in rabbits.
3. 5. HORMONE ESTIMATIONS
The hormone estim ations were perform ed in collaboration with Dr. Michael 
Wallace of the Department of Steroid Biochemistry, Glasgow Royal Infirmary. 
Androstenedlone, dehydroepiandrosterone (DHA), DHA sulphate, oestradiol.
4L
progesterone and testosterone were m easured in human serum  by- 
radio immunoassay. A ntisera for oestradiol, progesterone and testosterone 
were raised  in sheep as described by Cook et al (1977). A ntisera 
against androstened ion e was obtained from Guildhay A ntisera, University 
of Surrey fief. No. HP/S/673 - lA). DHA anti sera  was purchased from 
Dr. B. Rudd, Department of Clinical Endocrinology, The Birmingham and 
Midland Hospital for Women. DHA sulphate was m easured by a non­
extraction method sim ilar to that described by Smith et al (1975). The 
other steroids w ere m easured after extraction into e th e r o r in the case 
of progesterone, N-Hexane. In all radioim m unoassays incubation with 
labelled steroid and anti serum  was for a period of at least 2 h, and antibody 
bound and free steroid were then separated with D extran-coated charcoal.
3.6 . ASSAYS FOR LEAD, ALCOHOL AND PHENYTOIN 
Blood lead concentrations were m easured by flam eless atom ic absorption 
spectrophotom etry (Perkin E lm er 306 and HGA 72). The blood alcohol 
concentration was m easured using gas liquid chromatography as described 
by Cooper (1971). Serum phenytoin concentration was m easured by gas 
chromatography as described by Thoma and Bondo (1974).
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4. SCREENING FOR ACUTE HEPATIC PORPHYRIA
4 .1 . INTRODUCTION
Each of the acute hepatic porphyrias (AIP, hereditary  coproporphyria 
and variegate porphyria) is inherited in an autosomal dominant fashion.
For every case presenting m clinical attack^there is a much la rg er 
num ber who a re  asymptomatic but at risk  of developing acute attacks on 
exposure to precipitating factors. It is important that these latent cases 
a re  identified and given appropriate counselling in o rd er to  prevent them 
developing attacks and to ensure early  diagnosis and treatm ent should one 
occur.
T here has been a number of studies of the use of urina lysis  and the m easurement 
of erythrocyte uroporphyrinogen-1 - synthase (E. URO synthase) activity for 
screening relatives of patients with A IP (Astrup, 1978 ; G re lie r et al, 1977; 
Doss & Tieperm ann, 1978 and Lam on et al, 1979). U rinalysis is of limited 
value as increased excretion of porphyrin p recu rso rs  is present in only 1 
in every 3 latent cases. The m easurem ent of the activity of E. URO synthase, 
which is depressed in AIP, is m ore sensitive but there is considerable overlap 
between norm al and porphyric subjects, and 20-40% of re la tives have values 
within the overlap zone. The interpretation of the E. URO synthase activity 
in association with the family pedigree is helpful in some cases and this 
combined with urinalysis perm its the classification of up to 90% of relatives
43.
(Lamon et al, 1979). There have been no reports of the use of enzyme 
assays to screen for latent cases of hereditary coproporphyria or variegate 
porphyria.
We have assessed  the value of m easuring, in peripheral blood cells, 
the activ ities of both the enzyme which is genetically deficient and the 
rate-contro lling  enzyme, ALA synthase, when screening relatives of 
patients with AIP o r hereditary  coproporphyria.
4. 2. ACUTE INTERMITTENT PORPHYRIA
4 .2 .1 . Subjects and Methods
The activ ities of leucocyte ALA synthase (L. ALA synthase) and E. URO 
synthase and the 24 h urinary  excretion of ALA and PEG were m easured in 
19 patients with AIP and 35 blood relatives. The norm al subjects described 
in Chapter 3 page 38 were used as controls.
The AIP patients included 7 m ales and 12 females and th e ir  mean age was 
30 years (range 8-45 years). All had experienced one or m ore symptomatic 
attacks with associated increased urinary excretion of ALA and PEG. Nine 
of the patients were in clinical attack and ten in clinical rem ission when studied.
The 35 relatives were all firs t degree blood relatives of eleven of the above- 
mentioned cases of AIP. Their mean age was 35 years (range 4-65 years) 
and fifteen were m ales and twenty, fem ales. None had a history of symptoms 
suggestive of acute porphyria.
44.
4 .2 .2 . Results
Patients with AIP
The mean activity of L. ALA synthase in the patients with AIP was 908 
nmol ALA/g p ro t/h  (range 273-3, O il) which was significantly increased 
compared with the norm al subjects who had a mean of 173 nmol ALA/g p ro t/h  
(range 50-372) (Figure 12). The mean activity of E. URO synthase in the 
AIP patients was 17 nmol URO/^1 RBC/h (range 8-29) and this was significantly 
depressed compared with the norm al subjects with a mean of 33 nmol URO/
1 RBC/h (range 16-51) (Figure 13 ). There was no significant difference 
between the m ale and female porphyria patients with respect to e ither ALA 
synthase or URO synthase activities. No significant correlation was found 
between the activ ities of L. ALA synthase and E. URO synthase in the 
porphyria patients when examined as one group or as m ales and fem ales 
separately.
The urinary  excretion of ALA and PEG was increased in a ll 9 patients studied 
in clinical attack,but in only five of the 10 patients in clinical rem ission. The
activ ities of L. ALA synthase and E. URO synthase in the patients in clinical 
attack w ere sim ilar to those in the patients in rem ission (Table 6 ). Likewise, 
the activ ities of both enzymes in the patients with increased urinary ALA and 
PEG were s im ila r to those in the patients with norm al urinalysis (Table 6 ).
T here was considerable overlap between the norm al subjects and the AIP patients 
with respect to both L, ALA synthase and E. URO synthase activ ities.
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Activity of leucocyte ALA synthase in patients with acute interm ittent 
porphyria and their blood relatives compared with norm al subjects.
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The best separation of norm al subjects and patients with AIP with respect 
to L. ALA synthase was obtained by using the mean value of the normal 
subjects plus 1 standard deviation, i .e .  250 nmol ALA/g p ro t/h . All 20 
AIP patients had a value of m ore than this and all but twelve of the 63 (19%) 
norm al subjects had a value less  than this (Table 7 ). Surprisingly^the 
m ost useful separation with respect to E. URO synthase was . ' found to
be equal to the mean value of the norm al subjects minus 1 standard deviation,
i .e .  25.1 nmol UR0/1  RBC/h, All but one of the 20 porphyria patients had 
a value of less  than th is and all but seven (11%) of the norm al subjects had 
a value of m ore than this. Much improved separation of norm als and AIP 
patients was obtained by using both L. ALA synthase and E. URO synthase.
None of the norm al subjects had both L. ALA synthase activity of m ore than 
250 nmol ALA/g p ro t/h  and E. URO synthase activity of le ss  than 25.1 nmol 
URO/1 RBC/h^whereas all but one of the AIP subjects had (Table 7 ).
Relatives of AIP Patients
Increased urinary excretion of ALA an d /o r PBG was present in only six of the 
35 (17%) firs t degree blood relatives of AIP patients.
The activ ities of L. ALA synthase ranged from 96-1, 301 nmol ALA/g pro t/h  
and had a trim odal distribution, one peak corresponding.to the mean 
of the AIP patients, one to the mean of the normal subjects and one to the 
overlap of the norm als and AIP patients (Figure 1^. The activities of E. URO 
synthase ranged from 10-37 nmol URO/1 RBC/h with a bimodal distribution, one 
peak corresponding to the mean for the normal subjects and the other to the
Normal 
Sub je cts 
(n = 63)
AIP
Patients 
(n = 19)
AIP
Relatives 
(n=  35)
L.ALA.S. >250 
(nmol ALA/g prot/h) 19% 100% 66%
E. URO.S. < 2 5 . 1  
(nmol URO/lRBC/h) 11% 95% 57%
BOTH 0 95% 49%
Table 7
Prevalence of Increased L. ALA synthase activity and depressed 
E, URO synthase activity in norm al subjects, patients with AIP and 
blood relatives of AIP patients.
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mean for the AIP patient (Figure 13). Twenty three of the 35 rela tives 
(66%) had L. ALA synthase activ ities of m ore than 250 nmol ALA/g prot/h , 
twenty (57%) had E. URO synthase activities of less than 25.1 nmol URO/1 
RBC/h and seventeen (49%) had both increased L. ALA synthase and 
depressed E. URO synthase (Table 7). Each of the 6 rela tives with 
increased urinary  excretion of ALA and /o r PBG had both L. ALA synthase 
activity of m ore than 250 nmol ALA/g p ro t/h  and E. URO synthase activity 
of le ss  than 25.1 nmol URO/1 RBC/h.
When relatives were separated into norm als and latent AIP, the sex 
distribution remained very s im ilar to that for the total group (57% females)^ 
irrespective  of whether the separation was determined by increased L. ALA 
synthase (59% females), reduced E. URO synthase (55% fem ales), both 
enzymes (56% females), o r urinalysis (50% females).
The 17 relatives with increased activity of L. ALA synthase and depressed 
E. URO synthase activity w ere compared biochemically with the 10 AIP patients 
in clinical rem ission. Erythrocyte URO synthase activity was s im ilar in the 
two groups but L. ALA synthase activity was significantly increased in the 
patients who had experienced a clinical attack and a higher percentage of the 
la tte r  group had increased urinary excretion of ALA and PBG (Table 8).
4 ,2 .3 . Discussion
Patients with AIP
In the patients with AIP, no correlation was apparent e ith er between the enzyme
AIP
patients in 
rem ission 
(n = 10)
Latent AIP 
subjects
(n = 17)
mean
L. ALA. S.
988 494
(nmol Al A 
/g  p ro t/h ) range 273-3011 317-1301
mean
E.URO.S.
18 16
(nmol URO 
/IRBC/h) range 9-29 10-25
Percentage with increased 
U rinary A LA and PBG 60% 35%
Table 8
Biochemical comparison of latent cases of AIP with patients in clinical 
rem ission. Leucocyte ALA synthase is significantly higher in the 
la tte r  (p< 0, 05, student t test).
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activ ities in peripheral blood cells and urinary excretion of porphyrin 
precursors^or between the enzyme activ ities and clinical state of relapse 
or rem ission. The increased porphyrin p recu rso rs  excreted in the urine 
in AIP a re  mainly hepatic in origin and can be expected to reflect changes 
in hepatic haem biosynthesis. The absence of correlation between the 
urinary  excretion of porphyrin p recu rso rs  and the enzym es of haem 
biosynthesis in peripheral blood cells indicates that the la tte r  do not 
accurately  reflect changes in the activ ities of their counterparts in the 
liver.
Relatives of AIP Patients
The genetic tra it for AIP is known to be inherited in an autosom al dominant 
sex-independent manner. All the relatives examined w ere  f irs t degree 
blood relatives of cases of AIP and therefore approxim ately 50% can be 
expected to carry  the gene. Only 17% of the relatives had increased 
u rinary  excretion of ALA and/or PBG and this is consistent with previous 
studies and confirms that urinalysis only detects 1 in 3 latent cases.
The m easurem ent of E. URO synthase activity allows the detection of m ore 
latent cases but considerable overlap occurs between norm al and porphyric 
subjects. The use of L. ALA synthase alone also suffers from the same 
disadvantage. The present study dem onstrates that the use of both enzymes 
perm its much improved separation of norm al and porphyric subjects; none of 
the form er and 95% of the la tte r  having both increased L. ALA synthase and 
depressed E. URO synthase activities. Using both enzymes^49% of the
48.
relatives were classified as latent cases of AIP and there was no bias 
towards either sex. These findings a re  consistent with an autosomal 
dominant sex-independent mode of inheritance of AIP.
The present study dem onstrates that the vast m ajority of patients with the 
genetic tra it a re  clinically latent. None of the 17 relatives found to have 
the tra it  had experienced any symptoms. There was no c lear-cu t biochemical 
difference between the latent cases and patients in clinical rem ission though 
L. ALA synthase activity was significantly higher and the prevalence of 
increased urinary  excretion of porphyrin p recu rso rs  g rea te r in the la tte r.
The higher ALA synthase activity in those who have experienced a clinical 
attack may reflect higher circulating levels of endogenous porphyrinogenic 
agents and it may be worth comparing the steroid profiles of latent and 
m anifest cases. The development of a clinical attack is, however, largely 
determ ined by exposure to exogenous precipitating factors and there is no 
reason for assum ing that clinially latent cases are  immune from subsequently 
developing attacks.
4. 3. HEREDITARY COPROPORPHYRI/\
4. 3 .1 . Subjects and Methods
The activ ities of L. ALA synthase and leucocyte coproporphyrinogen (L. COPRO) 
oxidase and the 24 h urm ary excretion of ALA, PBG and coproporphyrin and faecal 
coproporphyrin excretion have been studied in 6 patients with hereditary 
coproporphyria and 9 blood relatives.
49.
Five of the hereditary  coproporphyria patients w ere fem ales and one male 
and the ir mean age was 32 years (range 12-45 years). All had experienced 
at least one clinical attack. Two w ere in attack and four in rem ission  when 
studied.
The 9 relatives studied consisted of 2 daughters of one of the above patients, 
and 3 s is te rs , both the parents, paternal aunt and paternal grandm other of 
another. T heir mean age was 27 years (range 5-71 years). None had any 
history suggestive of cutaneous o r system ic m anifestations of hereditary  
coproporphyria.
4 ,3 ,2 . R esults
Patients with H ereditary Coproporphyria
In the patients with hereditary coproporphyria, the activity of L. ALA synthase 
was increased and the activity of L. COPRO oxidase depressed^compared 
with norm al subjects (Figure 14), In all 6 patients the values for each enzyme 
lay out with one standard deviation from the mean for the controls, i .e .  L. ALA 
synthase m ore than 250 nmol ALA/g p ro t/h  and L. COPRO oxidase le ss  than 
45 nmol Proto/g p ro t/h . All patients had increased u rinary  excretion^and all
but one patient increased faecal excretion^of coproporphyrin. Increased urinary  
excretion of ALA and PBG was present in the two patients in attack.
Relatives of H ereditary Coproporphyria Patients
Increased faecal coproporphyrin excretion was present in 1 relative but norm al 
u rinary  and faecal excretion in the other eight. Four of the relatives (44%) had
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L. COPRO oxidase activ ities of less  than 45 nmol p ro to /g  p ro t/h  and in 
each of these cases the L. ALA synthase activity was m ore than 250 nmol 
ALA/g p ro t/h  (Figure 14), These four relatives w ere considered to be 
latent cases of hereditary coproporphyria. One relative had increased 
L. ALA synthase activity but norm al L. COPRO oxidase activity and this 
was attributed to the inducing effect of her phenytoin a n ti-convulsant therapy 
on L, ALA synthase activity.
The 4 latent cases were comparable to the clinically m anifest hereditary  
coproporphyria patients with regards to activities of L, ALA synthase and 
L. COPRO oxidase though the prevalence of increased coproporphyrin excretion 
was higher in the patients (100%) than in the latent cases (25%).
4 .3 .3 . Discussion
This lim ited study indicates that the m easurem ent of L. ALA synthase 
and L. COPRO oxidase activ ities is a useful method for detecting latent 
cases of hereditary  coproporphyria. U rinalysis on its own is of limited 
value as it was abnorm al in only 1 of the 4 latent cases. Our resu lts  a re  
consistent with an autosomal dominant sex-independent mode of inheritance.
As with AIP there was no clear-cut difference in enzyme activ ities between 
latent cases and patients in clinical rem ission, though the prevalence of 
increased porphyrin excretion was higher in the la tte r.
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4 .4 . DISCUSSION OF SCREENING FOR ACUTE PORPHYRIA 
Our studies have dem onstrated that the assessm ent of activ ities of haem 
biosynthetic enzymes in peripheral blood cells is a reliab le  m eans of detecting 
latent cases of AIP and hereditary coproporphyria. The m easurem ent of 
the activ ities of the ra te  controlling enzyme,L. ALA synthase,as well as 
the appropriate genetically deficient enzyme is considerably m ore discrim inating 
than the m easurem ent of e ither one on its own. It should be possible to 
screen for latent cases of variegate porphyria in a sim ilar way^once a suitable 
peripheral blood cell assay  for protoporphyrinogen oxidase is developed.
The use of these enzyme assays for screening have two m inor disadvantages. 
F irstly , non-genetic factors may affect the activities of haem biosynthetic 
enzyme Sj re  suiting in m isleading resu lts . Peripheral blood reticulocytosis, 
elevated blood lead con cent ra t ion, and the ingestion o f alcohol o r enzyme inducing 
drugs o r horm ones,all modify the activities of haem biosynthetic enzymes in 
peripheral blood cells (McCoIl & Goldberg, 1980). Subjects being screened 
should be asked about drug and alcohol ingestion and confirmed to have normal 
haematology. The second disadvantage is the technical complexity of the 
present enzyme assays as a screening test. There is a need for the development 
of sim pler but equally reliable methods which would allow much w ider screening 
for latent cases of acute hepatic porphyria. The present enzyme assays provide 
a useful standard for assessing  the accuracy of any new screening test.
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5. DRUGS AND HAFM BIOSYNTHESIS
5 .1 . INTRODUCTION
It has been recognised for some time that the ingestion of certain drugs 
may precipitate attacks of acute hepatic porphyria in patients with the 
genetic tra it. Following the introduction into medical practice of 
sulphonai in 1893 and barbiturates in 1903 there were numerous reports 
of cases of "acute toxic haematoporphyria" related to these drugs 
(Waldenstrom, 1937). Throughout the current century there has been 
a growing incidence of attacks of acute porphyria related to the increasing 
use of drugs many of which a re  porphyrinogenic (Eales, 1979). At the 
present tim e,drug ingestion is the m ost commonly identified precipitating 
factor of severe attacks,and research  in this field is of g reat importance 
if m ore attacks a re  to be prevented.
Porphyrinogenic drugs all share the ability to stimulate increased activity 
of the initial enzyme of haem biosynthesis, ALA synthase (Smith & De Matte is, 
1980). It is the overactivity of this enzyme in hepatic^and possibly also 
extrahepatic,tissues of patients with acute porphyria that resu lts  in the 
biochemical and clinical features of an acute attack. ALA synthase is under 
negative feedback control by "free" or "regulatory" haem and most porphyrinogenic 
drugs are  thought to exert their effect by depleting the free haem pool (De 
Matte is, 1975). Drugs may do this in a t least three ways.
F irstly , a high proportion of porphyrinogenic drugs induce the mixed function
53.
oxidase enzyme system with associated increased concentration of the 
haem op rote in cytochrome P450 (Cyt. P450) (Rifkind et al, 1973). These 
drugs are  thought to prim arily  stimulate increased synthesis of the Cyt.
P450 apoprotein which combines with free haem to form the holocytochrome; 
the consequent depletion of free haem resulting in stimulation of ALA synthase 
(Rajamanicham et al, 1975; Bhat et al, 1977; Padmanaban, 1973) (Figure 15). 
Secondly, certain drugs may deplete free haem by inhibiting enzymes involved 
in its synthesis and examples of this include griseofulvin which inhibits 
ferrochelatase (Tephly et al, 1971) and sulphonamides which inhibit 
uroporphyrinogen-1 -synthase (Peters et al, 1980). Thirdly, drugs with 
allyl o r ethynyl substituents, such as sedormid, deplete haem by degrading 
it to abnormal green pigment derivatives (Ortiz de Monte llano et al, 1978),
It is also possible that some drugs may increase ALA synthase by mechanisms 
other than depleting free haem, for example by interfering with the normal 
feedback control mechanism.
The acute hepatic porphyrias are  an example of pharmacogenetic disease; 
subjects with the genetic tra it showing an idiosyncratic reaction to many 
commonly prescribed drugs. Prevention of attacks re lies on accurate 
identification of porphyrinogenic drugs as well as detection of patients with 
the genetic tra it. All drugs which stimulate ALA synthase activity a re  lipid 
soluble but unfortunately do not share any common chemical structure and, 
therefore, individual assessm ent of drugs is necessary. There are three 
main ways in which the porphyrinogenicity of a drug may be assessed 
(Moore, 1980). F irstly , the effect on ALA synthase activity and porphyrin
3 CRN
Cytochrome P450 
Apoprotein
Glycine
Succinyl 
Co A
HAEM
i ®
ALA synthase
Haem Biosynthetic 
Pathway
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Cyt. P450
Figure 15
HAEM BIOSYNTHESIS AND THE MIXED FUNCTION OXIDASE ENZYME 
(M .F .O .) SYSTEM.
During induction of the M. F.O . system Cyt. P450 apoprotein combines 
with haem to form the holocytochrome. This depletion of haem stimulates 
ALA synthase activity by negative feedback control.
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production in various form s of cell cultures may be examined. , This is 
a very sensitive method and will often produce false positive resu lts.
Secondly, it is possible to examine the effects of the drugs alone or combined 
with known porphyrinogenic agents on hepatic ALA synthase activity and 
porphyrin production in whole laboratory animals. Neither of these methods 
can be directly extrapolated to the human situation on account of in ter species 
variations in drug metabolism and enzyme induction and because of the 
problem of dose equivalence (Gram & Gillette, 1971). Lastly, there is anecdotal 
evidence of the drugs causing biochemical and clinical attacks of porphyria.
This last method also produces false positive and false negative results and 
clearly is ethically unsuitable for routine testing of new drugs. At the 
present time assessm ent of available evidence divides the drugs which have 
been tested into tliree groups, i.e . those which are almost certainly 
porphyrinogenic, e .g . barbiturates and sulphonamides, those which are 
alm ost certainly safe, e .g . penicillins and phenothiazines and those with 
conflicting evidence, e .g . phenylbutazone and sodium valproate (Moore, 1980).
In this chapter in vivo studies are  presented of the effects of various drugs on 
ALA synthase activity and Cyt. P450 content of ra t hepatic tissue. In 
addition the in vivo effects of phenytoin on ALA synthase activity in peripheral 
blood cells of rabbits and humans are  described. The relevance of these 
findings to the screening of drugs for porphyrinogenicity and to wider aspects 
of drug metabolism is discussed.
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5 .2 . TESTING FOR PORPHYRINOGENICITY OF DRUGS IN RATS
5 ,2 .1 .  Introduction
Over the past 4 years our department has received numerous enquiries 
regarding the safety of specific drugs in patients with acute hepatic 
porphyria. When no reliable information has been available from 
published litera tu re , I have proceeded to test the particu lar drug in 
laboratory anim als. Twenty six drugs have been tested over this 
period consisting of 12 drugs used in the management of a rth ritis , 6 
drugs used in depressive illness and 8 miscellaneous drugs. All drugs 
were tested in ra ts  by assessing  their effect on hepatic ALA synthase 
activity and when possible on hepatic Cyt. P450 content.
5 .2 .2 , M aterials and Methods
Animals Fully-grown male Sprague-Dawley ra ts  which had been in our 
animal house for at least 2 weeks were used. Twelve ra ts  were used for 
testing each drug, 6 ra ts  receiving the drug and 6 ra ts  the placebo. The 
drugs were adm inistered intraperitoneally or orally^once per day^for periods 
ranging from 2-6 days. On the final day of the study^the ra ts  were sacrificed 
Ih after receiving the drug. The ra ts  were housed separately and throughout 
the study had free access to w ater and food. The test and placebo animals 
were checked for comparable weights before and after the study. If any of 
the anim als died during the study the whole study was repeated. Details of 
sacrifice, removal of the liver and m easurem ent of ALA synthase and Cyt. 
P450 are  given in Chapter 3. Statistical analysis was performed using the
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non-param etric Mann Whitney U-Test.
Drugs The drugs were adm inistered in a dosage equal to 2. 5 tim es 
the recommended human dosage expressed as mg/kg body wt/day. Twenty 
of the drugs were adm inistered intraperitoneally. A p roprietary  parenteral 
preparation was used when available and when not available a suitable 
preparation was formulated. The anti-depressant drugs were administered 
orally^as parenteral preparations were not possible due to problems of 
drug solubility. The placebo consisted of a sim ilar volume of the solvent 
or c a r r ie r  of the drug being tested. Phenobarbitone was used to test the 
model. The first 10 drugs tested were assessed for porphyrinogenic 
effects after both 2 days and 6 days of drug adm inistration requiring 24 
animals for each drug tested. Thereafter, all drugs were assessed  only 
after 3 days.
5. 2. 3. Results and Discussion
Phenobarbitone resulted in a marked and significant increase in hepatic ALA 
synthase activity and Cyt. P450 content when assessed at both 2 days and 6 
days a f te r  commencing intraperitoneal adm inistration (Table 9). This 
confirmed the efficacy of the ra t model. Eleven of the 26 drugs tested 
resulted in a significant increase in activity of ALA synthase. This consisted 
of 3 of the 12 an ti-a rth ritic  drugs (namely, azopropazone, sodium aurothiomalate 
and chloroquine) (Table 9), 5 of the 6 anti-depressants (namely, amitriptyline, 
imipramine, m ianserin, phenelzine and viloxazme (Table 10) and 3 of the 8
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DRUG DOSE
(mgAg/day)
ALA. S. CYT. P450
(Percentage change from controls)
Amitriptyline 10 +110 (p<0. 01) not tested
Imipramine 10 +205 (p(0. 01) not tested
Mianserin 12 + 42 (p<0. 05) + 25
Phenelzine 6 ' +500 (p<0. 01) not tested
Tryptophan 400 -3 + 10
Viloxazme 4 + 73 (p<0.01) + 19
Table 10
Effect of anti-depressant drugs on hepatic ALA synthase activity 
and Cytochrome P450 content. Animals sacrificed 3 days after 
commencing oral dosing.
DRUG DOSE ALA. S. CYT. P450
(mgAg/day) (Percentage cha nge from controls)
Chloramphenicol 3Q0 + 10 + 11
D isopyramide 25 + 4 + 1
Ergotamine 0.1 + 2 + 23
Hydrallazine 20 + 4 - 26
Isoniazid 50 +102 (p^O. 02) + 51 (p 40. 05)
Metronidazole 100 + 67 (p<0.02) + 57 (p<0. 05)
Streptomycin 100 + 56 (p <0. 05) + 114 (p<0. 05)
Cimetidine 50 + 10 - 24
Table 11
Effect of m iscellaneous drugs on hepatic ALA synthase activity 
and cytochrome P450 content. Drugs were administered 
intraperitoneally and ra ts  sacrificed 3 days after commencing 
dosing.
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miscellaneous drugs (namely, isoniazid, metronidazole, and streptomycin) 
(Table 11). The increase in ALA synthase produced by these 11 drugs 
varied from 42% to 500%. The phenobarbitone increased ALA synthase 
activity by 200%. None of the drugs significantly depressed ALA synthase 
activity or Cyt. P450 content. The high proportion (5 out of 6) of the 
positive anti-depressant drugs may be related to their high lipid solubility.
There was a positive correlation of increased Cyt. P450 and increased ALA 
synthase activity. Of the 24 drugs in which both were monitored, 6 
significantly increased both ALA synthase and Cyt. P450, 3 increased ALA 
synthase alone and none increased Cyt. P450 alone. Following phenobarbitone 
and azopropazone, both of which increased ALA synthase and Cyt. P450, it 
was noted that the increase in the form er was more marked a t 2 days and the 
la tte r at 6 days. The mechanism of the relationship of the increase of ALA 
synthase activity and Cyt. P450 content is discussed more fully in the 
following section.
5. 3. SEQUENTIAL STUDIES OF HEPATIC ALA SYNTHASE ACTIVITY AND 
CYT. P450 CONTENT AFTER COMMENCING PHENYTOIN 
ADMINISTRATION TO RATS
5. 3,1. Introduction
Phenobarbitone is an example of a drug which resu lts  in a marked increase 
in activity of hepatic ALA synthase and which is also a potent inducer of the 
mixed function oxidase enzyme system. Sequential studies have shown that 
following the commencement of continued phenobarbitone adm inistration to 
rats^the increase in ALA synthase is most marked initially and thereafter
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re tu rns towards p re-trea tm en t values, whereas the r ise  in Cyt. P450 
content is sustained (Meyer, 1978). We have monitored in ra ts  changes 
in hepatic ALA synthase activity and Cyt. P450 content following the 
commencement of another porphyrinogenic anticonvulsant drug, phenytoin.
5 . 3. 2. M aterials and Methods
Thirty fully-grown adult male Sprague-Dawley ra ts  ranging in weight 
from 200 g to 252 g were studied. They received daily intraperitoneal 
injections of phenytoin in a dosage of 15 mg/kg body weight. Six of the 
ra ts  were sacrificed on day 0 after receiving only an injection of sterile 
w ater and a further six on each of days 1, 3, 6 and 12 of phenytoin injections. 
A further thirty sim ilar ra ts  were studied in an identical manner except 
for the substitution of phenytoin by s terile  w ater. The anim als had free 
access to food and water. Hepatic ALA synthase activity and Cyt. P450 
content were measured as previously described (Chapter 3).
5. 3, 3. Results and Discussion
Hepatic ALA synthase activity was significantly increased after 1, 3 and 
6 days but not a fte r 12 days of phenytoin adm inistration when compared with 
p re-treatm ent values (Figure 16 ), Hepatic Cyt. P450 content showed little 
change on days 1 and 3 but was significantly elevated on days 6 and 12 
(Figure 16), There was no significant change in hepatic ALA synthase activity 
or Cyt. P450 content following placebo injections (Figure 17).
Phenytoin is a further example of a drug which both stim ulates ALA synthase 
activity and induces the mixed function oxidase system. This sequential study
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indicates that the increase in ALA synthase activity is m ost pronounced 
during the induction phase of the mixed function oxidase system, when 
the Cyt. P450 level is rising. When the la tter reaches its plateait A LA 
synthase activity re tu rns towards norm al. This m ost probably indicates, 
as one would expect, that increased haem requirem ent for Cyt. P450 
synthesis is m ost marked during the initial induction phase of the mixed 
function oxidase system.
5 .4 . PHENOBARBITONE ADMINISTRATION AND ALA SYNTHASE 
ACTIVITY IN PERIPHERAL LEUCOCYTES OF RABBIT
5 .4 .1 . Introduction
There is "little known about the effects of therapeutic drugs on ALA synthase 
activity in extra-hepatic tissues. Percy .& Shanley (1979) found no increase 
in ra t brain ALA synthase activity following phenobarbitone adm inistration.
We have studied ALA synthase activity in peripheral leucocytes and liver 
of rabbits receiving phenobarbitone.
5 .4 .2 . M aterials and Methods
Fourteen fully-grown adult male New Zealand rabbits were studied. Seven 
received daily intraperitoneal injections of phenobarbitone in a dosage of 
50 m g/kg body weight and seven received placebo injections of sterile  water. 
The anim als were each housed separately and consumed sim ilar quantities 
of food. They were sacrificed 1 h after the third injection by a traumatic 
blow to the cranium. The anim als were immediately exsanquinated by cardiac
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aspiration and their livers excised. ALA synthase activity was 
m easured in liver and peripheral leucocytes as described in Chapter 3.
5 .4 .3 . Results and Discussion
ALA synthase activities in hepatic tissue and leucocytes of the rabbits 
receiving placebo injections were sim ilar to those in corresponding human 
tissues. The activity of ALA synthase was significantly increased in 
leucocytes as well as in hepatic tissue of the phenobarbitone-treated rabbits 
(Figure 18). The percentage increase in activity was g reater in the leucocytes 
than in the liver. In order to accurately compare the increase in enzyme 
activity in these two tissues, however, it would be necessary  to sacrifice 
the animals at varying time intervals after commencing the drug as the 
timing of the peak rise  in activity may differ in the liver and leucocytes.
5. 5, ALA SYNTHASE ACTIVITY IN PERIPHERAL LEUCOCYTES OF
NQN-PORPHYRIC SUBJECTS ON PHENYTOIN ANTICONVULSANT THERAPY
5. 5.1 . Patients and Methods
Single venous blood samples for m easurem ent of leucocyte ALA synthase 
activity were obtained from 16 out-patients who had been taking phenytoin 
a n ti-convulsant therapy for varying periods of time.
Sequential blood samples were obtained from a further 6 out-patients newly 
commenced on the drug in a dosage of 100 mg three tim es daily. The first 
sample was obtained before commencement of therapy and 5-7 further samples 
were obtained from each patient over the subsequent 2 weeks. These 6 
patients had been referred  to the clinic for investigation of convulsions.
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None of the patients was taking any other medication and all had normal 
haematological indices and blood lead concentrations. All samples were 
obtained at the same time of day.
5. 5. 2. Results and Discussion
The 16 patients in whom single estim ations were performed had widely 
varying activities of leucocyte ALA synthase. Eight showed marked 
elevation and eight sim ilar values compared to control subjects. There 
was no correlation with age, sex, haematological indices, drug dosage or 
drug concentration. There was a relationship between the enzyme activity 
and duration of therapy. The enzyme activity was norm al in those who had 
been on therapy for less  than 3 days, markedly increased in patients who had 
been taking the drug for 3-11 days and normal or slightly increased with 
longer therapy (Table 12).
The 6 subjects in whom leucocyte ALA synthase activity was measured 
sequentially following commencement of therapy all showed a sim ilar pattern. 
There was no change in activity during the first 2 days of therapy. All 
showed a marked increase in activity between the third and eleventh day 
of therapy, returning to normal by the fourteenth day (Figure 19). The 
mean peak rise  in enzyme activity as compared to p re-treatm ent values was 
eight tim es (range six to twenty tim es). In the 6 subjects studied^ the re was 
no correlation between the degree of r ise  in enzyme activity and age, sex 
or drug concentration.
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Figure 19
Sequential study of leucocyte ALA synthase activity in 6 non-porphyric 
subjects following commencement of phenytoin anti-convulsant therapy. 
Each patient is identified by different symbol and mean values indicated 
by broken line.
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These resu lts  indicate that in non-porphyric human subjects therapeutic 
doses of phenytoin stimulate ALA synthase activity in circulating leucocytes. 
This is consistent with our observations in the rabbit. The transient nature 
of the increase of the leucocyte ALA synthase activity is sim ilar to that noted 
in the hepatic studies. As already discussed, the rise  in hepatic ALA synthase 
activity following commencement of phenytoin adm inistration is most probably 
the result of utilization of free haem for the increased synthesis of Cyt. P450. 
The stimulation of leucocyte ALA synthase by phenytoin may indicate 
that this drug is inducing a haem -requiring enzyme system in leucocytes^ 
as well as in the liver. Several drugs have been noted to induce enzymes 
in extra-hepatic tissues of laboratory anim als and tissue culture preparations 
(Bacq, 1971). There is, however, very little information regarding in-vivo 
drug-related enzyme induction in human extra-hepatic tissues.
An alternative explanation for the stimulation of leucocyte ALA synthase by 
phenytoin is that induction of hepatic Cyt. P450 results in increased hepatic 
utilization not only of hepatic free haem but of total body free haem. This 
would result in a depletion of haem in other tissues and a compensatory 
increase in ALA synthase activity. Studies of the effects of phenytoin on 
ALA synthase in isolated leucocyte culture preparation might resolve this issue.
5. 6. DISCUSSION OF DRUGS AND HAEM BIOSYNTHESIS
The most interesting observation in this chapter is that therapeutic doses 
of phenytoin stim ulate ALA synthase activity in leucocytes as well as in the 
liver. This most probably indicates increased utilization of leucocyte free
63.
haem for the induction of a haem -requiring enzyme system within the 
leucocyte o r within the liver. Whatever the explanation, phenytoin Is 
clearly modifying haem metabolism within the leucocyte. The m ajor use 
of haem synthesized within the leucocyte is for the formation of haem-containing 
peroxidases which a re  important in the oxidation of phagocytosed circulating 
debris. It would be interesting to a sse ss  the effect of phenytoin or sim ilar 
drug on this aspect of leucocyte function.
Human studies of drug-related  enzyme induction have to date relied on 
indirect methods or single estim ations of enzyme activity in liver biopsy 
tissue. Our findings that enzyme induction or changes related to enzyme 
induction a re  occurring within human leucocytes may considerably facilitate 
in vivo human studies of enzyme induction as leucocytes a re  considerably 
m ore accessible than hepatic tissue and sequential sam ples can be obtained.
The extent to which the changes in the leucocytes reflect those occurring in 
hepatic tissue rem ains to be discovered.
As discussed at the beginning of the chapter, there is no ideal way of testing 
the safety of drugs for patients with acute porphyria. It is worth considering 
whether studies of the effects of drugs on leucocyte ALA synthase activity 
might be useful in this respect. This could be perform ed in-vivo examining 
drug-related  changes in leucocyte ALA synthase in non-porphyric subjects 
or in-vitro using cultures of leucocytes from norm al subjects or patients 
with acute porphyria. Though these models would overcome the problem 
of variation in enzyme induction between species (Bacq, 1971) they would be
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subject to the disadvantage that the changes in the leucocytes may not 
accurately reflect changes in the liver.
The observation that drug-related stimulation of ALA synthase activity is 
often transient should be considered when interpreting resu lts  of drug 
porphyrinogenicity studies. If ALA synthase activity is measured too early 
or too late after commencing the drug^false negative resu lts  may occur.
It has often been debated whether drugs which induce attacks of acute 
porphyria may be deleterious to patients with the non-a cute erythropoietic 
porphyrias, i.e . congenital porphyria and erythropoietic protoporphyria.
The observation that ALA synthase is induced in blood cells as well as in 
the liver is strong evidence that porphyrinogenic drugs will increase the 
overproduction of porphyrins in these erythropoietic porphyrias and thus 
aggravate the cutaneous manifestations.
C H A P T E R  6
A L C O H O L
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6. ALCOHOL AND HAEM BIOSYNTHESIS
6.1. INTRODUCTION
Acute alcohol ingestion is an important factor for precipitating attacks 
of acute hepatic porphyria. Chronic alcohol ingestion, on the other hand, 
is important in the aetiology of cutaneous hepatic porphyria (Goldberg et al, 
1978). Haem biosynthesis is modified by alcohol in norm al as well as in 
porphyric subjects. In 1935, Franke and Fickentschir noted in normal 
subjects, that drinking 1 litre  of bear or 90ml of cognac generally doubled 
urinary coproporphyrin excretion (Goldberg & Rimington, 1962). Or ten 
et al (1963) noted that chronic alcoholics had increased urinary excretion 
of coproporphyrin, mainly isom er III, but normal excretion of uroporphyrin, 
ALA and PEG. Acute alcohol dosing increases the activity of ALA synthase 
and depresses the activities of ALA dehydratase and ferrochelatase^in ra t 
hepatic tissue (Shanley et al, 1968, Moore et al, 1974). Increased hepatic 
ALA synthase activity also occurs with chronic alcohol dosing of ra ts  (Rubin 
et al, 1970). In 1977, Bonkowsky and Pomeroy reported increased activity 
of hepatic ALA synthase in human chronic alcoholics with liver disease. 
Alcohol also modifies haem biosynthesis in extra-hepatic tissue, causing a 
marked depression of ALA dehydratase activity in circulating erythrocytes 
of both ra ts  and humans (Moore, 1971). In patients with alcohol-related 
sideroblastic anaemia^there is increased activity of bone m arrow ALA 
synthase (F raser & Schacter, 1977) and accumulation of protoporphyrin and
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coproporphyrin in erythrocytes (Ali & Sweeney, 1974).
In this chapter the effects of acute and chronic alcohol consumption on 
haem biosynthesis in non-porphyric human subjects are  studied.
6 .2 . ACUTE ALCOHOL INGESTION AND HAEM BIOSYNTHESIS
6 .2 .1 . Subjects and Methods
Studies were performed on 8 healthy male volunteers. They ranged in age 
from 19 to 31 years and each was confirmed to have normal haemoglobin 
concentration, total white cell count and blood lead concentration. None 
was taking any form of drug therapy and all abstained from alcohol for 7 
days p rio r to the commencement of the study. Throughout the study each 
subject consumed his normal diet.
On the f irs t day, at 09.00 hours, each subject drank 200 ml of 69.5% proof 
Vodka (1. 316 mol ethanol) over 15 mln. Whole blood (35 ml) was withdrawn 
immediately p rio r to his consuming the alcohol and again 2, 6, 24 and 30 h 
after completion of the drink. Of this, 30 ml was heparinized and used for 
the enzyme assays. The activities of the mitochondrial enzymes ALA synthase, 
coproporphyrinogen oxidase and ferrochelatase were m easured in leucocytes 
and of the cytosolic enzymes ALA dehydratase, uroporphyrinogen-1-synthase 
and uroporphyrinogen decarboxylase in erythrocytes. On each occasion the 
remaining 5 ml of blood was used for measuring the haemoglobin concentration, 
total white cell count, reticulocyte count and ethanol concentration. All urine
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passed in the 24 h p rio r to and 48 h following the alcohol consumption 
was collected and the 24h urinary excretion of ALA, PEG, uroporphyrin 
and coproporphyrin m easured. In four of the subjects the enzymes were 
monitored over a sim ilar 30 h period without alcohol consumption.
6 .2 .2 . Results
The mean whole blood alcohol concentration of the 8 subjects was 22 mmol/I 
(range 18-24) at 2 h falling to 3 m m ol/I (range 1-9) at 6 h and undetectable 
at 24 h and 30 h following the alcohol ingestion. There were no consistent 
alterations in the haemoglobin concentration, total white cell count or reticulocyte 
count throughout the period of the study. There was significant alteration in 
the activity of each of the enzymes studies as described below. Alterations 
hi the mitochondrial enzymes are  shown in Figure 20 and in the cytosolic 
enzymes in Figure 21 .
Mitochondrial enzymes:
Leucocyte ALA synthase. There was a rise  in the mean activity of this 
enzyme, being mo st marked a t 6 h and returning to the pre-alcohol level 
at 30 h.
Leucocyte coproporphyrinogen oxidase. This was depressed at 6 h and 
sim ilar to pre-alcohol values a t 2, 24 and 30 h.
Leucocyte ferrochelatase. This showed the m ost marked alterations. Its 
activity was significantly depressed a t 2, 6, 24 and 48 h, this being most 
pronounced at 6 h.
ETHANOL CONTROL
UJ 400n
Si
f t ” ”
P<CH»I
400i
200-
gr 100-
ip'<0-05
p<(KXW>
2A do
I ■
100-
—I---------------1
24 30
IP40-01)
^4 30 6 2 T 30
Figure 20
Time after completing drink (h)
Effect of consuming 200 ml Vodka on the activities of ALA synthase, 
coproporphyrinogen oxidase and ferrochelatase in peripheral leucocytes 
of 8 healthy subjects. The values at each time studied have been compared 
with the pre-ethanol values (time 0) using the Wilcoxon paired samples 
ranking test. Activities of these enzymes in four of the subjects over a 
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Effect of consuming 200 ml Vodka on the activities of ALA dehydratase, 
uroporphyrinogen-1“synthase and uroporphyrinogen decarboxylase in 
peripheral erythrocytes of healthy subjects.
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Cytosolic enzym es:
Erythrocyte ALA dehydratase. The mean activity was markedly depressed 
at 2 h and sim ilar to the pre-alcohol level at 6, 24 and 30 h.
There was little alteration 
at 2 and 6 h but the activity was significantly increased a t 24 and 30 h.
Erythrocyte ujT!PPn)hyrinogen_d^ This was depressed at
6 h and sim ilar to pre-alcohol values a t 2, 24 and 30 h.
There was a significant negative correlation of alteration of activities of 
leucocyte'A LA synthase and leucocyte ferrochelatase by linear regression 
analysis:
Ferrochelatase = -75. 7 - 0. 084 x ALA synthase
(r = -0 .7 1 2 , P < 0.05)
There was also a significant positive correlation of depression of erythrocyte 
uroporphyrinogen decarboxylase and leucocyte ferrochelatase activities. 
Ferrochelatase = -74.5 + 0.423 x Uroporphyrinogen decarboxylase 
( r  = 0.882, F < 0.005)
The above two correlations were also significant using the non-param etric 
Spearman rank correlation test (F< 0. 05 and F<. 0.02 respectively). No 
significant correlation was found for ethanol concentration at 1 h post drink and 
alteration in enzyme activity.
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No consistent alteration was found in the activity of the enzymes repeated 
in four of the subjects over a sim ilar time without alcohol ingestion 
(Figures 20 and 21),
The 24 h urine volume was increased in each subject on tlie day of the 
test compared with the previous and subsequent 24 h period (Table 13 ).
The mean 24 h urinary excretion of ALA and PEG was also higher on the day 
of the test. Uroporphyrin could not be detected in any of the samples. The 
most marked and only significant increase was in the coproporphyrin 
excretion which, on the day of the test, exceeded our upper lim it of the 
normal rànge (432 nmol/24 h) in three of the 8 subjects. The mean urinary 
coproporphyrin excretion was also increased on the day following the alcohol 
consumption but this was not statistically  significant.
6 .2 .3 . Discussion
The alcohol consumption in this acute study resulted in increased activities 
of leucocyte ALA synthase and erythrocyte uroporphyrinogen-1-synthase and 
depressed activities of the other four enzymes studied. The mechanism of 
these alcohol-induced changes is not clear. ALA synthase is under negative 
feedback control by haem and therefore decreased free haem concentration due 
to reduced formation of haem. Increased utilization of haem or destruction of 
haem could explain the r ise  in activity. The alcohol-related depression of 
four of the enzymes of the pathway could resu lt in decreased haem synthesis.
The negative correlation of alteration of ALA synthase activity and ferrochelatase 
activity would support this hypothesis. Alcohol may also resu lt in increased 
utilization of haem as it induces the formation of the haemoprotein cytochrome
Pre-ethanol Post-ethanol
24 hours 0-24 hours 24-48 hours
ALA (umol/24 h) 18 (8-20) 22 (11-26) 19 (10-22)
PEG (umol/24 h) 3.5 (0-11) 9 (0-15) 6 (0-13)
UEO (nmol/24h) 0 0 0
COPRO (nmol/24h) .109 (5-149) 796* (100-1735) 815 (80-1200)
Urine Volume (ml) 1701
(1550-2000)
2781*
(2100-3502)
1667
(1200-2100)
Table 13
Effect of ethanol on 24 h urinary volume and excretion of porphyrins
and p recu rso rs  in 8 subjects. Values are  mean (range shown in parentheses).
*The urine volume and coproporphyrin excretion is significantly
increased (p <0. 025 for each) during the 24 hours following ethanol ingestion
compared with the pre-ethanol values. Statistical analysis performed
using WUcoxon paired samples ranking test.
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P450 (Rubin et al, 1968). Increased hepatic concentration of cytochrome 
P450 has been noted within 2 h of enteral alcohol dosing of ra ts  (Pennington 
et al, 1978). A third mechanism may be important. The intramitochondrial 
NADH/NAD + ratio  is of importance in the regulation of ALA synthase (Labbe 
et al, 1970). Alcohol a lte rs  the intramitochondrial redox state and may thereby 
increase ALA synthase activity (Shaiiley et al, 1968). The only other enzyme 
noted to increase in activity was uroporphyrinogen-1 - synthase and this occurred 
later, at 14 and 30 h post alcohol ingestion^at a time when no detectable alcohol 
remained in the blood. This delayed response may indicate that the r ise  in 
activity of uroporphyrinogen-1 -synthase is a secondary compensatory 
phenomenoh. Uroporphyrinogen-1 -synthase has recently been suggested 
to play a secondary rate-controlling role in the pathway when ALA synthase is 
derepressed (Brodie et al, 1977). It is therefore interesting to note that the 
two enzymes which increased in activity are  the two enzymes which are  of 
importance in controlling the rate of the pathway. The mechanism by which 
alcohol or one of its metabolites depresses the activities of ALA dehydratase, 
uroporphyrinogen decarboxylase, coproporphyrinogen oxidase and ferrochelatase 
rem ains unclear.
The increased urinary excretion of coproporphyrin observed during the 24 h 
following the alcohol consumption may be due to increased synthesis of this 
porphyrin and/or increased renal clearance. There is little information 
available on the mechanism of renal handling of coproporphyrin. If tubular 
reabsorption is important the alcohol induced diuresis might tem porarily
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increase renal clearance. The relative magnitude of the increase in 
coproporphyrin excretion compared with the increased urine volume is 
against a purely renal explanation.
These enzyme changes noted in peripheral blood cells may be relevant 
to some of the haematological effects of alcohol consumption. Alcohol 
is known to depress erythropoiesis (Myrhed et al, 1977; Houribane & Weir, 
1970) and this is thought to be the result of prim ary depression of haem 
synthesis with consequent depression of globin synthesis (Ibrahim et al, 1979; 
Freedman et al, 1975). The very marked depression of ferrochelatase 
activity noted may be of particu lar relevance to the aetiology of alcohol- 
related sideroblastic anaemia. Ferrochelatase is the final enzyme m the 
pathway and responsible for the insertion of iron into protoporphyrin to form 
haem. Sideroblastic anaemia is characterised by accumulation of non-haem 
iron in the mitochondria of blood cell p recurso rs. Patients with alcohol- 
related sideroblastic anaemia have also been found to have increased activity 
of ALA synthase in bone m arrow  (F rase r & Schacter, 1977) and accumulation 
of protoporphyrin and coproporphyrin in erythrocytes (All & Sweeney, 1974). 
All these changes may be explained by depression of ferrochelatase.
It Is probable that the alcohol ingestion is causing sim ilar alterations in the 
enzymes of haem biosynthesis in hepatic cells to those noted in peripheral 
blood cells. In ra ts, acute alcohol ingestion produces sim ilar changes in 
ALA synthase, ALA dehydratase, uroporphyrinogen decarboxylase and 
ferrochelatase to those which we have observed in human peripheral blood
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cells (Moore, 1974; Doss, 1980). The increased urinary coproporphyrin 
excretion may indicate depression of hepatic coproporphyrinogen oxidase 
activity. If sim ilar changes a re  occurring in the human liver following 
alcohol ingestion^ the se may be relevant to our understanding of the 
m echanisms of certain alcohol-related hepatic d isorders. Alcohol is 
an im portant aetiological agent in the development of cutaneous hepatic 
porphyria. Patients with this condition are  thought to have a genetic 
deficiency of hepatic uroporphyrinogen decarboxylase (Kushner et al, 1976;
Elder et al, 1978). A further acquired factor, e .g . alcohol excess, 
certain drugs and chem icals or liver disease, is necessary  before the 
patients excrete excess urinary uroporphyrin and develop symptoms of 
the disease (Tiepermann & Doss 1978). Our finding of alcohol-related  depression 
of uroporphyrinogen decarboxylase and increase of ALA synthase^may 
explain the mechanism by which alcohol can precipitate this condition in 
patients possessing the genetic tra it. Hepatic siderosis is also a feature of 
this disease and alcohol has been incriminated as a factor in the development 
of this. Alcoholism and alcoholic liver disease a re  also associated with 
increased hepatic iron deposition (Jakobovits e t al, 1978) and alcohol is an 
important aetiological factor in the development of the so-called^idiopathic 
haem ochrom atosis (McDonald, 1964). The alcohol-related m arked depression 
of ferrochelatase, which inserts  iron into protoporphyrin to form haem, may 
play a role in the accumulation of non-haem iron in hepatic tissue.
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Most of the alcohol-related haematological and hepatic d isorders occur 
in the context of chronic ra ther than acute alcohol ingestion. It is, 
tlierefore, necessary  to examine the effect of chronic alcohol ingestion 
on haem biosynthesis.
6. 3. CHRONIC ALCOHOL INGESTION AND HAEM BIOSYNTHESIS
6 ,3 .1 . Subjects and Methods
Haem biosynthesis has been studied.in II  male chronic alcoholics who were 
admitted to hospital for alcohol withdrawal. Their mean age was 50 years 
(range 36-65 years). None had taken any form of medication in the month 
p rio r to admission and the consultant psychiatrists in charge agreed to 
withhold their routine therapy of chlordiazepoxide and multivitamin preparations, 
and instead manage the patients with psychological support and adequate 
nutrition and hydration. Informed consent was obtained from the patients.
Details of the alcohol history were obtained from the patients and their 
relatives and are  shown in Table 14. The estimated mean daily alcohol 
consumption was 230 g (range 100-400 g) and mean duration of alcohol abuse 
11 years (range 2-25 years). All patients reported drinking heavily up until 
the day p rio r to their arranged admission. Screening on admission showed 
tiie blood ethanol concentration to be 13 m m ol/litre  in one patient but none 
was detected in the rem ainder. The patients were closely supervised during 
their admission in order to prevent and detect any occult alcohol consumption. 
Severe withdrawal symptoms developed in 2 patients and they received appropriate 
therapy and were withdrawn from the sequential part of the study.
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All patients had a full general medical assessm ent on admission (Table i$ .
One patient was found to have hepatomegaly, peripheral neuropathy and 
Korsakoff's psychosis. A further patient had peripheral neuropathy, 
amblyopia and Korsakoff's psychosis and a further two patients had 
hepatomegaly. None of the patients had clinical stigmata of hepatocellular 
dysfunction. Routine liver function tests  performed on the day of admission 
showed elevated activity of gamma glutamyltranspeptidase in all 11 patients, 
elevated aspartate transam inase in eight and elevated alanine transam inase 
in seven (Table 16). Vitamin studies showed that nine of the patients had 
subnormal leucocyte ascorbic acid, three thiamine deficiency and one 
pyridoxine deficiency (Table 17), Haematological screening showed a haemoglobin 
concentration less  than 13,5 g/dl in 3 patients, elevated mean corpuscular 
volume in seven and low platelet counts in 2 patients (Table 18). All patients 
had norm al reticulocyte count and total white cell count. Haematinic 
screening showed the iron saturation elevated in 4 patients and reduced in one; 
the whole blood folate was low in 1 patient and none had Vit B12 deficiency (Table 17).
Venous blood was obtained from each patient within 18 h of admission for the 
m easurem ent of the activities of the enzymes of haem biosynthesis and the 
erythrocyte porphyrin and lead concentrations. In 8 patients it was possible 
to obtain further samples on the second, fifth and between the tenth and twentieth 
days of admission. The blood samples for the enzyme studies were always 
obtained a t the same time of day. A 24 h urine collection was obtained from
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each patient on the f irs t day of admission for the m easurem ent of porphyrin 
and p recu rso r excretion.
Eleven healthy male subjects (mean age = 40 years, range 21-69 years) 
admitted to hospital for elective arthroscopy of the knee were used as 
control subjects. Blood was obtained from them within 18 h of hospital 
admission for haem enzyme studies. Statistical analysis of comparison 
of test and control subjects was performed using the non-param etric 
Mann Whitney U-Test.
6 .3 .2 . Results
Studies on Day of Admission
The activity of leucocyte ALA synthase was significantly increased and 
the activities of erythrocyte ALA dehydratase and uroporphyrinogen 
decarboxylase significantly decreased on the day of admission compared 
with the control subjects (Table 19). Erythrocyte uroporphyrinogen-I-synthase 
activity was elevated compared with the controls but this difference did not 
reach statistical significance. There was no statistical difference between 
the chronic alcoholics and controls with regards to leucocyte coproporphyrinogen 
oxidase or ferrochelatase activities, though in two of the chronic alcoholics 
(numbers 5 and 7) ferrochelatase activity was markedly depressed and in one 
of these (number 7) coproporphyrinogen oxidase activity was also depressed.
The erythrocyte porphyrin studies showed elevated protoporphyrin and 
coproporphyrin concentrations in one patient (number 7) elevated protoporphyrin
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in two further patients (numbers 3 and 4) and elevated coproporphyrin in 
a fourth patient (number 5) (Table 20). The 24 h urinary  excretion of 
ALA, PEG, uroporphyrin and coproporphyrin was in all cases within our 
range for norm al subjects. The blood lead concentration in the chronic 
alcoholics was slightly increased (mean 1.6 umol/1, range 0 .5 -2 .5  um ol/l) 
compared with the controls (mean 1. 3 umol/1, range 0. 6-2. 0 um ol/l).
Sequential Enzymes Studies
Leucocyte ALA synthase activity, which was elevated on the day of admission, 
remained elevated on the f irs t and fourth days post adm ission but was s im ila r 
to control subjects when m easured between the tenth and twentieth days post 
adm ission (F igure22). Erythrocyte ALA dehydratase activity, which was 
depressed on the day of admission, remained depressed on the f ir s t  and fourth 
days post admission but again had returned to norm al when m easured between 
the tenth and twentieth days (Figure 23), Erythrocyte uroporphyrinogen 
decarboxylase activity, which was depressed on the day of adm ission, was 
still depressed the following day but sim ilar to controls when m easured on the 
fourth day and between the tenth and twentieth days (Figure 24). Sequential 
studies of activities of erythrocyte uroporphyrinogen-I-synthase and leucocyte 
copropdrphyrmogen oxidase and ferrochelatase in the chronic alcoholics as 
a group showed no significant alterations from control subjects or from day 
of adm ission. The marked depression of leucocyte ferrochelatase activity 
in patients num bers 5 and 7 and of coproporphyrinogen oxidase activity in 
patient number 7, noted on the day of adm ission^corrected within 5 days of 
alcohol withdrawal.
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Figure 22
Leucocyte ALA synthase activity in Chronic Alcoholics following 
cessation of drinking. Statistical comparison of alcoholics versus 
controls by Mann Whitney U-Test.
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Figure 23
Erythrocyte A LA dehydratase activity in chronic alcoholics following 
cessation of drinking.
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Figure 24
Erythrocyte uroporphyrinogen decarboxylase activity in chronic 
alcoholics following cessation of drinking.
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6. 3. 3. Discussion
This study dem onstrates that chronic alcohol ingestion is associated 
with abnormal haem biosynthesis in peripheral blood cells which 
rev e rts  to norm al with withdrawal of alcohol. The observations in 
the chronic alcoholics are  similar^but not identical,to those noted in 
the acute alcohol study in healthy subjects. Increased activity of ALA 
synthase and depressed activ ities of ALA dehydratase and uroporphyrinogen 
decarboxylase w ere features of both studies. Increased activity of 
erythrocyte uroporphyrinogen-I-synthase was also noted in both, though 
it did not reach sta tistical significance in the chronic study. D epressed 
activ ities of leucocyte coproporphyrinogen oxidase and ferrochelatase 
noted in the acute study were net seen in the chronic alcoholics. The 
fact that the enzymatic changes noted in the present study w ere also 
seen following acute alcohol ingestion in healthy subjects is  strong evidence 
that these changes a re  due to the alcohol ra ther than any of the nutritional 
deficiencies present m the chronic alcoholics.
The urinary  excretion of porphyrins and p recu rso rs  was norm al 
in the chronic alcoholics, in contrast to the acute alcohol study w here increased 
urinary excretion of coproporphyrin was noted. The increased coproporphyrin 
in the acute alcohol situation may have been the resu lt of the depression of 
coproporphyrinogen oxidase which was not present in the chronic study. The 
absence of increased urinary coproporphyrin excretion in the chronic situation 
is in agreem ent with the observation in ra ts  that the coproporphyrinuria 
occurring on commencing alcohol is transient and does not p e rs is t with
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continued dosing (Doss et al, 1980). Increased urinary coproporphyrin 
excretion, however, has been noted in chronic alcoholics (Eider, 1976) 
and its absence in this study may be in part explained by the absence 
of liver disease and the effects of acute alcohol withdrawal.
Four of the chronic alcoholics had increased erythrocyte porphyrin 
concentrations. The increased erythrocyte protoporphyrin in patient 
number 4 may be explained by the iron deficiency anaemia and in patient 
number 3 by the elevated blood lead. The increased erythrocyte 
coproporphyrin in patient number 5 and increased erythrocyte protoporphyrin 
and coproporphyrin in patient number 7 are  more interesting as neither patient 
had evidence of iron deficiency or elevated blood lead. Excluding patient 
number 4 with iron deficiency anaemia, patients numbers 5 and 7 were the 
only anaemic chronic alcoholics. In both cases the anaemia was m acrocytic 
in type with normal folate and Vit B12 levels. The iron saturation was 
m arkedly increased in both cases suggesting a failure of iron utilization.
The enzymes of haem biosynthesis were particularly interesting in these 
two patients, both having markedly depressed activities of leucocyte 
ferrochelatase and in addition, patient number 7 having depressed 
coproporphyrinogen oxidase activity. The activities of these two enzymes 
were sim ilar to the controls in all the other non-anaemic alcoholics. It 
is reasonable to conclude that in these 2 patients the chronic alcohol ingestion 
was depressing the activities of these enzymes resulting in accumulation of 
their substrates (coproporphyrin, protoporphyrin and iron) and producing
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anaemia due to deficient haem synthesis. Both these enzymes had been 
noted to be depressed by acute alcohol ingestion and it is likely that 
in certain patients this persis ts  with chronic alcohol ingestion resulting 
in alcohol-induced anaemia. Patients with alcohol-related sideroblastic 
anaemia have increased bone m arrow  ALA synthase (F raser & Schacter,
1977), accumulation of protoporphyrin and coproporphyrin in erythrocytes 
(Ali & Sweeney, 1974) and accumulation of non-haem iron (Figure 25). All 
these features are  explained by depressed activity of coproporphyrinogen 
oxidase and ferrochelatase.
If the enzymatic changes noted in the peripheral blood cells of the chronic 
alcoholics are  also occurring in the liver they may be relevant to the 
role of alcohol in cutaneous hepatic porphyria. Most patients with this 
condition have a hereditary partial deficiency of hepatic uroporphyrinogen 
decarboxylase (Kushner et al, 1976; Elder et al, 1978). The alcohol-related 
accumulation of uroporphyrin in these patients may be explained by the alcohol 
further depressing uroporphyrinogen decarboxylase activity as  well as 
increasing the activity of the initial and rate-controlling enzyme of the pathway, 
ALA synthase.
¥F ig u re  25
P e rin u c le a r accum ula tion  o f iro n  in a lcoho l-induced  s id e ro b la s tic  
anaem ia. Stained w ith  P russian Blue.
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7. HORMONES AND HAEM BIOSYNTHESIS
7.1. INTRODUCTION
Hormonal factors affect haem biosynthesis and play an important role 
in the aetiology of attacks of acute hepatic porphyria. Attacks are more 
common in fem ales than m ales and rare ly  occur before puberty, being 
most common in the third decade (Tschudy, 1974). Pregnancy may
precipitate acute attacks and some women experience regular attacks 
occurring in the week p rio r to m enstruation (Lamon et al, 1978). The 
contraceptive pill and other forms of exogenous oestrogens may also 
precipitate attacks of acute porphyria and are  also important in the aetiology 
of porphyria cutanea tarda (Goldberg et al, 1978). There is evidence that 
hormonal influences affect haem biosynthesis in normal subjects; increased 
urinary excretion of porphyrins and p recursors being reported during 
pregnancy (Lyberatos et al, 1972; De Klerk et al, 1975; Brodie et al, 1977)  ^
and increased urinary excretion of ALA in women on the contraceptive pill 
(Koskelo et al, 1966).
Animal studies have shown that the activity of ALA synthase in rat hepatic 
tissue varies throughout the female sexual cycle, being highest in oestrus 
and lowest in dioestrus (Held & Przerwa, 1976) and a sim ilar pattern is 
observed in the harderian gland of the female ham ster (Moore et al, 1978). 
Certain steroid hormones have been noted to increase the activity of ALA 
synthase in rat hepatic tissue. Among the most potent tested to date are
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androstenedione, androstenediol, dehydroepiandrosterone (DHA) 
17-liydroxypregnenolone and aetiocholanolone (Paxton et al, 1974). The 
mechanism by which hormones increase ALA synthase activity is not 
clearly understood. ALA synthase is under negative feedback control by 
haem and any lowering of the intramitochondrial free haem concentration 
resu lts  in its induction. Certain synthetic acetylenic substituted steroids, 
including norethindrone and ethynyl oestradiol, have been shown to destroy 
m icrosom al haem and cytochrome P450 in ra ts  (White, 1979). The haem 
degrades to abnormal green coloured derivatives sim ilar though not identical 
to the green pigments formed by allylisopropylacetamide - a chemical used 
to producb experim ental porphyria in animals. These animal studies, 
however, may be of little relevance to the human situation as the hormones 
studied were synthetic ra ther than endogenous and the concentrations many 
tim es g reater than occur physiologically. Animal studies have shown that 
the steroid hormones which induce ALA synthase all have a sim ilar structure 
(Granick & Kappas, 1967). It is therefore possible that these hormones are  
able to competitively inhibit the feedback of haem by occupying its receptor 
site. The observation that both haem (Waxman et al, 1966) and oestradiol 
(Tschudy et al, 1967) cause sim ilar oscillatory changes in hepatic ALA synthase 
would be in favour of them both acting in a sim ilar way such as occupying a 
common receptor.
In patients with A IP there is an increased ratio of 5 beta/5 alpha steroids with 
increased urinary excretion of DHA and aetiocholanolone and increased plasma
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concentrations of DHA (Moore et al, 1973), This is the result of a 
deficiency of 5 alpha reductase activity (Bradlow et al, 1973). The 
relationship between this altered steroid metabolism and the abnormality 
of haem biosynthesis is now known. The overproduction of these 
porphyrinogenlc steroids, however, may be of importance in the aetiology 
of the acute attack.
In the following section we have studied the interrelationship of steroid 
hormones and haem biosynthesis in both porphyric and norm al subjects.
7. 2. ACUTE PORPHYRIC ATTACKS AND
THE FEMALE MENSTRUAL CYCLE
7 .2 .1 . Subjects and Methods
The timing of hospital admission in attack of A IP was examined in relation 
to the phase of the m enstrual cycle in 3 patients (J. Me. " 23 years old, J.C , - 
24 years old and P.W. - 30 years old), who suffered frequent attacks. They 
had experienced between them a total of 26 attacks requiring hospital admission 
and without apparent exogenous precipitating factors over the three year period 
studied. All had regular m enstrual cycles. A s a  result of our se lf-re fe rra l 
hospital admission system their admissions were usually within 1 or 2 days 
of the onset of symptoms of an attack.
7 .2 .2 . Results
hi the 3 patients studied, attacks were most common pre-m enstrually , seventy 
per cent of the adm issions occurring within the 7 days p rio r to the onset of 
menstruation (Figure 26).
P e r c e n t a g e  of  Admi s s i ons
60-1
PW Cycle % 24doys  Ten admissions50 -
40 -
3 0 -
20 -
10-
JC Cycle = 28 days Nine admissions30
20 -
28 26 22 20
J Cycle = 28 days  Eight admissions3 0 -
2 0 -
22 2028
First d a y  Menst ruat ion
Time Premenstruol ly in 2 day  intervals
Figure 26
Timing of admission in acute attack in relation to m enstrual cycle 
in 3 females with acute interm ittent porphyria.
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7.3. HAEM BIOSYNTHESIS THROUGHOUT MENSTRUAL CYCLE 
IN NORMAL FEMALES AND IN PATIENT WITH LATENT A IP
7 .3 .1 . Subjects and Methods
Studies of haem biosynthesis were made throughout the complete menstrual 
cycle in 6 healthy female volunteers (mean age - 30 years, range 26-45 years) 
and over a sim ilar time period in 6 healthy male volunteers (mean age - 30 
years, range 24-44 years). All subjects had normal blood lead and haemoglobin 
concentrations and none was taking any form of drug therapy. All abstained 
from alcohol throughout the study. Blood was withdrawn for assessm ent of 
leucocyte ALA synthase activity each Monday, Wednesday and Friday between 
9a.m . and 10a.m . In four of the m ales and four of the females the activity 
of URO synthase in peripheral erythrocytes was also monitored. The urinary 
excretion of ALA and PBG was monitored in four males and three females.
Fifty ml spot urine samples were used and resu lts  expressed in relation to 
creatinine excretion. In two of the females the plasma concentrations of 
androstenedione, dehydroepiandrosterone (DHA) and DHA sulphate were also 
monitored and in one female the plasma concentrations of oestradiol, 
progesterone and testosterone.
Sim ilar studies were performed throughout one complete m enstrual cycle in 
a 26 year old female (H. B. ) with latent A IP. The diagnosis was based on 
depression of the activity of erythrocyte URO synthase and increased activity 
of leucocyte ALA synthase in the presence of normal urinary excretion of 
porphyrins and p recu rso rs . The condition had been inherited from the patient's
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mother who showed the same biochemical disorder. The patient had 
never experienced a symptomatic attack of porphyria but has subsequently 
developed "idiopathic" hypertension. Throughout the m enstrual cycle 
the activities of leucocyte ALA synthase, erythrocyte URO synthase and 
the urinary excretion of ALA and PBG were monitored as described for 
the norm al females. Plasma concentrations of androstenedione, DHA 
and DHA sulphate were also monitored.
7 .3 .2 . Results in Normal Subjects 
Leucocyte ALA synthase
The mean ALA synthase activity was slightly higher in the females 
(150 nmol ALA/g prot/h) than In the m ales (122 nmol ALA/g prot/h) 
but th is difference was not statistically  significant. The female subjects 
showed m ore fluctuation of activity of leucocyte ALA synthase than the 
males (Figure 27, Table 21 ). In the 6 females studied, it was not 
possible to discern any association between the fluctuation in activity and 
phase of m enstruation (Figure27). There was no association of degree 
of fluctuation and subject age or body weight.
Erythrocyte URO synthase
The mean activity of erythrocyte URO synthase was 48. 5 nmol URO/1 RBC/h 
in the m ales and 41 nmol URO/1 RBC/h in the females. The degree of 
fluctuation of activity was sim ilar in the different sexes (Figure 28 ). No
FEMALES MALES
L.ALA.S. 
(nmol ALA/ 
g prot. I h )
300 n
200 -
D.S.(44yr)
100
30 0 1
200 -
E.H.(29yi100 G,T.(34yr)
200-,
S.M.OOyr:
l.D,(29yr)100 -
300-
200 -
W S.(27yi
100-
H.M.(26yr)
200
K.M.(26yr)
A.W (26yr)
200-1 M.H.(26yr
J.M.(24yr'100-
14 10 6
Pre-menstrua I
92 0 4 8 12 1
j Post-menstrual
5 13 17 21 25
First b a y  of 
Menstruation
DAYS
Figure 27
Activity of leucocyte ALA synthase throughout complete m enstrual 
cycle in 6 normal females and throughout sim ilar time period in 
6 norm al m ales.
Subjects Mean Activity Average fluctuation from mean
(n mol ALA/g 
protein/li)
(nmol A LA /g 
proteln/h)
(as % of 
mean)
MALES
G.T. 68 4 6
K.M. 98 7 7
D.S» 215 21 10
S. M. 103 16 15
J.M. 75 15 20
W. S. 175 26 15
Mean
for all 
m ales
122 15 12
FEMALES
M.C. 115 19 17
B.D. 77 16 21
E.H . 192 46 24
A.W. 218 61 28
M.H. 149 20 13
H. M. 152 74 49
Mean
for all 
females
150 26 25
LATENT
A IP
FEMALE
315 100 28
Table 21
Leucocyte ALA synthase activity throughout month in normal 
m ales and fem ales and in patient with latent A IP.
FEMALES MALES
ERYTHROCYTE 
URO. S. 
(nmol URO /
I RBC/h)
ôO  “
D.S.
E.H,
3 0 -
6 0  “ 1
H.M.5 0 -
-# S.M.
40
3 0 -
ws.
4 0 -
A.W
20 -
5 0 - 1
J.M.4 0 -
3 0 - M.H
2 0 -
1 3 5 7  9 II 13 15 17 19 21 23- 25
Days
16 14 12 10 8 6  4 2 4 2 4 6  8 10 12
Days Pre-menstrua! Days Post-menstrual
First Day of 
Menstruation
Figure 28
ActiviLy of erythrocyte URO synthase throughout complete menstrual 
cycle in 4 normal females and over sim ilar time period in 4 normal males.
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association was apparent between the fluctuations in ALA synthase and 
URO synthase activities.
Urinary ALA and PBG excretion
The mean urinary excretion and degree of fluctuation of excretion of 
ALA (Figure 2^ and PBG (Figure 30) were sim ilar in the two sexes. There 
was no discernable association between the urinary excretion of porphyrin 
p recu rso rs  and the enzyme activities, nor was there any association between 
the porphyrin p recu rso r excretion and phase of the m enstrual cycle.
Hormonal Studies
In subject E .H ., in whom the activity of leucocyte ALA synthase and plasma 
concentrations of oestradiol, testosterone and progesterone were monitored 
simultaneously throughout the m enstrual cycle, there was no clear association 
between the enzyme activity and concentration of any of of these hormones 
(Figure 31). In subjects A.W. and M .H ., there was no association between 
leucocyte ALA synthase activities and the plasma concentrations of the 
porphyrinogenlc steroids DHA, DHA sulphate and androstenedione (Figures 32, 33).
7. 3. 3. Results in Patient with Latent A IP
The mean activity of leucocyte ALA synthase in the patient with latent A IP 
(315 nmol ALA/g pro t/h) was considerably higher than in any of the normal 
subjects studied. The degree of fluctuation in leucocyte ALA synthase 
activity was more than occurred in the normal females when expressed as
FEMALES MALES
URINARY ALA 
(mmol ALA/ 
mmol Creatinine)
3 -
E.H.
GT.
3-1
A.W.2 -
G.F.
M.H.
2 4 6 a 10 12
Days Post-menstrual
14 12 10 8 6 4 2
Days Pre-menstrual
I 3 5 7 9 1 13 15 17 19 21 23 25
Days
First Day of 
Menstruation
Figure 29
Urinary excretion of ALA throughout menstrual cycle in 3 normal 
females and over sim ilar time period in 3 normal males.
FEMALES M ALES
URINARY PBG 
(mmol PBG/ 
mmol CREATININE)
3
2
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0
A.W. J M
0
M.H. G.F
0
14 12 10 8 6 4 2
Pre -  menstrual
1 3 5 7 9 II 13 15 17 19 21 23 252 4 6 8 10 12
Post-menstrual
First Day of 
Menstruation DAYS
Figure 3(3
Urinary excretion of PBG throughout m enstrual cycle in 3 normal females 
and over sim ilar time period in 3 norm al males.
E.H.
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First Day of 
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Figure 31
Activity of leucocyte ALA synthase and plasma concentrations of 
oestradiol, testosterone and progesterone throughout menstrual 
cycle of normal female (E.H. ).
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F ig u re  32
A c t iv ity  o f leucocyte  A LA  synthase and p lasm a concen tra tions  o f 
dehydroep iandroste rone  (DHA), dehydroep iandroste rone  sulphate (DBAS) 
and androstenedione throughout m e n s tru a l cyc le  in  n o rm a l fem ale  (A. W. ),
M.H.
(nmol ALA/ 
g prot/h)
200-n
Leucocyte ALA Synthase
100
-2 0
- 1 5DHA (nm ol/i)
- 1 0
um ol/l)
DMAS - 3 -5
2-5
r '2
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—4
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First Day of 
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Figure 33
Activity of leucocyte ALA synthase and plasma concentrations of 
dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHAS) 
and androstenedione throughout m enstrual cycle of normal female (M. H. ).
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absolute values (Table 21). The mean erythrocyte URO synthase
activity (21 nmol URO/1 RBC/h) was lower than that of any of the norm al 
subjects and below our lower lim it of norm al which Is 25.1 nmol URO/1 RBC/h,
The degree of fluctuation of erythrocyte URO synthase activ ity  was sim ilar 
t^o that noted in the norm al fem ales and m ales. Leucocyte ALA synthase 
activity was highest and erythrocyte URO synthase lowest at the tim e of 
m enstruation (Figure 34). Urinary excretion of ALA and PBG was sim ilar 
to the norm al m ales and fem ales and showed no association with phase of 
m enstruation or activity of the enzymes studied (Figure 34). No association 
was found between leucocyte ALA synthase activity and plasm a concentrations 
of androstenedione, DHA or DHA sulphate (Figure 35). The plasm a DHA 
concentration in this patient was above the norm al female range (0 .5- 11 
nm ol/l) on 5 of the 14 occasions m easured.
7 .4 . DISCUSSION
The studies in the 3 patients with recu rren t attacks of A IP, confirm that 
■ attacks a re  m ost common prem enstrually  and th is suggests that the hormonal 
fluctuations a sso c ia ted , with the fem ale m enstrual cycle a re  modifying hepatic 
haem biosynthesis in these patients. The fluctuation of leucocyte ALA 
synthase activity in the norm al fem ales and female with latent AIP  ^indicates 
that the female m enstrual cycle is affecting haem biosynthesis in norm al 
fem ales as well as in patients with latent and m anifest A IP. F u rth e r substantiative 
evidence that the fluctuations in enzyme activity w ere the resu lt of the hormonal 
changes associated with the m enstrual cycle might have been obtained by 
examining p re-pubertal or post-m enopausal fem ales but it was im possible
Cycle  ^ 3Û days5 0 0 - 1
4 0 0 -
2 0 0 -
r - 3 0100-
Efylhrocyle URO S 
•20 mmol URQ /IRBC/h
3-1 L-IO
2-
Unnary ALA 
mmol/mmol crealinme
0-* - 0  7
—0 6
- 0  5
- 0  3
- 0  2
- 0  1
D ays post-m enslruol
Figure 34
Activities of leucocyte ALA synthase and erythrocyte URO synthase and 
urinary excretion of ALA and PBG throughout m enstrual cycle of 26 year 
old woman (H. B. ) with latent acute interm ittent porphyria.
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Figure 35
Activity of leucocyte ALA synthase and plasma concentrations of 
dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHAS) 
and androstenedione throughout m enstrual cycle of 26 year old woman (H. B. ) 
with latent acute interm ittent porphyria.
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to obtain suitable volunteers. The fact that the fluctuations in ALA 
synthase activity were noted In leucocytes indicates that the hormonal 
fluctuations are  modifying haem biosynthesis in haematopoietic as well 
as hepatic tissue.
No correlation was apparent between the fluctuations in the activity of 
leucocyte ALA synthase and the phase of the m enstrual cycle or the plasma 
levels of certain hormones. A;number of explanations are  possible.
F irstly , the hormonal fluctuations associated with the m enstrual cycle are 
complex and ALA synthase is probably influenced by several of these 
hormones and also by their m etabolites. C lear association between the 
alteration In one hormone and ALA synthase activity may be obscured by 
the influence of other hormones on the enzyme. Secondly, a delay in the 
response of the enzyme to altering concentrations of an inducing steroid would 
be expected which might further complicate the association. Animal 
studies have shown that a single injection of oestradiol resu lts  in oscillations 
in the activity of ALA synthase lasting for up to 90 hours (Tschudy et al, 1967).
In the patient with latent A IP, the magnitude of the fluctuation of the activity 
of leucocyte ALA synthase through the cycle was m ore than that seen in the 
norm al fem ales. This is consistent with the partial block in the haem pathway 
at the level of URO synthase which exists in haematological as well as hepatic 
tissue of such patients. Animal studies have demonstrated that induction of 
ALA synthase by porphyrinogenic agents is considerably enhanced by the
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presence of a partial enzymatic block in the pathway (Maxwell & Meyer, 1975; 
Sinclair & Granick, 1978).
The observation that the human female m enstrual cycle is modifying haem 
biosynthesis in haematological as well as hepatic tissue may be of relevance 
to the understanding of sex horm one-related alterations in haematopoiesis.
Healthy women are known to have a reduced haemoglobin, red cell count 
and packed cell volume compared to their male counterparts (Wintrobe, 1967). 
Castration of the male ra t resu lts  in a fall in the red cell count which is 
reversed with testosterone adm inistration whereas castration of female rats 
causes a rise  hi the red cell count which is reversed by oestrogens (Gordon 
& Charipper, 1956). The stim ulatory effect of androgens on haematopoiesis 
has been utilized with varying degrees of success in the treatm ent of certain 
form s of aplastic anaemia in man (Kennedy, 1962). Our studies indicate 
that sex hormones may modify haematopoiesis as a result of their effect on 
the rate-controlling  enzyme of haem biosynthesis, ALA synthase. Haem synthesis 
is known to control globin synthesis (Freedman et al, 1974). Granick (1965) 
showed that steroids which induce ALA synthase in embryonic liver cells 
also accelerate haem and haemoglobin synthesis in chick blastoderm cultures.
Like these steroids the hormone, erythropoietin which plays a m ajor role in 
stimulating erythropoiesis, increased ALA synthase activity in rabbit bone 
m arrow  cultures (Bottomley & Smithee, 1969). Thus ALA synthase may be 
an important control point for the hormonal regulation of haematopoiesis.
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The marked fluctuation noted in the activity of leucocyte ALA synthase in 
norm al females and m ore particularly  in females with latent A IP should 
be borne in mind when using this enzyme as a screening test for latent 
cases of acute porphyria.
C H A P T E R  8
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8. NUTRITION AND HAEM BIOSYNTHESIS
8.1. INTRODUCTION
It has been recognised for some tim e that dieting or fasting can precipitate 
attacks of acute porphyria (Knudsen et al, 1967). In patients with AIP 
a reduction in carbohydrate or total caloric intake resu lts  in increased 
urinary excretion of porphyrin p recu rso rs  and sometimes clinical attack, 
w hereas carbohydrate and caloric supplementation resu lts  in reduced 
excretion of porphyrin p recu rso rs  (Felsher & Redeker, 1967; Verspohl 
etal, 1979). There is also evidence that the administration of carbohydrate, 
either orally or as intravenous laevulose, resu lts  in biochemical and clinical 
improvement in patients hi acute attack of porphyria (Brodie et al, 1977).
Studies in ra ts  have demonstrated that carbohydrate or protein restriction 
m creases hepatic ALA synthase activity whereas carbohydrate or protein 
supplementation rep resses  hepatic ALA synthase activity (Tschudy et al, 1964). 
Allylisopropylacetamide (A.I. A .) or drug-mediated induction of ALA synthase 
is sim ilarly affected by carbohydrate restriction and supplementation (Rose 
et al, 1961). The mechanism of this "glucose effect", which also affects 
other enzymes, is unknown (Goldberg, 1974). Alteration of caloric intake 
resu lts  in hormonal changes which may affect ALA synthase activity (Kappas 
& Granick, 1968). In chick embryo liver,A , I. A. -induced porphyrin 
biosynthesis is maximal at low insulin to glucagon m olar ratios (F ischer 
et al, 1978). The "glucose effect" on ALA synthase may also be due to 
changes in concentrations of free haem as starvation augments and glucose- 
loading diminishes haem catabolism as measured by carbon monoxide evolution
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(Luiidh & Ugander, 1976). Several other mechanisms have been postulated 
as discussed by Tschudy (1978). At present, however, both the mechanism 
and the physiological function of the "glucose effect" rem ain unclear.
In addition to the effect of the total caloric intake, certain minor dietary 
constituents may affect haem biosynthesis. Pyridoxal phosphate is the 
cofactor for ALA synthase and the only vitamin derivative known to serve 
as a cofactor for any of the enzymes of the pathway. Both normal rabbits 
and rabbits with chemically-induced porphyria excrete less ALA and PBG 
when rendered pyridoxine deficient with deoxypyridoxine (Druyan & Haegar- 
Aronsen, ,1965). In the rat, however, dietary pyridoxine deficiency does 
not im pair hepatic ALA synthase induction (Chabner et al, 1970). Oral 
iron in the form of fe rric  citrate has a pronounced synergistic effect on the 
induction of hepatic ALA synthase in experimental animals (Stein et al, 1969). 
This may be due to iron depleting the "free haem pool" by increasing haem 
degradation (De M atteis & Sparks, 1973)^or by decreasing haem synthesis 
by inhibiting uroporphyrinogen decarboxylase activity (Kushner et al, 1975). 
Though iron excess plays an important role in the aetiology of cutaneous 
hepatic porphyria, there is no evidence that either iron excess or deficiency 
have any effect on the acute hepatic porphyrias. Folic acid and other pteridine 
derivatives exert a protective and enhancing effect on the activity of URO 
synthase (Piper et al, 1979; Piper et al, 1977). There is some evidence 
that oral folic acid adm inistration resu lts  in clinical and biochemical 
improvement in patients in attack of AIP (Wider de Xifra et al, 1979).
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We have assessed  the value of the intravenous administration of laevulose 
to patients in attack of A IP. In addition we have studied in non-porphyric 
obese subjects, the effect of fasting on the urinary excretion of ALA and 
PBG and on the activity of ALA synthase In peripheral leucocytes.
8.2 . LAEVULOSE THERAPY IN ACUTE PORPHYRIA
8. 2.1. Patients and Methods
We have assessed  the effect of intravenous laevulose infusions on the 
duration and severity of attacks in 3 female patients (J. Me, J. C. and P. W. ) 
with A IP. The study was retrospective and covered a 4 year period.
During the firs t 2 yearsyeach patient received intravenously 20% laevulose 
(2 litres/day) during the firs t 3 days of each admission in attack.
After 2 years^this practice was discontinued because of its damaging effects 
on the patients veins. In the second 2 year period^we attempted to maintain 
the patients' caloric intake using the glucose polymer Caloreen (Roussel) 
which the patients either drank or received via a fine bore nasogastric tube. 
Inevitably, the daily carbohydrate and total caloric intake was considerably 
less  over the second 2 year period,
8 .2 .2 . Results
The frequency of adm issions was sim ilar over the "laevulose" and the "no- 
laevulose" periods (F igure36). In each patient the mean duration of admission 
in attack was considerably longer during the "no-laevulose" period (Figure36). 
Peripheral neuropathy complicated 3 attacks in 2 patients during the "no-
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Effect of laevulose infusions on the duration and severity of attacks in 
3 female patients with acute interm ittent porphyria. Each bar represents 
one admission in attack.
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laevulose" 2 year period whereas neurological complications did not 
occur in any of the attacks treated with laevulose.
8 .2 .3 . Discussion
Though this study is retrospective and subject to many varying factors, 
it supports previous reports that the intravenous infusion of laevulose 
is beneficial in the management of patients in attack of A IP. The
reduced effectiveness of enterally adm inistered Caloreen can be explained 
by the sm aller doses received. The nausea and vomiting^which is an 
almost invariable feature of an attack of . AIP  ^ considerably compromises 
any attem pts at enteral feeding. This study also highlights the fact that 
repeated intravenous infusions of 20% laevulose, whether via peripheral 
or central line, result in considerable venous damage and so complicates 
the management of future attacks. In patients with frequent attacks the 
early construction of an arterio-venous fistula should be considered in 
o rder to facilitate venous access.
8 .3 . STARVATION AND HA EM BIOSYNTHESIS
8 .3 ,1 . Patients and Methods
Five female and one male patient admitted to hospital for weight reduction 
were studied. Their mean age was 35 years (range 19-54 years) and their
mean body weight on admission was 106kg (range 89-122kg). All were
suffering from simple obesity but were otherwise healthy. None was
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taking any form of drug therapy.
During the first 2 days of admission they were maintained on the diet 
which they had been taking at home, which in each case was 800 kcalories.
On the morning of the third day of admission all food was withdrawn and 
the patients received only w ater and physiological doses of vitamins 
B%, B5, Eg, C and D. The fasting was continued for a mean of 21 days 
(range 15-35 days). Within 48 h of. commencing the "water diet"^ all 
patients developed ketonuria which gave a strongly-positive reaction with 
the ketostix test (Ames). The ketonuria persisted throughout the fasting 
period in each patient confirming adherence to the diet. The mean weight 
loss during fasting was 11.8kg (range 20.4 - 6.8  kg). Routine biochemical 
monitoring showed the well recognised metabolic changes associated with 
fasting, namely increased plasma concentrations of cholesterol, creatinine 
and urate and reduced plasma concentration of urea. The plasma glucose 
concentration and routine haematology remained normal throughout the period 
of study.
Blood was withdrawn at 9. 00a.m. for measurement of leucocyte ALA synthase 
activity on the day p rio r to commencement of fasting and on each of the first 
5 days of fasting and again on the tenth and fifteenth days of fasting. On each 
of these days a 24 h urine collection was obtained for m easurement of ALA 
and PBG excretion.
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1.3.2. Results
Prior to the commencement of fasting the activity of leucocyte ALA 
synthase and the urinary excretion of ALA and PBG were within our 
normal range in all subjects. There was no significant alteration in 
either the enzyme activity or the porphyrin p recursor excretion with 
fasting (Figures 37, 38).
8. 3. 3. Discussion
Our study indicates that in non-porphyric subjects, fasting does not a lter 
the activity of ALA synthase m leucocytes. This is in contrast to the increase 
in ALA synthase activity which occurs in hepatic tissue of healthy laboratory 
anim als. The differing enzymatic responses to fasting in leucocytes and 
liver may be a reflection of the different roles these two tissues play in the 
regulation of carbohydrate metabolism.
This study also dem onstrates that fasting does not result in overproduction 
of ALA or PBG in normal subjects. Hepatic overproduction of these porphyrin 
p recu rso rs  requires both increased activity of the initial enzyme ALA synthase 
and a partia l block la te r  in the pathway. Induction of hepatic ALA synthase 
activity by fasting^will only result in overproduction of porphyrin p recursors 
in the presence of an enzymatic block la ter in the pathway such as exists in 
patients with any of the acute hepatic porphyrias.
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9. HAEMATIN THERAPY FOR ACUTE HEPATIC PORPHYRIA
9. 1. INTRODUCTION
The adm inistration of haematin or haemin will suppress the activity 
of chemically-induced ALA synthase in laboratory anim als and cell 
cultures (Granick, 1966). This is presumed to be the result of 
supplementation of the intra-m itochondrial free haem pool. The 
exogenous haematin is incorporated into functionally active hepatic 
cytochrome P450 and tryptophan pyrrolase (Correia et al, 1979) and 
increased mono-oxygénase activity has been noted following haematin 
adm inistration to hepatic and extrahepatic (including brain) tissue 
preparations (Jonen et al, 1978; Omiecinski et al, 1978; Omiecinski 
et al, 1980), Exogenous haematin induces the activity of haem 
oxygenase and is itself catabolized by this enzyme in the same way as 
endogenously synthesized haem (Tenhunen et al, 1970; Landaw et ai, 
1970). The induction of haem oxygenase may explain the increased 
rate of destruction and lowered hepatic concentrations of cytochrome 
P450 and catalase which have been noted following adm inistration of 
large doses of haem (Marver et al, 1968; Hamato & Higashi, 1979; 
Sassa & Granick, 1970; Bock et al, 1973),
The demonstration that haematin was able to suppress the induction of 
ALA synthase raised the possibility that it might be of value in treating 
attacks of acute hepatic porphyria. Information regarding its safety in 
animal studies is required prio r to embarking on clinical tria ls .
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9.2. HAEMATIN TOXICITY IN ANIMALS
As far back as 1911, W. H. Brown, in his studies of m alaria, noted 
that the Intravenous injection of large doses of haematin to dogs produced 
a dose related pyrexial reaction (Brown, 1911, 1912, 1913). This was 
probably related to impure preparations and it has been found more 
recently that pyrogenic reactions can be eliminated by crystalisation and 
re-crystalisation  of the haemin (Dhar et al, 1975). Brown (1913) also 
noted that the adm inistration of haem in a dosage of 20mg/kg was consistently 
followed by albuminuria and the appearance of granular and cellular casts 
in the urine. He found sim ilar, though less severe, changes using a dose 
of lOmg/kg. Anderson (1942) noted that the intravenous administration of 
haematin to dogs sufficient to cause an initial plasma concentration between 
10 and 72mg/100ml resulted in a generalised vascular reaction with 
vasodilatation, haemorrhage and throm bosis. Haemorrhage in the subarachnoid 
space and central nervous system caused convulsions and renal, endocardial 
and myocardial haem orrhages also occurred. Very rapid intravenous 
injection frequently resulted in a marked toxic reaction and death. Corcoran 
and Page (1945) noted a transitory  renal hyperaemia in dogs given intravenous 
haematin in a dosage of 14. 5mg/kg at a rate of 0. 28mgAg/min. A larger 
dose of 23. 7mgAg at a rate of 0 .49m gAg/m in caused intense efferent a rte rio la r  
vasoconstriction resulting in uraemia and proteinuria. At a higher level 
still of 32. 6m gAg adm inistered at a rate of 0. 835mgAg/min there were 
generalised petechial haem orrhages with ischaemia of glomeruli and tubular 
degeneration. Lips (1978) examined the toxicity of intravenous haematin in 
ra ts. The L.D. 50 was 0.43m gA g with 95% confidence lim its of 0.54 and
0. 35 mgAg* At toxic levels the ra ts  showed hypotension, widespread 
haemorrhaging and renal failure. Increasing the intravenous injection 
time from 1 min to 2 min in one rat appeared to reduce the toxic effects.
9.3. FATE OF HAEMATIN ADMINISTERED INTRAVENOUSLY 
TO HEALTHY ANIMALS AND HUMANS
Intravenously adm inistered haematin is handled in the same way as haem
released by intravascular haemolysis. It is rapidly bound to the haem-
binding B-globulin, haemopexin (Hanstein & M uller-Eberhard, 1968;
Heide et al, 1964). When this becomes saturated, excess haematin is
bound to albumin forming methaemalbumin (Dhar et al, 1978). In healthy
human subjects the circulating haemopexin concentration averages
77 mg/100 ml which is sufficient to bind 19 mg haematin. Above a
plasma haematin concentration of 0. 6 mg/100ml haemopexin will be
saturated and the excess haematin binds to albumin in a 2:1 m olar ratio
(Rosenfeld & Surgenor, 1950). An average healthy person has 125 g of
circulating albumin which should be sufficient to bind 2. 6 g haematin.
Theoretically, therefore, a haematin dose of up to 2. 6 g (serum concentration
of 100 mg/100 ml) would be protein bound. The rate of administration,
however, may be important as rapid injection without adequate time for
equilibration could result in circulating free haematin.
The haem-haemopexin complex is rapidly taken-up by the liver in both 
experimental animals (Snyder & Schmid, 1965; Sears & Huser, 1966; 
M uller-Eberhard et al, 1969; M uller-Eberhard et al, 1970; Muller- 
Eberhard & Liem, 1974), and man (Sears, 1969) and the haemopexin then
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released back into the circulation (Smith & Morgan, 1978). Albumin 
serves only as a tem porary storage site from which haematin is 
transferred  to haemopexin as the la tte r becomes available. Injected 
haematin is taken-up almost exclusively by the liver (M uller-Eberhard 
& Liem, 1974). The I. V. adm inistration of ^^Fe-haem at in in man 
resu lts  in rapid accumulation of radioactivity over the liver with only 
slight increases occurring over the spleen and sacrum (Sears, 1970; 
Liem et al, 1975).
9 .4 . REVIEW OF PREVIOUSLY PUBLISHED EXPERIENCE OF 
HAEMATIN IN ACUTE HEPATIC PORPHYRIA
9 .4 .1 . Patients and Methods
A review of the world litera tu re  has allowed us to collate clinical and 
biochemical details of haematin therapy of 45 attacks of acute hepatic 
porphyria in 32 patients over the past 10 years (Bonkowsky et al, 1971; 
Watson et al, 1973; Dhar et al, 1975; Peterson et al, 1976; Watson et al, 
1978; Brezis et al, 1979; Lamon et al, 1979). Twenty six of the patients 
had A IP and six,porphyria varie gata. The mean age was 35 years (range 
18-52 years) and twenty four were females and eighty m ales. Nearly all 
the patients had received a tr ia l of high dose glucose orally or intravenously 
p rio r to the haematin. The haematin was administered as intravenous 
infusions over 13-30 min and the infusions were given every 12 or 24 h.
The total daily dose varied from 1.8 - 8 .0  m gAg body weight and the courses 
lasted from 1-13 days. High glucose intake was maintained during most
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courses of haematin therapy.
9.4.2,. Biochemical Response
In all patients studied the haematin reduced the plasma concentrations of 
ALA and PBG by 65-100% of their pre-haem atin values. The reduction in 
ALA has been slightly m ore pronounced than PBG. In patients in whom the 
ALA and PBG levels w ere closely monitored, they have fallen within 24 h 
of the first infusion, reached a trough usually on the final day of the 
infusions and then risen again on discontinuing the haematin to plateau^ 
several days later^at a level of 50-100% of the pre-haem atin level. The 
haematin has resulted in a sim ilar reduction in the urinary excretion of 
uroporphyrin.
Using the data presented by Lamon et al (1979)^it is possible to compare 
the significance of the reduction in urinary excretion of ALA and PBG with 
haematin courses of m ore than,and less than,25mgAg body weight. With 
the nine high dose courses^the reduction in ALA was significant at p <
0. 002 in eight and reduction in PBG at p <  0. 002 in seven. With the ten
lower dose courses,the reduction in ALA was significant at p <0.002 
in only four and the reduction in PBG significant at p <  0. 002 in only five.
In the series  by Watson et al (1978) the mean reduction in serum ALA and 
PBG concentrations in courses of more than 1, OOOmg haematin was 90% 
compared to 77% with sm aller courses. The percentage reduction in ALA 
and PBG following haematin appears to be independent of the pre-haem atin 
levels of these porphyrin p recurso rs. In the series by Watson et al (1978) 
the haematin lowered the plasma ALA and PBG concentrations by a sim ilar
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percentage (83%), irrespective of whether the pre-haem atin concentrations 
were more than or less than 165ug/100ml.
The clearance of exogenous haematin administered to patients m attack 
of acute porphyria has been studied by Lamon et al (1979) and Petryka et 
al (1976). Both noted that the curve of plasma haematin disappearance 
could be resolved into two exponential components. The half-life of the 
first component was between 4. 5 h and 15.5 h and for the second component 
between 20 h and 53. 5 h. The first component is thought to represent the 
rate of hepatic uptake of haem-haemopexin complexes. Once all available 
haemopexin is taken up by the liver^the remaining haem bound to albumin 
must await the release of haemopexin from the liver in order to bind it and 
allow further hepatic uptake. The second component, therefore, reflects 
the rate of release of haemopexin from the liver. The adm inistration of 
haematin resu lts  in a precipitous fall in the serum haemopexin concentration 
which retu rns to normal within 7-10 days of completion of haematin 
adm inistration.
9 .4 .3 . Clinical Response
C ritical analysis of the published reports shows that the clinical response 
has not been as consistent as the biochemical response. Twenty four (54 
per cent) courses have been associated with sustained clinical improvement, 
ten (22 per cent) with tem porary improvement then relapsing within 2-14 days 
(3 fatal) and in eleven (24 per cent) there was no apparent benefit with three 
of these patients dying in attack. The clinical response to the haematin therapy
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In these patients must be viewed in association with their clinical severity.
Twenty six of these attacks in 17 patients can be classified as Class A 
(Watson et al, 1978) as there was a combination of gastrointestinal symptoms, 
mental disturbance, hypertension and tachycardia but no significant peripheral 
neuropathy. In these attacks^the haematin resulted in sustained improvement 
in fifteen (58 per cent)^temporary improvement in seven (27 per cent) and 
no change in four (15 per cent) (Table 22). Ten attacks in 8 patients were 
of Class B severity ,as there was^in addition, severe peripheral neuropathy.
The haematin therapy was associated with improvement of the neuropathy in 
six (60 per cent) but no change in four (40 per cent) (Table 23). Nine attacks 
in 7 patients were of Class C severity^there being severe generalised 
neuropathy resulting in resp irato ry  em barrassm ent. In three (33 per cent) 
of these attacks the haematin therapy was associated with maintained improvement 
of the neuropathy, in three tem porary improvement initially occurred but 
the patients la te r died and in three there was no improvement and this was 
followed by death (Table 24). In most cases where improvement of neuropathy 
occurred it commenced about the final day of the haematin infusion and 
continued slowly for several months, however, in a few cases dram atically 
rapid improvement has been reported.
No serious side-effects have been observed following haematin administration 
to patients in acute attack of porphyria. In a small number of cases the 
haematin has produced phlebitis around the injection site with associated 
mild pyrexia. One 40 year old male with A IP in rem ission developed 
transitory  acute renal failure following the rapid bolus intravenous injection
Age Sex Type of Clinical response Reference
porphyria
31 M A IP Improved Watson et al, 1973
32 " Improved Dhar et al, 1975
l35 " " Improved Watson et al, 1978
52 F A IP Improved Dhar et al, 1975
50 F A IP No change
42 M AlP Tem porary improvement Watson et al, 1978
35 F A IP Improved
34 F PV Tem porary improvement
.34 " Improved
31 F PV Improved M 11
27 F A IP Improved
,27 Improved
30 M A IP Tem porary improvement
33 M PV No change Lamon et al, 1979
49 F A IP No change
25 F A IP Tem porary improvement
31 F A IP Tem porary improvement
[21 F AlP Tem porary improvement
[21 " Improved
43 M AlP No change
33 F A IP Tem porary improvement 11 II
"31 F A IP Improved
31 " Improved
31 ” Improved
31 " ” Improved
31 ” " Improved
Brackets on left side of table group attacks in individual patients
Table 22
Clinical response to haematin therapy of 26 Class A attacks in 17 patients.
Age Sex Type of 
porphyria
Abdominal
pain
Neuropathy
36 F PV no data improved
36 no data improved
45 F AlP no data improved
22 F AlP no data no change
19 F AlP improved improved
31 F AlP improved no change
21 F AlP improved improved
26 F AlP tem porary
improvement
no change
24 F AlP improved improved
24 no change no change
Watson et al, 1978
Lamon et al, 1979
Table 23
Clinical response to haematin therapy of 10 Class B attacks in 8 patients.
Age Sex Type of 
porphyria
Neuropathy Reference
33 F AIP no improvement - died Bonkowsky et al, 1971
56 F PV Improved Dhar et al, 1975
21 F AIP Improved Peterson et al, 1976
19 M AIP early improvement-died Watson et al, 1978
42 F PV early improvement-died
18 M AIP Improved Brezis et al, 1979
49 M AIP early improvement Lamon et al, 1979
49 no improvement died
49 no improvement
Table 24
Clinical response to haematin therapy of 9 Class C attacks in 7 patients.
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of 1, OOOmg haematin (Dhar et al, 1978). Following the injection the 
patient developed oliguria passing only 200ml over the subsequent 24 h.
The urine was initially almost black in colour and haematin was readily 
demonstrable spectroscopically. The urine also contained protein (13.8g/l), 
red blood cells (25/high power field), white blood cells (5/high power field) 
and granular casts. The patient was treated with intravenous diuretics and 
alkalinization of the urine and the urinary output and blood urea and creatinine 
concentrations returned to normal within 4 days. The transito ry  renal 
failure was thought to be the result of circulating free haematin due to the 
sudden injection of such a large quantity.
9,5. PERSONAL EXPERIENCE OF HAEMATIN THERAPY 
IN ACUTE HEPATIC PORPHYRIA
9 .5 .1 . Patients and Methods
Over the past 3 years we have adm inistered 14 courses of haematin to 8 
patients with acute hepatic porphyria in relapse. Six of the patients were 
females and 2 m ales. The mean age was 27 years (range 19-56 years). All 
had AIP except one female who had porphyria variegata (case 5). They all 
had both clinical and biochemical evidence of attack at the time of haematin 
adm inistration and had failed to respond adequately to carbohydrate administration. 
All but two of the patients w ere treated in our own wards. Cases numbers 5 and 
6 were both unfit for transfer and 1 personally delivered the haematin and 
adm inistered it in their local hospitals in Birmingham and Liverpool.
The haematin solution was prepared as described in Chapter 3 and administered 
within 7 days of preparation. It was stored at 4°C and removed from the
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re fridge rat or 30 min p rio r to adm inistration. The appropriate volume 
was drawn up into a plastic syringe through a 5pm filter aspiration needle 
(Monoje ct 303, Sherwood Medical Industries Inc., St. Louis, Missouri,
U .S.A. ). The haematin was then injected via a 0. 22pm filter (Millipore,
Millex) into the rubber bung of a slowly running intravenous infusion of 
physiological saline. The dose of each injection was 4m gA g body weight 
and patients received injections at either 12-hourly or 24-hourly intervals.
The duration of the courses of haematin varied from 3-5 days.
The response to the haematin therapy was assessed from both a biochemical 
and clinical point of view. The 24 h urinary excretion of ALA, PBG, 
uroporphyrin and coproporphyrin was monitored throughout each course, 
except for the sixth course adm inistered to case number one. The 
activity of leucocyte ALA synthase was monitored daily throughout 9 courses 
to 6 patients. The activity of erythrocyte URO synthase was monitored 
throughout 5 courses and the activities of erythrocyte ALA dehydratase, 
erythrocyte uroporphyrinogen decarboxylase, leucocyte coproporphyrinogen 
oxidase and leucocyte ferrochelatase throughout 3 courses. Routine 
haematology and biochemistry was monitored daily in all patients. During 
4 courses to 4 patients the plasma concentrations of dehydroepiandrosterone 
were also monitored. In an attempt to obtain some objective evidence of 
clinical response the analgesic requirem ent was monitored in each conscious 
patient throughout the period of study. The patients received their analgesia 
"as required for pain" and, therefore, the daily analgesic consumption could 
be used as a means of quantitating their pain and clinical condition. This 
has previously been found to be the most effective means of monitoring
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clinical condition in patients with porphyria.
9 .5 .2 . Haematin Therapy and Urinary Porphyrin and P recursor Excretion 
The urinary ALA was increased in all cases immediately p rio r to haematin 
therapy, the mean being 220um ol/24h (range 51-374). In all but one of 
the courses there was an associated reduction m the urinary ALA excretion.
The mean reduction, comparing the 3 days pre-haem atm  with days of therapy, 
was 43 per cent (Table 25). T he urinary PBG excretion was increased 
in all but one patient p rio r to haematin administration, the mean being 
274 umol/24h (range 8-471). All but 2 of the courses were associated with 
a reduction in urinary PBG excretion,with a mean reduction of 35 per cent. 
Urinary uroporphyrin was increased in all subjects p rio r to the haematin 
(mean 2, 700 nmol/24h) and all but two courses were associated with reduced 
excretion (mean reduction = 36 per cent). The urinary coproporphyrin 
excretion was slightly increased p rio r to five of the courses and this showed 
little change during haematin therapy. After completion of the haematin 
therapy the urinary excretion of ALA, PBG and uroporphyrin rose over the 
following three days plateauing at a level of 50-100 per cent of the pre-haematin 
values (Table 26). No patient demonstrated any "rebound" phenomenon. There 
was no significant difference in the depression of urinary porphyrin or 
p recu rso r excretion in relation to the two dose schedules employed (Table 27).
9 .5 .3 . Haematin Therapy and activity of enzymes of haem biosynthesis in 
peripheral blood cells
Prior to haematin therapy leucocyte ALA synthase activity was increased in
each case studied with a mean activity of 631 nmol/ALA/g p rote in/h
Haematin
Dose
(mgAg/24h
Duration 
of therapy 
(days)
Perce
urina
ALA
:ntage cl 
ry  excre 
PBG
lange in 
2tion of 
URO COPRO
Case 1 
course i 4 3 -24 -53 -23 +24
course ii 8 3 +13 + 5 -20 +50
course iii 4 3 -51 -44 -19 +39
course iv 4 5 -50 -45 -68 +19
course v 4 3 -33 -22 +20 +116
Case 2 4 4 -12 - 7 -50 +37
Case 3 
course i 8 3 "68 -70 - 9 -32
course ii 4 3 -54 -20 -56 +19
Case 4 4 3 -76 -70 -81 +71
Case 5 8 3 - 4 +12 -36 -40
Case 6 8 3 -84 -33 -46 -42
Case 7 8 3 -46 -66 0 -31
Case 8 4 3 -64 -41 -75 -22
MEAN -43 -35 -36 +16
Table 25
Percentage change In urinary excretion of ALA, PBG, uroporphyrin (URO) 
and coproporphyrin (COPRO) following commencement of haematin therapy 
in patients in attack of acute porphyria. Values during haematin therapy 
have been compared with values obtained over 3 days immediately prior 
to therapy.
Mean Urinary excretion of
ALA PBG URO COPRO 
(umol/24h) (umol/24h) (nmol/24h) (nmol/24h)
3 days
pre-haem atin 220 274 2, 700 640
during
haematin 125 178 1, 727 600
3 days
post-haematin 145 214 2, 010 450
Table 26
Mean urinary excretion of porphyrins and p recurso rs before, during 
and following haematin therapy.
No. of 
courses
Mean percentage change in urinary excretion 
during haematin treatment
ALA PBG URO COPRO
Haematin 
4 mg/kg/24 h 9 -45 -38 -46 +51
Haematin
8mgAg/24h 5 -38 -30 -20 -19
Table 27
Effect of Haematin dosage on reduction of urinary porphyrin and 
p recurso r excretion.
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(range 310-1, 500). Seven of the courses repressed the activity of ALA 
synthase, in four of these to withm the normal range (Fig- 39). The 
enzyme assays were performed 20-24 h after each haematin infusion and 
in each of these 7 courses the enzyme activity was reduced within this 
period of time. On one occasion leucocyte ALA synthase activity was 
assessed 1 h after the haematin infusion and was found to be only 45 nmol 
ALA /g  pro te in/h, which is below our lower lim it for norm al subjects. The 
activity of ALA synthase rose again within 48 h of completion of each of these 
7 courses to levels sim ilar or slightly lower than the pre-treatm ent values. 
There was no evidence of rebound phenomenon. Two courses of haematin 
were complicated by severe phlebitis and in these leucocyte ALA synthase 
activity was not repressed  (Fig. 40) though the urinary excretion of ALA,
PBG and uroporphyrin was reduced.
There was no significant change of the activities in peripheral blood cells 
of ALA dehydratase, URO synthase, uroporphyrinogen decarboxylase, 
coproporphyrinogen oxidase or ferrochelatase following haematin 
adm inistration (Table 28).
9 .5 .4 . Haematin Therapy and plasma Dehydroepiandrosterone levels.
The plasma concentrations of DHA prior to haematin adm inistration were 
above our upper range of normal (i. e. 11 nmol/1) in three of the 4 patients 
studied (Fig. 41). In each patient haematin adm inistration resulted in a 
fall hi the DHA level. On completion of haematin therapy the plasma DHA 
concentration rose again in 2 patients within 48 h but remained depressed
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Figure 41
Effect of haematiii on plasma levels of dehydroeplandrosterone in 
4 patients in attack of acute intermittent porphyria.
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in the other 2 patients for 2 weeks. The number of patients studied 
was insufficient to allow meaningful statistical analysis. We confirmed 
that porphyrins and their p recu rso rs  did not interfere with the plasma 
hormone radio-immunoassay.
9 .5 .5 . Clinical Response to Haematin Therapy
Clinical sum m aries of each of the 8 patients treated with intravenous 
haematin a re  presented in the Appendix.
Abdominal pain was the m ajor symptom of the 12 attacks in which the 
patients remained conscious. Following haematin administration the 
pain was reduced in 7 attacks, unaltered in two and increased in three.
Peripheral neuropathy was the m ajor clinical sign in 10 attacks. Following 
haematin therapy the neuropathy objectively improved in 7 attacks, showed 
no change in two and continued to progress in one. When neurological 
improvement occurred this was observed within 7 days of commencing the 
haematin and slowly continued over the ensuing months. Two of the 14 
attacks were fatal in spite of haematin therapy. Both of these patients had 
been completely paralysed and on assisted  ventilation p rio r to the commencement 
of the haematin. A summary of the severity of each attack and the clinical 
response following haematin is shown in Table 29.
In an attempt to achieve a m ore objective assessm ent of the clinical response, 
the analgesic requirem ent was monitored in the 12 courses to conscious 
patients. This was reduced following five of the courses, unchanged following
Age
(years) Sex
Clinical 
C lass of 
attack *
Response to Haematin
Abdominal
pain Neuropathy
Outcome
Case 1 
course i 
course ii 
course iii 
course iv 
course v
29
29
30
30
31
F B
A
B
B
C
improved
improved
improved
worse
worse
improved
improved
improved
improved
improved
survived
Case 2 26 F B improved improved surv ived
Case 3 
course i 
course ii
23
25
F A
A
improved 
no change
survived
Case 4 19 M A no change survived
Case 5 57 F C com atose no change died
Case 6 19 F C com atose no change died
Case 7 24 F B improved improved survived |
Case 8 21 M A improved survived
1
C lassifcation is as described by Watson et al 1978, i .e .
C lass A = Includes gastrointestinal symptoms and signs, hypertension and 
tachycardia, psychiatric m anifestations but absent or mild 
peripheral neuropathy
C lass B = As above but severe peripheral neuropathy
C lass C = Life threatening generalised  neuropathy with respiratory  
failure
Table 29
Clinical response to haematin therapy.
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three and increased following four (Table 30). The imperfect correlation 
between the reduction in analgesic requirement and improvement in 
abdominal pain is explained by the development of painful phlebitis 
following 2 courses of haematin. There was no discernible difference 
in clinical response between the two dose schedules employed.
No m ajor side-effects were observed following haematin adm inistration. 
Painful thrombophlebitis with associated mild pyrexia and leukocytosis 
occurred following 2 courses and mild phlebitis with no systemic upset 
was noted following a further 3 courses. In each case the haematin had 
been injected into an antecubital or m ore distal arm  vein. Blood urea 
and creatinine concentrations were monitored daily in all patients and 
there was no evidence of any r ise  associated with the haematin administration. 
The two patients who died had moderately elevated concentrations of urea 
and creatinine ^ terminally. These, however, had been rising p rio r to the 
haematin adm inistration and the haematin did not accelerate this rise . The 
cause of death in both these cases was considered to be severe chest 
infection and anoxia and not renal failure. At post-m ortem  both macroscopic 
and m icroscopic examination of their kidneys was normal. The patient who 
had received 6 courses of haematin over 2 years at no time showed evidence 
of renal impairment and post mortem examination showed normal renal 
histology.
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9.6. DISCUSSION
Our resu lts  confirm that intravenous haematin lowers the urinary excretion 
of ALA, PBG and uroporphyrin in patients in attack of acute hepatic porphyria. 
It has been assumed by previous w orkers that this is the result of haematin 
repressing  hepatic ALA synthase activity. Our ability to demonstrate 
repression of this enzyme in leucocytes supports this hypothesis. In the 
two patients who developed marked phlebitis, leucocyte ALA synthase was 
not suppressed though there was a reduction in the excretion of porphyrin 
p recu rso rs . It is possible that the inflammatory reaction affected the 
leucocyte response. The clinical response was unfortunately not as 
consistent as the biochemical response, definite improvement accompanying 
only about half of the courses and in several of these it was tem porary.
The m ajority of acute attacks of porphyria resolve spontaneously and this 
makes it impossible to be certain that clinical improvement was due to 
haematin ra th er than spontaneous rem ission. Because of the ra rity  and 
nature of the condition a double blind controlled tria l would be difficult to 
mount.
The only side-effect noted following haematin administration was inflammation 
and throm bosis of the veins into which the solution was injected. Di a 
recurren t and sometimes life-threatening condition such as  acute porphyria, 
it is important to conserve accessible peripheral veins in order to 
facilitate the patients future management. The infusion of haematin 
through a central venous line spares the peripheral veins but patient acceptance 
of repeated insertion of central lines is very limited. The m ajor toxic effect
1 1 0 .
noted following the adm inistration of high doses of haematin to laboratory 
anim als was generalized vascular damage. It is probable that the 
venous damage is s im ilar to this^being due to the relatively high concentration 
of non-protein-bound haematin at the site of Injection. If this is  the case, 
phlebitis might be avoided by slower adm inistration of a m ore dilute solution. 
The mixing of haematin with human albumin solution p rio r  to Injection might 
also help by reducing the non-protein-bound component. It is unfortunate 
that haematin in its present form has no biochemical or clinical effect when 
adm inistered orally (Tschudy et al, 1979). The development of an effective 
o ral therapy would have great advantages.
One theoretical complication of repeated courses of haematin is  tissue  
iron overload, as every gramme of haematin contains approxim ately lOOmg 
iron. In o u r patient who had received 6 courses over 2 years  th ere  was 
no evidence of hepatic siderosis at post m ortem examination. The doses of 
iron a re  unlikely to be sufficient to cause tissue damage but even slight 
increases in hepatic iron stores might aggravate the porphyria p rocess 
as is known to occur in cutaneous hepatic porphyria.
The dose of haematin currently used in the treatm ent of acute porphyria is 
largely arbitrary and may not be optim^^l* Animal toxicity studies indicate 
that there  is little  scope for any significant increase in dosage and indeed 
patients with acute porphyria^with the ir reduced protein binding capacity due 
to reduced plasm a albumin concentration and occupation of binding sites 
by the high levels of circulating porphyrins^ may be m ore prone to haematin 
toxicity (Steele et al, 1978; Morgan et al, 1980),
I l l ,
We found no difference in clinical or biochemical response between the 
4mg/24h and the 8mg/24h regim es and it is possible that the dose could 
be reduced further without loss of efficacy. The use of lower doses 
could theoretically  improve efficacy,as animal studies have demonstrated 
that large doses induce haem oxygenase activity which catabolizes both 
exogenous and endogenous haem (Srivastava et al, 1980 a, b). Studies a re  
required of different doses and different ra tes  of adm inistration of haematin 
and may lead to considerable improvement of both the clinical and 
biochemical response.
Haematin therapy may help in the elucidation of the relationship between 
the biochemical d isorder of haem biosynthesis and the clinical neuropathy.
If the neuropathy is due to neuronal haem deficiency, then clinical response 
to haematin wül depend on its ability to enter the nervous system . Lam on 
et al (1979) were unable to detect haematin in CSF of 2 patients with acute 
porphyric relapse being treated  with haematin, though th is may have been 
due to the relatively insensitive spectrophotom etrlc method employed. 
Confirmation that haematin can produce clinical improvement without entering 
the nervous system,would disprove the neuronal haem deficiency theory. If 
the neuropathy is the result of the hepatic overproduction of porphyrin 
p recu rso rs , then clinical improvement can be expected to accompany the 
effective suppression of this by haematin.
1 1 2 .
One interesting observation following haematin adm inistration was the fall 
in the plasma concentration of dehydroepiandrosterone. This hormone 
is known to be increased in the acute hepatic porphyrias due to deficient 
5 alpha reductase activity (Paxton et al, 1974). The normalization of 
the dehydroepiandrosterone levels with haematin suggests that the abnormal 
steroid metabolism in the acute porphyrias is secondary to haem deficiency 
impairing 5 alpha reductase activity. Hepatic drug metabolism is also 
impaired in the acute porphyrias and this is believed to be due to deficiency 
of the haemoprotein enzyme cytochrome P450 (Anderson et al, 1976).
Impaired hepatic metabolism in the acute porphyrias and its correction by 
haematin may be relevant to the aetiology of acute porphyric neuropathy.
It is possible that the neuropathy is the result of deficient hepatic synthesis 
of a circulating neurotrophic factor or deficient hepatic catabolism of a 
circulating neurotoxic factor.
Our conclusion from our own studies and our review of the litera tu re  is that 
haematin therapy causes consistent biochemical improvement,with associated 
clinical improvement in approximately fifty per cent of cases. The only 
side-effect noted following the recommended dosage has been thrombophlebitis 
and this should be preventable. Because of the variable clinical response one 
cannot be dogmatic about its place in the management of acute attacks of 
porphyria. It should probably be considered in attacks which are  unresponsive 
to the removal of precipitating factors and laevulose infusions, especially 
where there is evidence of developing neuropathy. It appears to have little 
place in the management of chronic attacks. Clearly, further research and 
development is indicated in order to improve the clinical response to this
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potentially useful form of therapy.
One intriguing future development could be the supplementation of the 
hepatic haem pool with endogenous ra ther than exogenous haem. This 
could be achieved by inducing a degree of intravascular haemolysis.
Haem released in this way is handled in the same way as exogenous 
haematin, being bound by haemopexin and transported to the liver.
Haemoglobin synthesis is not impaired in the acute hepatic porphyrias 
and intravascular haemolysis might be a means of utilizing the considerable 
reserves of erythropoietic haem synthesis to correct hepatic haem deficiency. 
Clearly, numerous practical problems would be encountered, such as achieving 
controllable intravascular haemolysis, but research  into the effects of 
haemolysis on hepatic haem biosynthesis may be fruitful.
C H A P T E R  10
F I N A L  D I S C U S S I O N  A N D  C O N C L U S I O N
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10. FINAL DISCUSSION AND CONCLUSIONS
This thesis has concentrated on the management of the acute hepatic 
porphyrias examining, in turn, the detection of subjects with the genetic 
trait, the factors which may precipitate attacks in these subjects and 
the treatment of the established attack.
The measurement in peripheral blood cells of the activities of both the 
rate-controlling enzyme of haem biosynthesis, ALA synthase, and the 
appropriate genetically deficient enzyme has been shown to be a sensitive 
and specific means of detecting latent cases of acute porphyria. Enzymatic 
screening of affected families has confirmed that the genetic tra it is 
inherited in an autosomal dominant, sex-independent manner. The 
family studies have also demonstrated that the vast majority of subjects 
with the genetic tra it remain clinically latent,and the reason why a minority 
develop severe clinical manifestations was examined. There was no 
difference in the activity of the genetically-deficient enzyme in clinically 
latent and manifest cases. The activity of ALA synthase, however, was 
higher in patients who had experienced attacks of A IP and it is suggested 
that this may reflect higher circulating levels of endogenous inducing agents 
such as certain steroid hormones. A study comparing endogenous inducing 
agents in these two groups is indicated and may reveal a potential means 
of reducing the incidence of clinical attacks.
The effects on haem biosynthesis of each of the precipitating factors for 
acute porphyria, namely drugs, alcohol, hormones and fasting were
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examined in peripheral blood ceils of non-porphyric subjects. All, 
except fasting, increased the activity of ALA synthase, confirming 
the means by which they cause biochemical relapse in porphyric subjects.
The mechanism by which these factors stimulate ALA synthase activity 
was investigated with particular reference to the role of induction of the 
mixed function oxidase enzyme system. The relevance of the observed 
changes in haem biosynthesis induced in peripheral blood of healthy 
subjects by porphyrinogenic agents extends outwith the field of the 
porphyrias. The stimulation of ALA synthase in leucocytes demonstrates 
the important fact that enzyme induction in human subjects is not restricted 
to hepatic tissue. The effects of alcohol on haem biosynthesis in blood 
cells is relevant to the biochemical basis of alcohol-induced sideroblastic 
anaemia,and the hormonal effects on blood ALA synthase to the hormonal 
regulation of erythropoiesis.
The two currently available means of treating attacks of acute porphyria 
have been assessed. The early administration of intravenous laevulose 
resulted in reduction of both duration and severity of attacks, though,in 
patients experiencing frequent attacks, venous access soon became compromised. 
Intravenous haematin therapy resulted in biochemical improvement,shown 
by repression of leucocyte ALA synthase and reduction m the urinary excretion 
of porphyrin p recursors .  The clinical response, however, was less 
consistent,with objective signs of improvement accompanying only half of 
the courses. The only side-effect noted following haematin therapy was
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localized thrombophlebitis. Two of our patients died in acute attack 
in spite of receiving both laevulose and haematin, illustrating that 
current therapy remains unsatisfactory. Advancement of the therapy 
of acute hepatic porphyria is hindered by our lack of understanding of the 
pathogenesis of the neuropathy.
The elucidation of the association between the biochemical abnormality 
of haem biosynthesis and the neuropathy which characterizes the clinical 
presentation of the acute porphyrias, remains a major challenge. Our 
observation that the effect of porphyrinogenic factors on haem biosynthesis 
a re  not limited to hepatic tissue lends some support to the hypothesis that 
the neuropathy is due to disordered haem biosynthesis within nervous 
tissue,though, to date, it has not been possible to demonstrate that 
porphyrinogenic agents are modifying intra-neuronal haem biosynthesis. 
Further studies of neuronal haem biosynthesis and its response to 
porphyrinogenic factors are required. The theory that the clinical attack 
is due to neurotoxic effects of porphyrin precursors is, at present, widely 
discarded, due to the inability to reproduce such effects in animal models. 
The development, however, of biological models of metabolic neurological 
disease is fraught with technical difficulties and, therefore, the porphyrin- 
precursor neurotoxicity theory should not be abandoned too readily. It is 
conceivable that both theories are correct and that impaired neuronal haem 
biosynthesis makes the nervous system more susceptible to damage by the
117.
high circulating levels of porphyrin p recursors . The pursuit of the 
association between abnormal haem biosynthesis and neurological 
dysfunction is likely to contribute significantly to the understanding and 
treatment of other more common neurological and psychiatric disorders^ 
and should be actively encouraged.
R E F E R E N C E S
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CLINICAL CASE HISTORIES OF PATIENTS TREATED WITH HAEMATIN 
Case 1
This 29 year old woman was admitted in May 1978 with severe abdominal 
pain, vomiting and constipation. She was known to have had AIP since 
1971 and had suffered 13 previous attacks requiring hospital admission 
but only two of these had been complicated by peripheral neuropathy. On 
most previous adm issions she had been treated with I. V. 20% laevulose^ 
but this was no longer feasible as all suitable veins had been compromised.
She was, therefore, treated  with nasogastric infusions of the glucose 
polymer Caloreen (Roussel Laboratories Ltd) amounting to 2, ODD kcal/24 h.
Over the ensuing 6 weeks she gradually developed peripheral motor neuropathy 
and by early  July there was marked distal paresis  of upper and lower limbs 
and diminished resp ira to ry  function. On July 5 th ., her firs t course of 
intravenous haematin (4mg/kg/24 h for 3 days) was commenced. On the 
day following the final infusion she felt much improved. There was also 
improvement in her resp ira to ry  function which was maintained. Her peripheral 
m otor function improved slowly over the following 7 weeks. At the end of 
August, however, she developed increasing abdominal pain and generalized 
muscle pains and evidence of peripheral sensory neuropathy. On 31st. August^ 
her second course of haematin was commenced (8 mg/kg/24 h for 3 days). The 
day following completion of this she again felt much improved and required 
less analgesia. Sensory discrim ination returned to normal within 3 days.
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Improvement was maintained and 4 weeks la te r she was able to be 
discharged home and able to walk with the aid of a zim m er. She was 
re-adm itted 8 months la ter on 18th. April 1979 with a further attack.
On the 3rd. May  ^there was evidence of motor and sensory peripheral 
neuropathy and some deterioration of resp iratory  function. On 6th. May  ^
her third course of haematin (4mg/kg/24 h for 3 days) was commenced. 
Following this there was again improvement of resp irato ry  function and a 
reduction in her analgesic requirement^and she was able to be discharged 
home 12 days la ter. The biochemical and clinical response to the first
3 courses of haematin are  shown in Figure 42.
On 5th. July 1979 she was re-adm itted in a further attack^ and found to be
4 weeks pregnant. She was unwilling to consider a therapeutic abortion^ 
and over the following weeks developed generalized neuropathy with severe 
impairment of resp ira to ry  function and bulbar paralysis and also severe 
hypertension. Eventually^she agreed to a therapeutic abortion and this was 
perform ed on 23rd. August. The day following, her fourth course of haematin 
(4mgAg'/24 h for 6 days) was commenced. She felt generally improved^
and there was some objective evidence of improved motor function over the 
following month. On the 9th. October, however, the pain again became much 
m ore severe and, as she appeared to be going into a further attack, a fifth 
course of haematin (4mgAg/24 h for 3 days) was commenced. She felt better 
on the final day of the course and again it was possible to reduce her analgesia. 
The blood p ressure, however, remained high and 7 days after the haematin she
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developed a hypertensive exudative retinopathy (Fig. 43). The blood pressure 
settled 2 weeks la te r and she was discharged home.
On 20th. May 1980 she was re-adm itted with abdominal pain and weakness 
of dorsiflexion of both hands. Her pain and paralysis increased over the 
following week and on 3rd. June her sixth course of haematin (4mg/kg/24 h 
for 2 days) was commenced. On the second day of haematin therapy she 
felt and looked m ore ill. There was marked peripheral vasoconstriction.
Her tem perature was elevated at 38 .5°C and the total white cell count was 
increased at 19.2 x 10^/1 due to a neutrophilia. No infection could be 
isolated from the patient or the haematin solution. She was commenced 
on intravenous ampicillin and flucloxacillin. On 5th. June^she was transferred  
to the intensive care unit because of progressing paralysis and ventillatory 
em barrassm ent. The following day she had an episode of cardiac asystole 
lasting 20 minutes from which she was successfully resuscitated. There 
was no evidence of cerebral impairment following this but she required to 
be maintained on the ventillator for the following 10 weeks due to severe 
paralysis. In mid August she was weaned-off the ventillator. Two weeks 
la te r  she developed a further attack with increasing pain and paralysis. On 
28th. September^ 1980^she had a further episode of asystole and resuscitation 
was unsuccessful.
Post m ortem examination showed acute tracheitis extending down both bronchi. 
In addition there were several focal areas of pulmonary infarction. The heart 
and kidneys appeared normal. Detailed histological examination of the central 
nervous system revealed no abnorm alities. The peripheral somatic and 
autonomic nerves have been submitted for special studies and the results
4
f r,
Figure 43
Hypertensive retinopathy due to attack of acute interm ittent porphyria 
in 31 year old woman (Case 1).
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Case 2
This 26 year old woman^with a family history of AIP  ^ was admitted to 
M anchester Royal Infirm ary in February 1978 with abdominal pain, weakness 
of the lower limbs and strange mental behaviour. She was confirmed to 
be in an attack of porphyria. She had a past history of severe bronchial
asthma for which she had been receiving dexamethasone 2mg T. I. D. for the 
past 6 years. The steroids were continued and she was given a high calorie 
and protein diet. Over the following 5 months she continued to have frequent 
attacks of severe abdominal pain. Her mental state also became worse and 
she suffered from depression, paranoid delusions and auditory and visual 
hallucinations which made her in-patient care very difficult. In August 1978, 
she was transferred  to our unit for assessm ent for haematin therapy. On 
arriv a l in Glasgow she complained of abdominal pain, nausea, constipation 
and painful weakness of all her limbs. Pulse and blood p ressure  were normal 
but there was marked peripheral m otor neuropathy and she was unable to walk.
She was convinced that the nurses were poisoning her food and only ate food 
in sealed containers and refused all oral medication. The consultant psychiatrist 
who assessed  her was of the opinion that she was suffering from an exogenous 
psychosis without clouding of consciousness^secondary to her porphyria. Her 
albumin was low at 27g/l, cholesterol increased at 10.5 mmol/1, and urate, 
gamma-glutamyl transpeptidose, aspartate transam inase and alanine transam inase 
also m oderately increased. Haematology was normal. An electroencephalogram 
was normal and nerve conduction studies showed prolongation of distal motor 
latencies in the feet.
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On the 16th. August, she was commenced on a 4 day course of haematin in 
a dosage of 4m g/kg/day. This caused mild phlebitis of the peripheral vein 
but no other side-effect s. On the final day of the haematin, she felt a 
m arked improvement of her abdominal and generalized m uscle pains.
This improvement was short lived, her abdominal pain return ing  2 days 
la te r  and her m uscle pains 7 days la te r. Over the 10 days following the 
haem atin,there was objective improvement in m otor function as  assessed  
by our consultant neurologist. The haematin had no effect on her mental 
state. She was able to be discharged homP 12 days a fte r completion of the 
haem atin therapy. When reviewed in Glasgow two months la te r, she felt 
generally improved and was able to walk unassisted.
Over the subsequent six months at home,she suffered from  severe mental 
disturbance, which resulted in dom estic strife . She became very paranoid 
and demanding towards her husband and commited a large num ber of petty 
crim inal offences including, shoplifting and swindling m ail o rder companies.
She trained her children to steal lib rary  books and m essages for her. On two 
occassions she went m issing and was found by the police camping alone in 
the m oors. On one occasion her husband arrived home to find th e ir  6 hens 
with the ir heads cut-off and on another occasion to find th e ir  pet cat burnt 
alive having been soaked in paraffin. In April 1979, she was found unconscious 
in her back garden having attempted to commit suicide by taking an overdose 
of diazepam. After recovering from this she continued to exhibit b izarre  
mental behaviour and complained of interm ittent abdominal pains. She refused 
any further m edical attention. On 20th. January 1980,she trag ically  took a
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further and fatal drug overdose. Interestingly, her mother had suffered
severe psychiatric disturbance due to porphyria between 25-30 years of 
age but had no trouble thereafter and now occupies an important 
government position. The following poem was written by the patient 
6 months before her death.
That man is coming here once again 
I hope from chastising me he does refrain 
For with great fear and trepidation I wait 
Just what is to be that day's fate.
It could be new treatm ent
Of which I am in need
But who am I to decide this indeed
One day, however, I do Icnow
That I shall die even
As the wind doth blow.
Unconscious sleep will come to me 
Giving me peace from that everlasting gasp.
Oh, doctor Sir you must help me
Don't cross me off your books as a failure
For I do wish to respond
And be a credit to your work
thus making your job seem worthy of you.
155.
Case 3
This 23 year old g irl was admitted on 1st. November 1978 with severe 
abdominal and generalized muscle pains, which had developed following 
the consumption of a moderate quantity of alcohol. She had been 
diagnosed to have A IP in March 1976 and had had 10 previous attacks 
but never any evidence of peripheral neuropathy. Her abdominal and 
m uscle pains did not respond to carbohydrate adm inistration and she was 
requiring large doses of parenteral narcotic analgesia. Three weeks 
after admission on the 20th. November, intravenous haematin (4m g/kg/12 h 
for 3 days) was commenced. The final infusion^which was into a small 
peripheral vein^resulted in severe thrombophlebitis with associated pyrexia 
and leucocytosis. On the final day of the haematin she felt that the "porphyria 
pains" were relieved but continued analgesia was required because of the 
painful thrombophlebitis. Five days after completion of the haematin, the 
"porphyria pains" returned and she was unable to get home for a further 
6 weeks.
Over the following year she experienced recurrent attacks of abdominal pain 
and was ra re ly  free of pain. She was re-adm itted on 19th. February 1980 
with severe abdominal and generalized muscle pains, photophobia and vomiting. 
She was given large doses of diamorphine and high calorie nasogastric infusions. 
Two days la te r she was no better and had a tachycardia of 120/m in but no 
evidence of peripheral neuropathy. On 20th. February she was commenced on 
a 3 day course of haematin (4mg/kg/day). Two days after completing the 
haematin, she felt slightly better and the pain was less severe. Overall,
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however, the haematin had very little discernible effect on her clinical 
condition and she remained in hospital requiring intram uscular analgesia 
for a further 4 months. No phlebitis occurred with this second course 
which was adm inistered into a central venous line.
Case 4
This 19 year old man with A IP was transferred  to our unit for haematin 
therapy in March 1979. Over the previous 2 years he had suffered 
frequent attacks of abdominal pain and vomiting and had rarely  been 
symptom free. No precipitating factors were identified. He had never 
SLilïered mental disturbance but there was some mild peripheral sensory 
neuropathy. The day following his transfer his symptoms became more 
severe and he developed tachycardia and hypertension. Two days la ter 
a 3 day course of haematin (4mg/kg/24 h) was commenced. Following 
the final infusion he developed severe phlebitis with associated low grade 
pyrexia and leucocytosis (Fig. 44), The haematin did not resu lt in 
any subjective or objective clinical improvement.
Figure 44
Severe phlebitis due to haematin injection in right a rm  of 19 year 
old man (Case 4) with acute intermittent porphyria.
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Case 5
This 57 year old woman with no significant past or family history was 
admitted to hospital in Birmingham in February 1979 with abdominal 
pain, vomiting and constipation. She was diagnosed as having cholecystitis^ 
and a cholecystecomy performed on the same day. She was discharged 
5 days la te r  but over the following 2 weeks developed confusion, b izarre  
behaviour and peripheral neuropathy. On re-adm ission, investigations 
revealed acute attack of porphyria varie gat a with associated dilutional 
hyponatraemia. In spite of intravenous adm inistration of 20% laevulose 
and correction of the hyponatraemia, her neuropathy progressed and she 
became quadriplegic and required mechanical ventilation. Ten days la ter 
there was no improvement and a 3 day course of haematin (8mg/kg/24 h) 
was commenced, hi spite of th is,her condition continued to deteriorate 
and she developed a chest infection, hypotension and mild renal Impairment 
and eventually died two weeks la ter.
Post mortem examination showed extensive chest infection. Histological 
examination of the kidneys was normal.
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Case 6
This 19 year old girl was admitted to hospital in Liverpool on 6th. May 
1979 with severe lower abdominal pain. She was initially thought to have 
acute salpingitis or urinary trac t infection and cotrimoxazole was prescribed. 
Two days la te r her pain became more severe and she developed dilutional 
hyponatraemia and convulsions. Urinalysis at this point confirmed an 
acute attack of A IP. In spite of stopping all contra-indicated drugs and 
adm inistrating laevulose infusions, she continued to deteriorate. She 
developed quadriparesis and required assisted ventilation. On 22nd. May, 
a 3 day course of haematin (8m gA g/24 h) was commenced. Over the 
following 2 weeks she continued to deteriorate with extensive chest infection, 
hypotension and la tterly  deteriorating renal function. She died on 7th.
June.
Post mortem showed extensive chest infection. Histological examination 
of the kidneys was again normal.
I
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Case 7
This 24 year old woman was admitted to our unit on 26th. February 1979 
with abdominal pain, vomiting and constipation. She had had 12 previous 
adm issions for acute attacks of AIP over the preceeding 3 years. She 
was treated  with high carbohydrate nasogastric infusions but^in spite of 
this^eveloped peripheral motor neuropathy of upper and lower limbs.
On 2nd. March, a 3 day course of haematin (4mgAg24 h) was instituted.
On the final day of therapy she felt that the pain was much improved and 
3 days la te r  her peripheral reflexes had returned. Eight days after 
completion of therapy she relapsed with further progression of her neuropathy. 
She also complained of severe toothache and was found to have extensive 
caries and several septic foci. Dental clearance was performed and 
following this her neuropathy slowly recovered and she was able to be 
discharged home one month la ter. Over the subsequent year she was 
re-adm itted on 5 occasions in attack but none of these were complicated 
by neuropathy and all settled with symptomatic therapy and high calorie 
intake.
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Case 8
This 21 year old man (brother of case 7) was admitted to our unit on 
21st. September 1979 with a 7 day history of abdominal pain, vomiting 
and constipation. There was no peripheral neuropathy but he had marked 
postural hypotension. He was treated symptomatically and given high 
oral carbohydrate intake. Seven days after admission he remained in 
severe pain and a 3 day course of haematin (4mgAg24 h) was commenced. 
Two days after completion of haematin the pain settled and he was able to 
be discharged 10 days later. The haematin resulted in mild phlebitis.
